{"PMC7126276": [["IntroductionWith the progressively frequent communication of population around the world, epidemics obtain more chances to lead to a global transmission.", [["epidemics", "PROBLEM", 90, 99]]], ["Especially for the airborne epidemics, droplets produced by an infected person during his talk, cough and sneeze can cause surrounding individuals to be infected.", [["cough", "DISEASE", 96, 101], ["person", "SPECIES", 72, 78], ["the airborne epidemics", "PROBLEM", 15, 37], ["cough", "PROBLEM", 96, 101], ["surrounding individuals", "PROBLEM", 123, 146], ["infected", "PROBLEM", 153, 161], ["infected", "OBSERVATION", 153, 161]]], ["In recent years, these epidemics had broken out for several times and spread widely.", [["these epidemics", "PROBLEM", 17, 32]]], ["For example, Severe Acute Respiratory Syndrome (SARS) that emerged in 2003 brought a great disaster to the economy and human lives in China.", [["Acute Respiratory Syndrome", "DISEASE", 20, 46], ["SARS", "DISEASE", 48, 52], ["human", "ORGANISM", 119, 124], ["human", "SPECIES", 119, 124], ["human", "SPECIES", 119, 124], ["Severe Acute Respiratory Syndrome", "PROBLEM", 13, 46], ["Severe", "OBSERVATION_MODIFIER", 13, 19], ["Acute", "OBSERVATION_MODIFIER", 20, 25], ["Respiratory Syndrome", "OBSERVATION", 26, 46]]], ["Influenza H1N1 hit many countries in 2009 and led at least 12 220 people to death until December 30th 2009.", [["death", "DISEASE", 76, 81], ["Influenza H1N1", "ORGANISM", 0, 14], ["people", "ORGANISM", 66, 72], ["Influenza H1N1", "SPECIES", 0, 14], ["people", "SPECIES", 66, 72], ["Influenza H1N1", "PROBLEM", 0, 14]]], ["In addition, common seasonal influenza would always affect human health as well.IntroductionDevelopment of the medicine science has accelerated the research and manufacture of vaccines.", [["influenza", "DISEASE", 29, 38], ["human", "ORGANISM", 59, 64], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 59, 64], ["common seasonal influenza", "PROBLEM", 13, 38], ["manufacture of vaccines", "TREATMENT", 161, 184], ["influenza", "OBSERVATION", 29, 38]]], ["Uninfected persons can be protected by being inoculated when an epidemic breaks out.", [["persons", "ORGANISM", 11, 18], ["persons", "SPECIES", 11, 18]]], ["However, when a new epidemic prevails among the crowd, new vaccines invariably tend to be not enough at all and cannot satisfy the total needs.", [["a new epidemic prevails", "PROBLEM", 14, 37], ["new vaccines", "TREATMENT", 55, 67]]], ["In this case, what kind of immunization strategy can furthest reduce the prevalence of an epidemic concerns many researchers and government.IntroductionRecently, researches on immunization strategy based on complex networks have been very popular [1], [2], [3].", [["[2]", "SIMPLE_CHEMICAL", 252, 255], ["immunization strategy", "TREATMENT", 27, 48], ["immunization strategy", "TREATMENT", 176, 197]]], ["Pastor-Satorras and Vespignani [1] studied the immunization strategy based on scale-free networks [4], and the results indicated that protection of just a tiny fraction of the most connected individuals raises dramatically tolerance to infections of the whole population.", [["infections", "DISEASE", 236, 246], ["Pastor", "TEST", 0, 6], ["the immunization strategy", "TREATMENT", 43, 68], ["tiny", "OBSERVATION_MODIFIER", 155, 159], ["fraction", "OBSERVATION", 160, 168], ["dramatically", "OBSERVATION_MODIFIER", 210, 222]]], ["Zanette and Kuperman [3] researched the propagation of epidemics based on the Watts\u2013Strogatz (WS) small-world network [5] under the action of immunization, and a similar conclusion that the most connected individuals should be protected preferentially was obtained.", [["Zanette", "CHEMICAL", 0, 7], ["individuals", "ORGANISM", 205, 216], ["Zanette", "TREATMENT", 0, 7], ["Kuperman", "TREATMENT", 12, 20], ["epidemics", "PROBLEM", 55, 64], ["immunization", "TREATMENT", 142, 154], ["small", "OBSERVATION_MODIFIER", 98, 103]]], ["These two researches were both based on the unweighted networks with single hierarchical structure and the classic targeted immunization strategy was proposed in the researches.", [["the classic targeted immunization strategy", "TREATMENT", 103, 145]]], ["Targets in this traditional targeted immunization strategy are decided by evaluating their importance in the global network so we call it global targeted immunization strategy in this paper.", [["this traditional targeted immunization strategy", "TREATMENT", 11, 58]]], ["Furthermore, we find that global targeted immunization strategy loses its superiority in controlling the epidemic propagation in the social contact networks with modular and hierarchical structure.", [["contact networks", "MULTI-TISSUE_STRUCTURE", 140, 156], ["global targeted immunization strategy", "TREATMENT", 26, 63], ["hierarchical structure", "OBSERVATION", 174, 196]]], ["Therefore, it is progressively necessary to study the immunization strategy based on the modular and hierarchical networks and find a more effective one.IntroductionIn this paper, we propose one hierarchical targeted immunization strategy to control the epidemic spreading among the crowd with modular and hierarchical social contact network.", [["contact network", "MULTI-TISSUE_STRUCTURE", 326, 341], ["the immunization strategy", "TREATMENT", 50, 75], ["hierarchical targeted immunization strategy", "TREATMENT", 195, 238]]], ["Experiments\u2019 results show that hierarchical structure of the network is more important than the degrees of the immunized targets in controlling the epidemic propagation.", [["the immunized targets", "TREATMENT", 107, 128]]], ["The novel immunization strategy has been proven effective and stable.", [["The novel immunization strategy", "TREATMENT", 0, 31], ["stable", "OBSERVATION_MODIFIER", 62, 68]]], ["In Section 3, the models involved in all the simulation experiments and the hierarchical targeted immunization strategy are introduced in detail.", [["the hierarchical targeted immunization strategy", "TREATMENT", 72, 119]]], ["Finally, our conclusions are given in Section 5.Research motivationIn this section, we performed an experiment which proved that global targeted immunization strategy has its own disadvantages in controlling the epidemic propagation in the modular and hierarchical social contact networks.", [["contact networks", "MULTI-TISSUE_STRUCTURE", 272, 288], ["global targeted immunization strategy", "TREATMENT", 129, 166]]], ["The models involved in the experiment will be introduced in detail in Section 3.Research motivationBased on a modular and hierarchical network model [8], we carried out an epidemic-transmission experiment to research the effects of the global targeted immunization strategy and the random immunization strategy.", [["the global targeted immunization strategy", "TREATMENT", 232, 273], ["the random immunization strategy", "TREATMENT", 278, 310]]], ["In the experiment, an individual was selected randomly to be the fixed initial infected one.", [["infected", "OBSERVATION", 79, 87]]], ["Simulations at every immunized proportion were repeated for 1000 times.", [["Simulations at every immunized proportion", "TREATMENT", 0, 41]]], ["Same as the strategy used by Pastor-Satorras et al. [1] and Zanette et al. [3], the global targeted immunization strategy we adopted also supposed that the best connected individuals should be vaccinated preferentially.", [["individuals", "ORGANISM", 171, 182], ["the global targeted immunization strategy", "TREATMENT", 80, 121]]], ["To eliminate the randomness, the immunized targets in the random immunization would be selected again in every repeated experiment.", [["the randomness", "PROBLEM", 13, 27], ["the immunized targets", "TREATMENT", 29, 50], ["the random immunization", "TREATMENT", 54, 77]]], ["The results are shown in Fig. 1.Research motivationThe results show that as the number of immunized individuals increases, effects of the two immunizations tend to be better.", [["immunized individuals", "PROBLEM", 90, 111], ["the two immunizations", "TREATMENT", 134, 155]]], ["However, the targeted immunization works not much better than the random immunization.", [["the targeted immunization", "TREATMENT", 9, 34], ["the random immunization", "TREATMENT", 62, 85]]], ["When the immunized proportion is less than 0.5, random immunization strategy always works better than targeted immunization.Research motivationIt has been illuminated in the literature [8] that the modular and hierarchical network model is a \u201csmall-world\u201d network.", [["random immunization strategy", "TREATMENT", 48, 76], ["targeted immunization", "TREATMENT", 102, 123], ["illuminated", "OBSERVATION_MODIFIER", 155, 166], ["modular", "OBSERVATION_MODIFIER", 198, 205], ["hierarchical network", "OBSERVATION", 210, 230]]], ["According to Zanette et al. [3], targeted immunization has shown a substantial improvement in the disease control for the WS small-world networks.", [["targeted immunization", "TREATMENT", 33, 54], ["the disease control", "TREATMENT", 94, 113], ["substantial", "OBSERVATION_MODIFIER", 67, 78], ["improvement", "OBSERVATION_MODIFIER", 79, 90], ["disease", "OBSERVATION", 98, 105]]], ["Therefore, the results shown in Fig. 1 indicate that modular and hierarchical structure of the network makes the targeted immunization lose its superiority in controlling the epidemic propagation.", [["modular and hierarchical structure of the network", "PROBLEM", 53, 102], ["the targeted immunization", "TREATMENT", 109, 134], ["modular", "OBSERVATION", 53, 60], ["hierarchical structure", "OBSERVATION", 65, 87]]], ["Furthermore, the fact that random immunization strategy works better reflects the existence of a better strategy to control the epidemic propagation in the modular and hierarchical network.", [["random immunization strategy", "TREATMENT", 27, 55], ["the epidemic propagation", "PROBLEM", 124, 148]]], ["In this paper, we mainly researched the impacts of the network\u2019s modular and hierarchical structure on immunization strategy to find a new strategy better to control the epidemic spreading in the modular and hierarchical networks.Network model ::: Material and methodsTo construct spatial-correlated social contact networks with both hierarchical structure and overlapping communities, we proposed a mixing pattern of modular and growing hierarchical structure in the literature [8] by using individual\u2019s geospatial distribution information.", [["contact networks", "MULTI-TISSUE_STRUCTURE", 307, 323], ["immunization strategy", "TREATMENT", 103, 124], ["epidemic", "OBSERVATION_MODIFIER", 170, 178], ["modular", "OBSERVATION_MODIFIER", 196, 203], ["hierarchical networks", "OBSERVATION", 208, 229], ["modular", "OBSERVATION_MODIFIER", 418, 425], ["growing", "OBSERVATION_MODIFIER", 430, 437], ["hierarchical structure", "OBSERVATION", 438, 460]]], ["In the networks, individuals are abstracted as nodes, and contact relations are abstracted as edges.Network model ::: Material and methodsSuch as roommates in a dormitory or families in a household, local social network, which represents the most frequent contact relations, can be regarded as a module of the whole social network.", [["social network", "MULTI-TISSUE_STRUCTURE", 205, 219], ["social network", "MULTI-TISSUE_STRUCTURE", 316, 330], ["nodes", "OBSERVATION", 47, 52]]], ["Hence, the modular model is defined as a complete network with an only parameter node number n, in which individuals would own a rather high probability to contact with each other.Network model ::: Material and methodsThe hierarchical structure of the contact network, which depicts different types of relations among individuals, consists of multiple layers of networks.", [["contact network", "MULTI-TISSUE_STRUCTURE", 252, 267], ["modular", "OBSERVATION_MODIFIER", 11, 18], ["node", "OBSERVATION", 81, 85], ["hierarchical structure", "OBSERVATION", 222, 244], ["contact network", "OBSERVATION", 252, 267], ["multiple", "OBSERVATION_MODIFIER", 343, 351], ["layers", "OBSERVATION_MODIFIER", 352, 358]]], ["The layer number of a network is denoted by \u03b1.", [["layer", "OBSERVATION_MODIFIER", 4, 9], ["number", "OBSERVATION_MODIFIER", 10, 16]]], ["Each layer contains a number of independent networks, which represent the same type of social relation.", [["layer", "OBSERVATION_MODIFIER", 5, 10], ["number", "OBSERVATION_MODIFIER", 22, 28]]], ["These independent networks are all internally connected, and there is no edge between different independent networks.", [["no", "UNCERTAINTY", 70, 72]]], ["Individuals of an independent network in layer \u03b1 come from several independent networks in layer \u03b1\u22121 and connect with each other by a new-type relation.Network model ::: Material and methodsIn this paper, we reconstructed the contact network in one dormitory building of a university.", [["layer \u03b1\u22121", "CANCER", 91, 100], ["layer \u03b1", "PROTEIN", 41, 48], ["layer \u03b1\u22121", "PROTEIN", 91, 100]]], ["The dormitory contact network is defined as the modular model (\u03b1=0), which consists of 6 individuals.", [["the modular model", "TEST", 44, 61]]], ["A dormitory floor (\u03b1=2) has 2 classes and a dormitory building (\u03b1=3) has 6 floors.", [["a dormitory building", "TREATMENT", 42, 62]]], ["The number of nodes in the whole contact network amounts to 1512.Network model ::: Material and methodsThe hierarchical network is generated based on the modular model, and it is a gradually growing process to connect nodes from modular models to a global hierarchal contact network.", [["nodes", "ANATOMY", 14, 19], ["nodes", "MULTI-TISSUE_STRUCTURE", 14, 19], ["number", "OBSERVATION_MODIFIER", 4, 10], ["nodes", "OBSERVATION", 14, 19], ["nodes", "OBSERVATION", 218, 223]]], ["Each layer \u03b1 of the hierarchical network is generated based on the layer \u03b1\u22121, except the layer \u03b1=0 which are composed of modular networks.", [["layer \u03b1\u22121", "PROTEIN", 67, 76], ["modular networks", "PROTEIN", 121, 137], ["layer", "OBSERVATION_MODIFIER", 5, 10], ["hierarchical network", "OBSERVATION", 20, 40], ["layer", "OBSERVATION_MODIFIER", 67, 72], ["layer", "ANATOMY_MODIFIER", 89, 94], ["modular networks", "OBSERVATION", 121, 137]]], ["The independent networks in the lower layer, which are used to construct a network in layer \u03b1, are called sub-networks of the high-layer network.", [["lower layer", "ANATOMY", 32, 43], ["layer network", "MULTI-TISSUE_STRUCTURE", 131, 144], ["layer \u03b1", "PROTEIN", 86, 93], ["lower layer", "OBSERVATION_MODIFIER", 32, 43]]], ["Construction of a network in layer \u03b1 follows two steps: First, the number of sub-networks (ns) that compose a high-layer network is fixed.", [["layer \u03b1", "PROTEIN", 29, 36]]], ["Suppose (v,e) represents a sub-network, and then all the fixed sub-networks to construct the high-layer network could be denoted by {(vi,ei)}, where vi and ei are respectively the node set and the edge set of a sub-network i.", [["node", "ANATOMY", 180, 184], ["node", "OBSERVATION", 180, 184], ["edge", "OBSERVATION_MODIFIER", 197, 201]]], ["Second, new edges are added between individuals in different sub-networks at a probability of p.", [["new", "OBSERVATION_MODIFIER", 8, 11], ["edges", "OBSERVATION_MODIFIER", 12, 17]]], ["Then the newly generated network G could be formalized as: (1)G=(\u222avi,\u222aei+e\u2032),i\u2208[1,ns] where e\u2032 stands for the newly added edges.Network model ::: Material and methodsThe probability p to add a new edge between a pair of individuals who are in different sub-networks is defined as: (2)p=\u03bb(di/maxdi+dj/maxdj)/2(3)\u03bb=exp(\u2212\u03b1) where \u03bb is a decline coefficient specifying the decreasing degree of p, di represents the actual degree of an individual i, and maxdi is the maximum degree of links that individual i might have in layer \u03b1\u22121.Network model ::: Material and methodsSocial contact networks always belong to weighted networks [9], [10], in which the weights are used to depict closeness of the relationships among people.", [["layer \u03b1\u22121", "GENE_OR_GENE_PRODUCT", 518, 527], ["people", "ORGANISM", 713, 719], ["maxdi+dj", "PROTEIN", 291, 299], ["maxdj", "PROTEIN", 300, 305], ["2(3", "PROTEIN", 307, 310], [")\u03bb", "PROTEIN", 310, 312], ["exp", "PROTEIN", 313, 316], ["\u2212\u03b1", "PROTEIN", 317, 319], ["\u03bb", "PROTEIN", 327, 328], ["people", "SPECIES", 713, 719], ["G", "TEST", 62, 63], ["ns", "TEST", 82, 84], ["a decline coefficient", "PROBLEM", 332, 353], ["edges", "ANATOMY_MODIFIER", 122, 127], ["decreasing", "OBSERVATION_MODIFIER", 369, 379], ["maximum degree", "OBSERVATION_MODIFIER", 462, 476]]], ["Then the decline coefficient \u03bb actually reflects the closeness of two individuals who are in different sub-networks.", [["-networks", "MULTI-TISSUE_STRUCTURE", 106, 115]]], ["(4), the weight w of an edge between two individuals is defined as the social distance, which is the inverse of \u03bb.", [["the weight w", "TEST", 5, 17]]]], "PMC7151792": [["Life Expectancy, Morbidity, and Disability ::: Life Expectancy, Morbidity, and DisabilityIn 2007 the percentage of population aged 65 years and above ranged from 3% to 4% in Laos and Cambodia, to 12% to 13% in New Zealand, Hong Kong, and Australia, to 21% in Japan (Figure 120-1).", [["Morbidity", "OBSERVATION", 17, 26]]], ["In general, with economic development, life expectancy increases and morbidity changes from higher prevalence of communicable to noncommunicable diseases.", [["noncommunicable diseases", "DISEASE", 129, 153], ["morbidity changes", "PROBLEM", 69, 86], ["noncommunicable diseases", "PROBLEM", 129, 153]]], ["The causes of death from chronic noncommunicable diseases ranged from approximately 90% in New Zealand and Australia, 80% in Singapore, South Korea, Japan, and China, 50% in India and Myanmar, to 35% in Cambodia and Laos.1 Life expectancy at birth is highest in Japan and the Hong Kong Special Administrative Region (SAR) of China (80%), and lowest in Laos (56%) (Figure 120-2).", [["death", "DISEASE", 14, 19], ["chronic noncommunicable diseases", "DISEASE", 25, 57], ["death", "PROBLEM", 14, 19], ["chronic noncommunicable diseases", "PROBLEM", 25, 57], ["chronic", "OBSERVATION_MODIFIER", 25, 32], ["noncommunicable", "OBSERVATION_MODIFIER", 33, 48], ["diseases", "OBSERVATION", 49, 57], ["New", "OBSERVATION_MODIFIER", 91, 94], ["Zealand", "OBSERVATION_MODIFIER", 95, 102], ["China", "ANATOMY", 160, 165]]], ["Ideally increasing life expectancy should be accompanied by compression of morbidity and disability.", [["compression of morbidity and disability", "PROBLEM", 60, 99], ["compression", "OBSERVATION", 60, 71], ["morbidity", "OBSERVATION", 75, 84]]], ["There is little available data to determine whether there is compression of morbidity and disability in Asia, nor what chronic diseases make the largest contribution to disability.", [["disability", "DISEASE", 90, 100], ["disability", "DISEASE", 169, 179], ["compression of morbidity", "PROBLEM", 61, 85], ["disability", "PROBLEM", 90, 100], ["chronic diseases", "PROBLEM", 119, 135], ["compression", "OBSERVATION", 61, 72], ["morbidity", "OBSERVATION", 76, 85]]], ["In Hong Kong SAR, China, active life expectancy at age 70 years is approximately 10 years for both men and women; however, total life expectancy and the life expectancy lived with disability (DLE) are longer in women compared with men, DLE being 4.4 years in women and 2.2 years in men.", [["disability", "DISEASE", 180, 190], ["DLE", "DISEASE", 192, 195], ["DLE", "DISEASE", 236, 239], ["men", "ORGANISM", 99, 102], ["women", "ORGANISM", 107, 112], ["women", "ORGANISM", 211, 216], ["men", "ORGANISM", 231, 234], ["women", "ORGANISM", 259, 264], ["men", "ORGANISM", 282, 285], ["men", "SPECIES", 99, 102], ["women", "SPECIES", 107, 112], ["women", "SPECIES", 211, 216], ["men", "SPECIES", 231, 234], ["women", "SPECIES", 259, 264], ["men", "SPECIES", 282, 285]]], ["Diseases making the largest contribution to disability are stroke, dementia, fractures, Parkinson\u2019s disease, and diabetes mellitus.Chronic diseases of major impact in the elderly population ::: Life Expectancy, Morbidity, and DisabilityThe prevalence of cognitive impairment among elderly Hong Kong Chinese aged 70 years and over is approximately 15% in two community surveys carried out in 1990\u201391 and 2001\u201302.", [["disability", "DISEASE", 44, 54], ["stroke", "DISEASE", 59, 65], ["dementia", "DISEASE", 67, 75], ["fractures", "DISEASE", 77, 86], ["Parkinson\u2019s disease", "DISEASE", 88, 107], ["diabetes mellitus", "DISEASE", 113, 130], ["cognitive impairment", "DISEASE", 254, 274], ["Diseases", "PROBLEM", 0, 8], ["stroke", "PROBLEM", 59, 65], ["dementia", "PROBLEM", 67, 75], ["fractures", "PROBLEM", 77, 86], ["Parkinson\u2019s disease", "PROBLEM", 88, 107], ["diabetes mellitus", "PROBLEM", 113, 130], ["Chronic diseases", "PROBLEM", 131, 147], ["cognitive impairment", "PROBLEM", 254, 274], ["largest", "OBSERVATION_MODIFIER", 20, 27], ["stroke", "OBSERVATION", 59, 65], ["dementia", "OBSERVATION", 67, 75], ["fractures", "OBSERVATION", 77, 86], ["Parkinson\u2019s", "OBSERVATION", 88, 99], ["diabetes mellitus", "OBSERVATION", 113, 130], ["diseases", "OBSERVATION", 139, 147], ["major", "OBSERVATION_MODIFIER", 151, 156], ["impact", "OBSERVATION_MODIFIER", 157, 163], ["Morbidity", "OBSERVATION", 211, 220]]], ["Age, female gender, history of Parkinson\u2019s disease and stroke, functional disability, low education level and low social class and income, were predisposing factors.", [["Parkinson\u2019s disease", "DISEASE", 31, 50], ["stroke", "DISEASE", 55, 61], ["functional disability", "DISEASE", 63, 84], ["Parkinson\u2019s disease", "PROBLEM", 31, 50], ["stroke", "PROBLEM", 55, 61], ["functional disability", "PROBLEM", 63, 84], ["Parkinson\u2019s", "OBSERVATION", 31, 42]]], ["A review of epidemiologic studies on dementia in China showed rates at the lower end of the rates in Caucasians, with regional variation in the ratio of vascular dementia to Alzheimer\u2019s diseases.2 The prevalence of dementia ranged from 0.46% to 7.0%, whereas the annual incidence ranged from 0.81% to 2.02%, being slightly higher in women and those with lower education.", [["vascular", "ANATOMY", 153, 161], ["dementia", "DISEASE", 37, 45], ["vascular dementia", "DISEASE", 153, 170], ["Alzheimer\u2019s diseases", "DISEASE", 174, 194], ["dementia", "DISEASE", 215, 223], ["vascular", "MULTI-TISSUE_STRUCTURE", 153, 161], ["women", "ORGANISM", 333, 338], ["women", "SPECIES", 333, 338], ["epidemiologic studies", "TEST", 12, 33], ["dementia", "PROBLEM", 37, 45], ["rates", "TEST", 62, 67], ["regional variation", "PROBLEM", 118, 136], ["vascular dementia", "PROBLEM", 153, 170], ["Alzheimer\u2019s diseases", "PROBLEM", 174, 194], ["dementia", "PROBLEM", 215, 223], ["lower", "ANATOMY_MODIFIER", 75, 80], ["regional variation", "OBSERVATION", 118, 136], ["vascular", "ANATOMY", 153, 161], ["dementia", "OBSERVATION", 162, 170], ["Alzheimer\u2019s", "OBSERVATION", 174, 185], ["dementia", "OBSERVATION", 215, 223], ["slightly", "OBSERVATION_MODIFIER", 314, 322], ["higher", "OBSERVATION_MODIFIER", 323, 329]]], ["Alzheimer\u2019s disease was the predominant type of dementia, followed by vascular dementia.", [["vascular", "ANATOMY", 70, 78], ["Alzheimer\u2019s disease", "DISEASE", 0, 19], ["dementia", "DISEASE", 48, 56], ["vascular dementia", "DISEASE", 70, 87], ["vascular", "MULTI-TISSUE_STRUCTURE", 70, 78], ["Alzheimer\u2019s disease", "PROBLEM", 0, 19], ["dementia", "PROBLEM", 48, 56], ["vascular dementia", "PROBLEM", 70, 87], ["predominant type", "OBSERVATION_MODIFIER", 28, 44], ["dementia", "OBSERVATION", 48, 56], ["vascular", "ANATOMY", 70, 78], ["dementia", "OBSERVATION", 79, 87]]], ["In contrast to western studies, the prevalence of Lewy body dementia was lower in Hong Kong Chinese, with a prevalence rate of 2.9% over a 2-year period.3 Similar to Caucasian populations, presence of the apolipoprotein epsilon-4 allele is associated with more rapid deterioration in cognitive function,4 and an association has also been observed between promoter polymorphism of the interlenkin-10 gene and Alzheimer\u2019s disease.5", [["body", "ANATOMY", 55, 59], ["Lewy body dementia", "DISEASE", 50, 68], ["Alzheimer\u2019s disease", "DISEASE", 408, 427], ["apolipoprotein epsilon-4", "GENE_OR_GENE_PRODUCT", 205, 229], ["interlenkin-10", "GENE_OR_GENE_PRODUCT", 384, 398], ["apolipoprotein epsilon-4 allele", "DNA", 205, 236], ["interlenkin-10 gene", "DNA", 384, 403], ["western studies", "TEST", 15, 30], ["Lewy body dementia", "PROBLEM", 50, 68], ["a prevalence rate", "TEST", 106, 123], ["the apolipoprotein epsilon", "TEST", 201, 227], ["more rapid deterioration in cognitive function", "PROBLEM", 256, 302], ["the interlenkin", "TREATMENT", 380, 395], ["Alzheimer\u2019s disease", "PROBLEM", 408, 427], ["Lewy body dementia", "OBSERVATION", 50, 68], ["lower", "OBSERVATION_MODIFIER", 73, 78], ["rapid", "OBSERVATION_MODIFIER", 261, 266], ["deterioration", "OBSERVATION", 267, 280]]]], "5c80832ecd995ec182c3a299d48662e65c686fd0": [["Mutations in the mitochondrial genome or in the nuclear genes related to mitochondrial functions are associated with a wide set of mitochondrial diseases that share some common changes in transcriptome.", [["mitochondrial genome", "ANATOMY", 17, 37], ["nuclear", "ANATOMY", 48, 55], ["mitochondrial", "ANATOMY", 73, 86], ["mitochondrial", "ANATOMY", 131, 144], ["mitochondrial diseases", "DISEASE", 131, 153], ["mitochondrial", "CELLULAR_COMPONENT", 17, 30], ["nuclear", "CELLULAR_COMPONENT", 48, 55], ["mitochondrial", "CELLULAR_COMPONENT", 73, 86], ["mitochondrial", "CELLULAR_COMPONENT", 131, 144], ["mitochondrial genome", "DNA", 17, 37], ["nuclear genes", "DNA", 48, 61], ["Mutations in the mitochondrial genome", "PROBLEM", 0, 37], ["mitochondrial functions", "PROBLEM", 73, 96], ["mitochondrial diseases", "PROBLEM", 131, 153], ["mitochondrial genome", "OBSERVATION", 17, 37], ["mitochondrial functions", "OBSERVATION", 73, 96], ["mitochondrial diseases", "OBSERVATION", 131, 153]]], ["1, 2 In particular, there are evidences for common induction of the unfolded protein response (UPR)-or the integrated stress response (ISR)-associated genes, including activating transcription factor 4 (ATF4) and its target genes, C/EBP homologous protein (CHOP) and asparagine synthetase (ASNS).", [["asparagine", "CHEMICAL", 267, 277], ["asparagine", "CHEMICAL", 267, 277], ["unfolded protein response", "GENE_OR_GENE_PRODUCT", 68, 93], ["UPR", "GENE_OR_GENE_PRODUCT", 95, 98], ["activating transcription factor 4", "GENE_OR_GENE_PRODUCT", 168, 201], ["ATF4", "GENE_OR_GENE_PRODUCT", 203, 207], ["C/EBP homologous protein", "GENE_OR_GENE_PRODUCT", 231, 255], ["CHOP", "GENE_OR_GENE_PRODUCT", 257, 261], ["asparagine synthetase", "GENE_OR_GENE_PRODUCT", 267, 288], ["ASNS", "GENE_OR_GENE_PRODUCT", 290, 294], ["stress response (ISR)-associated genes", "DNA", 118, 156], ["activating transcription factor 4", "PROTEIN", 168, 201], ["ATF4", "PROTEIN", 203, 207], ["target genes", "DNA", 217, 229], ["C/EBP homologous protein", "PROTEIN", 231, 255], ["CHOP", "PROTEIN", 257, 261], ["asparagine synthetase", "PROTEIN", 267, 288], ["ASNS", "PROTEIN", 290, 294], ["the unfolded protein response", "PROBLEM", 64, 93], ["the integrated stress response", "PROBLEM", 103, 133], ["ISR", "TEST", 135, 138], ["activating transcription factor", "TEST", 168, 199], ["C/EBP homologous protein (CHOP", "TREATMENT", 231, 261], ["asparagine synthetase", "TREATMENT", 267, 288]]], ["2, 3 Mitochondrial dysfunction induced by an inhibition of mitochondrial electron transfer chain (ETC) complex I with rotenone was also shown to induce the expression of the UPR/ISR genes ATF4 and CHOP.", [["Mitochondrial", "ANATOMY", 5, 18], ["mitochondrial", "ANATOMY", 59, 72], ["Mitochondrial dysfunction", "DISEASE", 5, 30], ["rotenone", "CHEMICAL", 118, 126], ["rotenone", "CHEMICAL", 118, 126], ["Mitochondrial", "CELLULAR_COMPONENT", 5, 18], ["mitochondrial", "CELLULAR_COMPONENT", 59, 72], ["electron transfer chain (ETC) complex I", "GENE_OR_GENE_PRODUCT", 73, 112], ["rotenone", "SIMPLE_CHEMICAL", 118, 126], ["UPR", "GENE_OR_GENE_PRODUCT", 174, 177], ["ISR", "GENE_OR_GENE_PRODUCT", 178, 181], ["ATF4", "GENE_OR_GENE_PRODUCT", 188, 192], ["CHOP", "GENE_OR_GENE_PRODUCT", 197, 201], ["mitochondrial electron transfer chain (ETC) complex I", "PROTEIN", 59, 112], ["UPR", "PROTEIN", 174, 177], ["ISR genes", "DNA", 178, 187], ["ATF4", "PROTEIN", 188, 192], ["CHOP", "PROTEIN", 197, 201], ["3 Mitochondrial dysfunction", "PROBLEM", 3, 30], ["CHOP", "TREATMENT", 197, 201], ["Mitochondrial dysfunction", "OBSERVATION", 5, 30]]], ["4 Environmental stresses induce rapid changes in gene expression that eventually alleviate cell damage and return cells to homeostasis.", [["cell", "ANATOMY", 91, 95], ["cells", "ANATOMY", 114, 119], ["cell", "CELL", 91, 95], ["cells", "CELL", 114, 119], ["rapid changes in gene expression", "PROBLEM", 32, 64], ["cell damage", "PROBLEM", 91, 102], ["rapid", "OBSERVATION_MODIFIER", 32, 37], ["cell damage", "OBSERVATION", 91, 102]]], ["Different environmental stresses induce the phosphorylation of translation initiation factor eIF2\u03b1 at Ser 51 by protein kinases PERK (ER stress), GCN2 (nutrient depletion), PKR (viral infection) or HRI (heme deprivation), resulting in the global repression of protein biosynthesis 5 that promotes viability of cells during mitochondrial dysfunction.", [["cells", "ANATOMY", 310, 315], ["mitochondrial", "ANATOMY", 323, 336], ["viral infection", "DISEASE", 178, 193], ["mitochondrial dysfunction", "DISEASE", 323, 348], ["Ser", "CHEMICAL", 102, 105], ["heme", "CHEMICAL", 203, 207], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 93, 98], ["Ser 51", "AMINO_ACID", 102, 108], ["PERK", "GENE_OR_GENE_PRODUCT", 128, 132], ["ER stress)", "GENE_OR_GENE_PRODUCT", 134, 144], ["GCN2", "GENE_OR_GENE_PRODUCT", 146, 150], ["PKR", "GENE_OR_GENE_PRODUCT", 173, 176], ["HRI", "GENE_OR_GENE_PRODUCT", 198, 201], ["cells", "CELL", 310, 315], ["mitochondrial", "CELLULAR_COMPONENT", 323, 336], ["translation initiation factor", "PROTEIN", 63, 92], ["eIF2\u03b1", "PROTEIN", 93, 98], ["Ser 51", "PROTEIN", 102, 108], ["protein kinases", "PROTEIN", 112, 127], ["PERK", "PROTEIN", 128, 132], ["ER", "PROTEIN", 134, 136], ["GCN2", "PROTEIN", 146, 150], ["PKR", "PROTEIN", 173, 176], ["HRI", "PROTEIN", 198, 201], ["heme", "PROTEIN", 203, 207], ["protein biosynthesis 5", "PROTEIN", 260, 282], ["Different environmental stresses", "PROBLEM", 0, 32], ["protein kinases", "TEST", 112, 127], ["ER stress", "TEST", 134, 143], ["GCN2 (nutrient depletion", "PROBLEM", 146, 170], ["PKR (viral infection", "PROBLEM", 173, 193], ["HRI (heme deprivation", "PROBLEM", 198, 219], ["the global repression of protein biosynthesis", "PROBLEM", 235, 280], ["mitochondrial dysfunction", "PROBLEM", 323, 348], ["nutrient depletion", "OBSERVATION", 152, 170], ["protein biosynthesis", "OBSERVATION", 260, 280], ["viability of cells", "OBSERVATION", 297, 315], ["mitochondrial dysfunction", "OBSERVATION", 323, 348]]], ["6 In addition to the global attenuation of translation, eIF2\u03b1 phosphorylation leads to an increased translation of mRNAs with small upstream open reading frames, including the transcription factor ATF4.", [["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 56, 61], ["ATF4", "GENE_OR_GENE_PRODUCT", 197, 201], ["eIF2\u03b1", "PROTEIN", 56, 61], ["mRNAs", "RNA", 115, 120], ["small upstream open reading frames", "DNA", 126, 160], ["transcription factor", "PROTEIN", 176, 196], ["ATF4", "PROTEIN", 197, 201], ["eIF2\u03b1 phosphorylation", "TREATMENT", 56, 77], ["an increased translation of mRNAs", "PROBLEM", 87, 120], ["small upstream open reading frames", "PROBLEM", 126, 160], ["attenuation", "OBSERVATION_MODIFIER", 28, 39], ["increased", "OBSERVATION_MODIFIER", 90, 99], ["small", "OBSERVATION_MODIFIER", 126, 131], ["upstream", "OBSERVATION_MODIFIER", 132, 140]]], ["5 ATF4 is a transcriptional activator of the genes involved in nutrient uptake, metabolism, redox regulation and apoptosis.", [["ATF4", "GENE_OR_GENE_PRODUCT", 2, 6], ["ATF4", "PROTEIN", 2, 6], ["transcriptional activator", "PROTEIN", 12, 37], ["nutrient uptake", "PROBLEM", 63, 78], ["apoptosis", "PROBLEM", 113, 122], ["nutrient uptake", "OBSERVATION", 63, 78]]], ["ATF4 acts as a common downstream target that integrates signals from different eIF2 kinases, and therefore the eIF2\u03b1/ATF4 pathway is commonly dubbed as ISR.", [["ATF4", "GENE_OR_GENE_PRODUCT", 0, 4], ["eIF2", "GENE_OR_GENE_PRODUCT", 79, 83], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 111, 116], ["ATF4", "GENE_OR_GENE_PRODUCT", 117, 121], ["ATF4", "PROTEIN", 0, 4], ["eIF2 kinases", "PROTEIN", 79, 91], ["eIF2\u03b1", "PROTEIN", 111, 116], ["ATF4", "PROTEIN", 117, 121], ["different eIF2 kinases", "TEST", 69, 91], ["the eIF2\u03b1/ATF4 pathway", "TREATMENT", 107, 129], ["eIF2 kinases", "OBSERVATION", 79, 91]]]], "89dd411ddccfdb3690c8adcc7e8542f0b55d3212": [["( Figure 1C and 1D and Movies II and III in the Data Supplement).", [["Figure 1C", "TEST", 2, 11]]], ["Because of progressive cardiogenic shock (invasive blood pressure, 60/40 mm Hg), vasopressors and intra-aortic balloon pump were initiated for hemodynamic support ( Figure 1E ).", [["blood", "ANATOMY", 51, 56], ["intra-aortic", "ANATOMY", 98, 110], ["cardiogenic shock", "DISEASE", 23, 40], ["Hg", "CHEMICAL", 76, 78], ["blood", "ORGANISM_SUBSTANCE", 51, 56], ["progressive cardiogenic shock", "PROBLEM", 11, 40], ["invasive blood pressure", "TEST", 42, 65], ["vasopressors", "TREATMENT", 81, 93], ["intra-aortic balloon pump", "TREATMENT", 98, 123], ["hemodynamic support", "TREATMENT", 143, 162], ["progressive", "OBSERVATION_MODIFIER", 11, 22], ["cardiogenic shock", "OBSERVATION", 23, 40], ["intra-aortic", "ANATOMY", 98, 110], ["balloon pump", "OBSERVATION", 111, 123]]], ["The patient was transferred to the intensive care unit.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["Chest radiography showed pulmonary congestion without signs of interstitial pneumonia ( Figure 1F) .", [["pulmonary", "ANATOMY", 25, 34], ["interstitial", "ANATOMY", 63, 75], ["pulmonary congestion", "DISEASE", 25, 45], ["interstitial pneumonia", "DISEASE", 63, 85], ["pulmonary", "ORGAN", 25, 34], ["Chest radiography", "TEST", 0, 17], ["pulmonary congestion", "PROBLEM", 25, 45], ["interstitial pneumonia", "PROBLEM", 63, 85], ["pulmonary", "ANATOMY", 25, 34], ["congestion", "OBSERVATION", 35, 45], ["without signs of", "UNCERTAINTY", 46, 62], ["interstitial", "ANATOMY_MODIFIER", 63, 75], ["pneumonia", "OBSERVATION", 76, 85]]]], "57c47ce2ae13578c7611519312f09871bc0c6eda": [["IntroductionAfter 17 years, physicians in Taiwan face another novel coronavirus outbreak originating in China.", [["coronavirus", "DISEASE", 68, 79], ["coronavirus", "ORGANISM", 68, 79], ["coronavirus", "OBSERVATION", 68, 79]]], ["1 With the past experience of severe acute respiratory syndrome (SARS), 2,3 we respond quickly this time.", [["acute respiratory syndrome", "DISEASE", 37, 63], ["SARS", "DISEASE", 65, 69], ["severe acute respiratory syndrome", "PROBLEM", 30, 63], ["severe", "OBSERVATION_MODIFIER", 30, 36], ["acute", "OBSERVATION_MODIFIER", 37, 42], ["respiratory syndrome", "OBSERVATION", 43, 63]]], ["However, a new pathogen inevitably raises new challenges.", [["a new pathogen", "PROBLEM", 9, 23], ["new", "OBSERVATION_MODIFIER", 11, 14], ["pathogen", "OBSERVATION", 15, 23], ["new", "OBSERVATION_MODIFIER", 42, 45]]], ["4 Clinical data and experience sharing may contribute to the control of emerging infectious diseases.", [["infectious diseases", "DISEASE", 81, 100], ["emerging infectious diseases", "PROBLEM", 72, 100], ["infectious", "OBSERVATION", 81, 91]]], ["5 Here we present two cases of 2019 novel coronavirus disease (COVID-19).Case reports Case 1A 74 year-old female visitor from Wuhan City, China presented to the hospital with fever, malaise, and poor appetite.", [["coronavirus disease", "DISEASE", 42, 61], ["fever", "DISEASE", 175, 180], ["malaise", "DISEASE", 182, 189], ["coronavirus", "ORGANISM", 42, 53], ["female", "ORGANISM", 106, 112], ["novel coronavirus disease", "PROBLEM", 36, 61], ["COVID", "TEST", 63, 68], ["fever", "PROBLEM", 175, 180], ["malaise", "PROBLEM", 182, 189], ["poor appetite", "PROBLEM", 195, 208], ["coronavirus disease", "OBSERVATION", 42, 61], ["fever", "OBSERVATION", 175, 180], ["malaise", "OBSERVATION", 182, 189]]], ["She reported no underlying medical conditions.", [["underlying medical conditions", "PROBLEM", 16, 45], ["no", "UNCERTAINTY", 13, 15]]], ["There was no chillness, cough, rhinorrhea, sore throat, myalgia, chest discomfort, dyspnea, abdominal pain, or diarrhea.", [["chest", "ANATOMY", 65, 70], ["abdominal", "ANATOMY", 92, 101], ["chillness", "DISEASE", 13, 22], ["cough", "DISEASE", 24, 29], ["rhinorrhea", "DISEASE", 31, 41], ["sore throat", "DISEASE", 43, 54], ["myalgia", "DISEASE", 56, 63], ["chest discomfort", "DISEASE", 65, 81], ["dyspnea", "DISEASE", 83, 90], ["abdominal pain", "DISEASE", 92, 106], ["diarrhea", "DISEASE", 111, 119], ["chest", "ORGANISM_SUBDIVISION", 65, 70], ["abdominal", "ORGANISM_SUBDIVISION", 92, 101], ["chillness", "PROBLEM", 13, 22], ["cough", "PROBLEM", 24, 29], ["rhinorrhea", "PROBLEM", 31, 41], ["sore throat", "PROBLEM", 43, 54], ["myalgia", "PROBLEM", 56, 63], ["chest discomfort", "PROBLEM", 65, 81], ["dyspnea", "PROBLEM", 83, 90], ["abdominal pain", "PROBLEM", 92, 106], ["diarrhea", "PROBLEM", 111, 119], ["no", "UNCERTAINTY", 10, 12], ["chillness", "OBSERVATION", 13, 22], ["sore throat", "ANATOMY", 43, 54], ["chest", "ANATOMY", 65, 70], ["abdominal", "ANATOMY", 92, 101], ["pain", "OBSERVATION", 102, 106], ["diarrhea", "OBSERVATION", 111, 119]]], ["Physical examination disclosed body temperature of 38.1 C, blood pressure of 129/68 mm Hg, heart rate of 79 beats per minute, respiratory rate of 18 breaths per minute.", [["body", "ANATOMY", 31, 35], ["blood", "ANATOMY", 59, 64], ["heart", "ANATOMY", 91, 96], ["respiratory", "ANATOMY", 126, 137], ["Hg", "CHEMICAL", 87, 89], ["body", "ORGANISM_SUBDIVISION", 31, 35], ["blood", "ORGANISM_SUBSTANCE", 59, 64], ["heart", "ORGAN", 91, 96], ["Physical examination", "TEST", 0, 20], ["body temperature", "TEST", 31, 47], ["blood pressure", "TEST", 59, 73], ["heart rate", "TEST", 91, 101], ["respiratory rate", "TEST", 126, 142]]], ["Chest radiography (CXR) revealed mild increased infiltration over bilateral lower lung field.", [["lower lung", "ANATOMY", 76, 86], ["lung", "ORGAN", 82, 86], ["Chest radiography", "TEST", 0, 17], ["CXR", "TEST", 19, 22], ["mild increased infiltration over bilateral lower lung field", "PROBLEM", 33, 92], ["mild", "OBSERVATION_MODIFIER", 33, 37], ["increased", "OBSERVATION_MODIFIER", 38, 47], ["infiltration", "OBSERVATION", 48, 60], ["bilateral", "ANATOMY_MODIFIER", 66, 75], ["lower", "ANATOMY_MODIFIER", 76, 81], ["lung", "ANATOMY", 82, 86], ["field", "ANATOMY_MODIFIER", 87, 92]]], ["Peripheral-blood white-cell count was 3770 per cubic millimeter (with 62.3% neutrophils and 32.1% lymphocytes).", [["Peripheral-blood white-cell", "ANATOMY", 0, 27], ["neutrophils", "ANATOMY", 76, 87], ["lymphocytes", "ANATOMY", 98, 109], ["blood", "ORGANISM_SUBSTANCE", 11, 16], ["white-cell", "CELL", 17, 27], ["neutrophils", "CELL", 76, 87], ["lymphocytes", "CELL", 98, 109], ["neutrophils", "CELL_TYPE", 76, 87], ["lymphocytes", "CELL_TYPE", 98, 109], ["blood white-cell count", "TEST", 11, 33], ["neutrophils", "TEST", 76, 87], ["lymphocytes", "TEST", 98, 109], ["blood", "ANATOMY", 11, 16], ["cubic millimeter", "OBSERVATION_MODIFIER", 47, 63]]], ["Nasopharyngeal swab was positive for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) by real-time reverse-transcriptase polymerase chain reaction (rRT-PCR) assay performed by the Centers for Diseases Control in Taiwan (Taiwan CDC).Case reports Case 1On day 6 in hospital, the patient remained febrile, malaise and poor appetite.", [["Nasopharyngeal swab", "ANATOMY", 0, 19], ["acute respiratory syndrome coronavirus", "DISEASE", 44, 82], ["febrile", "DISEASE", 306, 313], ["Nasopharyngeal swab", "ORGANISM_SUBSTANCE", 0, 19], ["SARS-CoV-2", "ORGANISM", 86, 96], ["patient", "ORGANISM", 289, 296], ["patient", "SPECIES", 289, 296], ["severe acute respiratory syndrome coronavirus", "SPECIES", 37, 82], ["SARS-CoV-2", "SPECIES", 86, 96], ["Nasopharyngeal swab", "TEST", 0, 19], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 37, 82], ["SARS", "TEST", 86, 90], ["CoV", "TEST", 91, 94], ["transcriptase polymerase chain reaction", "PROBLEM", 119, 158], ["rRT-PCR", "TEST", 160, 167], ["febrile", "PROBLEM", 306, 313], ["malaise", "PROBLEM", 315, 322], ["poor appetite", "PROBLEM", 327, 340], ["positive for", "UNCERTAINTY", 24, 36], ["severe", "OBSERVATION_MODIFIER", 37, 43], ["acute", "OBSERVATION_MODIFIER", 44, 49], ["respiratory syndrome", "OBSERVATION", 50, 70], ["febrile", "OBSERVATION", 306, 313]]], ["Follow-up CXR revealed increasing opacity at right middle and lower lung fields (Fig. 1A) .", [["right middle", "ANATOMY", 45, 57], ["lower lung", "ANATOMY", 62, 72], ["lung", "ORGAN", 68, 72], ["Follow-up CXR", "TEST", 0, 13], ["increasing opacity at right middle and lower lung fields", "PROBLEM", 23, 79], ["increasing", "OBSERVATION_MODIFIER", 23, 33], ["opacity", "OBSERVATION", 34, 41], ["right", "ANATOMY_MODIFIER", 45, 50], ["middle", "ANATOMY_MODIFIER", 51, 57], ["lower", "ANATOMY_MODIFIER", 62, 67], ["lung", "ANATOMY", 68, 72], ["fields", "ANATOMY_MODIFIER", 73, 79]]], ["Levofloxacin was initiated.", [["Levofloxacin", "CHEMICAL", 0, 12], ["Levofloxacin", "CHEMICAL", 0, 12], ["Levofloxacin", "SIMPLE_CHEMICAL", 0, 12], ["Levofloxacin", "TREATMENT", 0, 12]]], ["On hospital day 12, after a 6-day course of levofloxacin, her fever abated with improved appetite and physical activity.", [["levofloxacin", "CHEMICAL", 44, 56], ["fever", "DISEASE", 62, 67], ["levofloxacin", "CHEMICAL", 44, 56], ["levofloxacin", "SIMPLE_CHEMICAL", 44, 56], ["levofloxacin", "TREATMENT", 44, 56], ["her fever", "PROBLEM", 58, 67]]], ["She became free of symptoms afterward.Case 2A 73 year-old previously health female visitor returning from Wuhan City 3 days ago presented to the hospital with dry cough, fever, malaise and poor appetite.", [["dry cough", "DISEASE", 159, 168], ["fever", "DISEASE", 170, 175], ["malaise", "DISEASE", 177, 184], ["symptoms", "PROBLEM", 19, 27], ["dry cough", "PROBLEM", 159, 168], ["fever", "PROBLEM", 170, 175], ["malaise", "PROBLEM", 177, 184], ["poor appetite", "PROBLEM", 189, 202], ["free", "OBSERVATION_MODIFIER", 11, 15], ["cough", "OBSERVATION", 163, 168], ["fever", "OBSERVATION", 170, 175]]], ["She denied chillness, rhinorrhea, sore throat, chest discomfort, myalgia, dyspnea, abdominal pain, or diarrhea.", [["chest", "ANATOMY", 47, 52], ["abdominal", "ANATOMY", 83, 92], ["chillness", "DISEASE", 11, 20], ["rhinorrhea", "DISEASE", 22, 32], ["sore throat", "DISEASE", 34, 45], ["chest discomfort", "DISEASE", 47, 63], ["myalgia", "DISEASE", 65, 72], ["dyspnea", "DISEASE", 74, 81], ["abdominal pain", "DISEASE", 83, 97], ["diarrhea", "DISEASE", 102, 110], ["chest", "ORGANISM_SUBDIVISION", 47, 52], ["abdominal", "ORGANISM_SUBDIVISION", 83, 92], ["chillness", "PROBLEM", 11, 20], ["rhinorrhea", "PROBLEM", 22, 32], ["sore throat", "PROBLEM", 34, 45], ["chest discomfort", "PROBLEM", 47, 63], ["myalgia", "PROBLEM", 65, 72], ["dyspnea", "PROBLEM", 74, 81], ["abdominal pain", "PROBLEM", 83, 97], ["diarrhea", "PROBLEM", 102, 110], ["rhinorrhea", "OBSERVATION", 22, 32], ["sore throat", "ANATOMY", 34, 45], ["chest", "ANATOMY", 47, 52], ["myalgia", "OBSERVATION", 65, 72], ["abdominal", "ANATOMY", 83, 92], ["pain", "OBSERVATION", 93, 97], ["diarrhea", "OBSERVATION", 102, 110]]], ["Her body temperature was 38.7 C with blood pressure of 117/47 mm Hg, heart rate of 82 beats per minute, respiratory rate of 18 breaths per minute.", [["body", "ANATOMY", 4, 8], ["blood", "ANATOMY", 37, 42], ["heart", "ANATOMY", 69, 74], ["Hg", "CHEMICAL", 65, 67], ["body", "ORGANISM_SUBDIVISION", 4, 8], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["heart", "ORGAN", 69, 74], ["Her body temperature", "TEST", 0, 20], ["blood pressure", "TEST", 37, 51], ["heart rate", "TEST", 69, 79], ["respiratory rate", "TEST", 104, 120]]], ["CXR demonstrated non-specific mild increased infiltration over bilateral lower lung field.", [["lower lung", "ANATOMY", 73, 83], ["lung", "ORGAN", 79, 83], ["CXR", "PROTEIN", 0, 3], ["CXR", "TEST", 0, 3], ["non-specific mild increased infiltration over bilateral lower lung field", "PROBLEM", 17, 89], ["non-specific", "OBSERVATION_MODIFIER", 17, 29], ["mild", "OBSERVATION_MODIFIER", 30, 34], ["increased", "OBSERVATION_MODIFIER", 35, 44], ["infiltration", "OBSERVATION", 45, 57], ["bilateral", "ANATOMY_MODIFIER", 63, 72], ["lower", "ANATOMY_MODIFIER", 73, 78], ["lung", "ANATOMY", 79, 83], ["field", "ANATOMY_MODIFIER", 84, 89]]], ["Peripheral-blood white-cell count was 3420 per cubic millimeter (with 69.3% neutrophils and 26.9% lymphocytes).Case 2Nasopharyngeal swab was positive for SARS-CoV-2 by rRT-PCR assay reported from Taiwan CDC.Case 2On day 6 in hospital, the patient remained febrile, malaise and poor appetite.", [["Peripheral-blood white-cell", "ANATOMY", 0, 27], ["neutrophils", "ANATOMY", 76, 87], ["lymphocytes", "ANATOMY", 98, 109], ["2Nasopharyngeal swab", "ANATOMY", 116, 136], ["febrile", "DISEASE", 256, 263], ["blood", "ORGANISM_SUBSTANCE", 11, 16], ["white-cell", "CELL", 17, 27], ["neutrophils", "CELL", 76, 87], ["lymphocytes", "CELL", 98, 109], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 154, 164], ["patient", "ORGANISM", 239, 246], ["neutrophils", "CELL_TYPE", 76, 87], ["lymphocytes", "CELL_TYPE", 98, 109], ["patient", "SPECIES", 239, 246], ["SARS-CoV", "SPECIES", 154, 162], ["blood white-cell count", "TEST", 11, 33], ["neutrophils", "TEST", 76, 87], ["lymphocytes", "TEST", 98, 109], ["Case 2Nasopharyngeal swab", "TEST", 111, 136], ["SARS", "PROBLEM", 154, 158], ["CoV", "TEST", 159, 162], ["rRT", "TEST", 168, 171], ["PCR assay", "TEST", 172, 181], ["febrile", "PROBLEM", 256, 263], ["malaise", "PROBLEM", 265, 272], ["poor appetite", "PROBLEM", 277, 290], ["blood", "ANATOMY", 11, 16], ["cubic millimeter", "OBSERVATION_MODIFIER", 47, 63], ["febrile", "OBSERVATION", 256, 263]]], ["She reported worsening of cough.", [["cough", "DISEASE", 26, 31], ["cough", "PROBLEM", 26, 31], ["worsening", "OBSERVATION_MODIFIER", 13, 22], ["cough", "OBSERVATION", 26, 31]]], ["Follow-up CXR revealed patchy consolidation over bilateral lower lung field (Fig. 1B) .", [["lower lung", "ANATOMY", 59, 69], ["lung", "ORGAN", 65, 69], ["Follow-up CXR", "TEST", 0, 13], ["patchy consolidation over bilateral lower lung field", "PROBLEM", 23, 75], ["patchy", "OBSERVATION_MODIFIER", 23, 29], ["consolidation", "OBSERVATION", 30, 43], ["bilateral", "ANATOMY_MODIFIER", 49, 58], ["lower", "ANATOMY_MODIFIER", 59, 64], ["lung", "ANATOMY", 65, 69], ["field", "ANATOMY_MODIFIER", 70, 75]]], ["Parenteral cefepime and oral clarithromycin therapy were initiated.", [["Parenteral", "ANATOMY", 0, 10], ["oral", "ANATOMY", 24, 28], ["cefepime", "CHEMICAL", 11, 19], ["clarithromycin", "CHEMICAL", 29, 43], ["cefepime", "CHEMICAL", 11, 19], ["clarithromycin", "CHEMICAL", 29, 43], ["cefepime", "SIMPLE_CHEMICAL", 11, 19], ["oral", "ORGANISM_SUBDIVISION", 24, 28], ["clarithromycin", "SIMPLE_CHEMICAL", 29, 43], ["Parenteral cefepime", "TREATMENT", 0, 19], ["oral clarithromycin therapy", "TREATMENT", 24, 51]]], ["On day 9, she was afebrile with improved general condition.", [["afebrile", "PROBLEM", 18, 26]]], ["Antimicrobial therapy was shifted to oral moxifloxacin.", [["oral", "ANATOMY", 37, 41], ["moxifloxacin", "CHEMICAL", 42, 54], ["moxifloxacin", "CHEMICAL", 42, 54], ["oral", "ORGANISM_SUBDIVISION", 37, 41], ["moxifloxacin", "SIMPLE_CHEMICAL", 42, 54], ["Antimicrobial therapy", "TREATMENT", 0, 21], ["oral moxifloxacin", "TREATMENT", 37, 54]]], ["She remained free of symptoms afterward.DiscussionThe nonspecific presentations of these two cases are consistent with early reports of COVID-19 from China.", [["symptoms", "PROBLEM", 21, 29], ["COVID", "TEST", 136, 141], ["free", "OBSERVATION_MODIFIER", 13, 17], ["consistent with", "UNCERTAINTY", 103, 118]]], ["6, 7 Fever remains the most common complain.", [["Fever", "DISEASE", 5, 10], ["Fever", "PROBLEM", 5, 10], ["most common", "OBSERVATION_MODIFIER", 23, 34]]], ["Some cases didn't have cough, and upper respiratory tract infections (URI) symptoms such as rhinorrhea and sore throat were rare.", [["upper respiratory tract", "ANATOMY", 34, 57], ["cough", "DISEASE", 23, 28], ["upper respiratory tract infections", "DISEASE", 34, 68], ["URI", "DISEASE", 70, 73], ["rhinorrhea", "DISEASE", 92, 102], ["sore throat", "DISEASE", 107, 118], ["upper", "ORGANISM_SUBDIVISION", 34, 39], ["respiratory tract", "ORGANISM_SUBDIVISION", 40, 57], ["cough", "PROBLEM", 23, 28], ["upper respiratory tract infections", "PROBLEM", 34, 68], ["URI) symptoms", "PROBLEM", 70, 83], ["rhinorrhea", "PROBLEM", 92, 102], ["sore throat", "PROBLEM", 107, 118], ["cough", "OBSERVATION", 23, 28], ["upper", "ANATOMY_MODIFIER", 34, 39], ["respiratory tract", "ANATOMY", 40, 57], ["sore throat", "ANATOMY", 107, 118]]], ["Similar clinical manifestations have been reported in SARS, 8 since URI symptoms were uncommon and cough was not always present in SARS patients.", [["SARS", "DISEASE", 54, 58], ["cough", "DISEASE", 99, 104], ["SARS", "DISEASE", 131, 135], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144], ["Similar clinical manifestations", "PROBLEM", 0, 31], ["URI symptoms", "PROBLEM", 68, 80], ["cough", "PROBLEM", 99, 104]]], ["Although routine laboratory testing was not diagnostic, certain patterns of laboratory abnormalities were observed in COVID-19.", [["routine laboratory testing", "TEST", 9, 35], ["laboratory abnormalities", "PROBLEM", 76, 100], ["COVID", "TEST", 118, 123]]], ["Leukopenia, lymphopenia, anemia, elevation of liver enzymes and lactate dehydrogenase, have been reported in different series.", [["liver", "ANATOMY", 46, 51], ["Leukopenia", "DISEASE", 0, 10], ["lymphopenia", "DISEASE", 12, 23], ["anemia", "DISEASE", 25, 31], ["lactate", "CHEMICAL", 64, 71], ["lactate", "CHEMICAL", 64, 71], ["liver", "ORGAN", 46, 51], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 64, 85], ["liver enzymes", "PROTEIN", 46, 59], ["lactate dehydrogenase", "PROTEIN", 64, 85], ["Leukopenia", "PROBLEM", 0, 10], ["lymphopenia", "PROBLEM", 12, 23], ["anemia", "PROBLEM", 25, 31], ["elevation of liver enzymes", "PROBLEM", 33, 59], ["lactate dehydrogenase", "PROBLEM", 64, 85], ["lymphopenia", "OBSERVATION", 12, 23], ["anemia", "OBSERVATION", 25, 31], ["elevation", "OBSERVATION_MODIFIER", 33, 42], ["liver", "ANATOMY", 46, 51], ["lactate dehydrogenase", "OBSERVATION", 64, 85]]], ["6, 7 Also, a similar observation has been made in SARS.", [["SARS", "DISEASE", 50, 54]]], ["8 The clinical utility of CXR in the early diagnosis of COVID-19 is questionable.", [["CXR", "PROTEIN", 26, 29], ["CXR", "TEST", 26, 29], ["COVID", "TEST", 56, 61]]], ["In this report, initial CXR of both cases was non-diagnostic, and more evident radiological abnormalities were detected on day 6.", [["CXR", "PROTEIN", 24, 27], ["initial CXR", "TEST", 16, 27], ["radiological abnormalities", "PROBLEM", 79, 105]]], ["Similar findings were reported in the first case of COVID-19 in the United States, and pulmonary patch/consolidation was not detected by CXR until day 5 in hospital (day 9 of illness).", [["pulmonary", "ANATOMY", 87, 96], ["pulmonary", "ORGAN", 87, 96], ["CXR", "PROTEIN", 137, 140], ["COVID", "TEST", 52, 57], ["pulmonary patch/consolidation", "PROBLEM", 87, 116], ["CXR", "TEST", 137, 140], ["pulmonary", "ANATOMY", 87, 96], ["patch", "OBSERVATION_MODIFIER", 97, 102], ["consolidation", "OBSERVATION", 103, 116]]], ["9 Similarly, in a case series of SARS patients from the Amoy Gardens housing estate, 29.3% (22/75) cases had normal CXR on admission, however four of 22 cases developed acute respiratory distress syndrome (ARDS) afterward.", [["respiratory", "ANATOMY", 175, 186], ["SARS", "DISEASE", 33, 37], ["acute respiratory distress syndrome", "DISEASE", 169, 204], ["ARDS", "DISEASE", 206, 210], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["acute respiratory distress syndrome", "PROBLEM", 169, 204], ["ARDS", "PROBLEM", 206, 210], ["acute", "OBSERVATION_MODIFIER", 169, 174], ["respiratory distress syndrome", "OBSERVATION", 175, 204], ["ARDS", "OBSERVATION", 206, 210]]], ["8 In general, 80% (60/ 75) of cases experienced radiological worsening at a mean of 7.4 days.", [["radiological worsening", "PROBLEM", 48, 70], ["worsening", "OBSERVATION_MODIFIER", 61, 70]]], ["8 Both unifocal and bilateral lung infiltration could be observed in our report.", [["lung", "ANATOMY", 30, 34], ["lung", "ORGAN", 30, 34], ["bilateral lung infiltration", "PROBLEM", 20, 47], ["unifocal", "OBSERVATION_MODIFIER", 7, 15], ["bilateral", "ANATOMY_MODIFIER", 20, 29], ["lung", "ANATOMY", 30, 34], ["infiltration", "OBSERVATION", 35, 47]]], ["Of 99 COVID-19 cases in China, 25% presented with unilateral pneumonia and 75% presented with bilateral pneumonia.", [["pneumonia", "DISEASE", 61, 70], ["pneumonia", "DISEASE", 104, 113], ["COVID", "TEST", 6, 11], ["unilateral pneumonia", "PROBLEM", 50, 70], ["bilateral pneumonia", "PROBLEM", 94, 113], ["unilateral", "OBSERVATION_MODIFIER", 50, 60], ["pneumonia", "OBSERVATION", 61, 70], ["bilateral", "ANATOMY_MODIFIER", 94, 103], ["pneumonia", "OBSERVATION", 104, 113]]], ["7 As discussed above, COVID-19 cannot be reliably distinguished by clinical, radiologic, or laboratory criteria from other causes of pneumonia.", [["pneumonia", "DISEASE", 133, 142], ["COVID-19", "DNA", 22, 30], ["COVID", "TEST", 22, 27], ["laboratory criteria", "TEST", 92, 111], ["pneumonia", "PROBLEM", 133, 142], ["pneumonia", "OBSERVATION", 133, 142]]], ["Moreover, in the clinical setting of community transmission, exposure or travel history alone would be not useful to identify the risk population of COVID-19 cases.", [["COVID", "TEST", 149, 154]]], ["At the present time, RT-PCR assays were most widely used to detect SARS-CoV-2.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 67, 77], ["SARS-CoV", "SPECIES", 67, 75], ["RT-PCR assays", "TEST", 21, 34], ["SARS", "TEST", 67, 71], ["CoV", "TEST", 72, 75]]], ["Current data are insufficient to determine their sensitivity and specificity for SARS-CoV-2.", [["SARS", "DISEASE", 81, 85], ["SARS-CoV", "SPECIES", 81, 89], ["Current data", "TEST", 0, 12], ["SARS", "TEST", 81, 85], ["CoV", "TEST", 86, 89]]], ["A previous study demonstrated SARS virus could be detected in approximately one-third of patients during early phase of the illness, and most frequently during the second week of illness.", [["SARS virus", "DISEASE", 30, 40], ["illness", "DISEASE", 124, 131], ["SARS virus", "ORGANISM", 30, 40], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["SARS virus", "SPECIES", 30, 40], ["A previous study", "TEST", 0, 16], ["SARS virus", "PROBLEM", 30, 40], ["the illness", "PROBLEM", 120, 131], ["illness", "PROBLEM", 179, 186], ["SARS virus", "OBSERVATION", 30, 40]]], ["8 We believe that the diagnostic performance of molecular testing improves during the decades.", [["molecular testing", "TEST", 48, 65]]], ["However, more data are needed to address the issue.DiscussionAnother challenge is the surge of clinical needs of laboratory testing.", [["laboratory testing", "TEST", 113, 131]]], ["It is anticipated that there will be an overwhelming demand for the supply chain of testing reagents and laboratory equipment, and the availability of well trained and experienced staff during the outbreak.", [["testing reagents", "TEST", 84, 100]]], ["Feng et al. proposed a CRISPR-based technique for the diagnosis of COVID-19 (https://www. broadinstitute.org/files/publications/special/COVID-19% 20detection%20(updated).pdf).", [["CRISPR", "DNA", 23, 29], ["pdf", "DNA", 170, 173], ["COVID", "TEST", 67, 72], ["special/COVID", "TREATMENT", 128, 141]]], ["After RNA extraction, the test result could be read using a dipstick in less than an hour.", [["RNA extraction", "TREATMENT", 6, 20], ["the test", "TEST", 22, 30], ["a dipstick", "TEST", 58, 68]]], ["RNA-based metagenomic sequencing is another promising approach, and has been used to diagnose COVID-19 in the first cluster related to the Huanan Seafood Market in China.", [["COVID-19", "DNA", 94, 102], ["RNA", "TEST", 0, 3], ["COVID", "TEST", 94, 99], ["metagenomic", "OBSERVATION", 10, 21]]], ["10 Currently, clinical management and treatment of COVID-19 is largely supportive.", [["clinical management", "TREATMENT", 14, 33], ["treatment of COVID", "TREATMENT", 38, 56]]], ["In the cases of pneumonia, our diagnostic capacity could be hindered by the nature of isolation units.", [["pneumonia", "DISEASE", 16, 25], ["pneumonia", "PROBLEM", 16, 25], ["our diagnostic capacity", "TEST", 27, 50], ["isolation units", "TREATMENT", 86, 101], ["pneumonia", "OBSERVATION", 16, 25]]], ["For example, for the first COVID-19 case in the United States, only point-of-care laboratory testing was permitted initially.", [["laboratory testing", "TEST", 82, 100]]], ["9 The current rate of co-infection and distribution of coexisting organisms in the cases of COVID-19 remain undefined.", [["COVID-19", "CHEMICAL", 92, 100], ["COVID-19", "CHEMICAL", 92, 100], ["co-infection", "PROBLEM", 22, 34], ["coexisting organisms", "PROBLEM", 55, 75], ["COVID", "TEST", 92, 97], ["co-infection", "OBSERVATION", 22, 34], ["coexisting organisms", "OBSERVATION", 55, 75]]], ["Of note, current evidence suggests that co-infection is not uncommon in the patients with community-acquired pneumonia.", [["co-infection", "DISEASE", 40, 52], ["pneumonia", "DISEASE", 109, 118], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["co-infection", "PROBLEM", 40, 52], ["community-acquired pneumonia", "PROBLEM", 90, 118], ["co-infection", "OBSERVATION", 40, 52], ["pneumonia", "OBSERVATION", 109, 118]]], ["11 In a prospective study of 2259 patients with pneumonia and specimens submitted for comprehensive bacterial and viral testing, etiologic agents were detected in only 38% cases.", [["specimens", "ANATOMY", 62, 71], ["pneumonia", "DISEASE", 48, 57], ["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["a prospective study", "TEST", 6, 25], ["pneumonia", "PROBLEM", 48, 57], ["specimens", "TEST", 62, 71], ["comprehensive bacterial and viral testing", "TEST", 86, 127], ["pneumonia", "OBSERVATION", 48, 57]]], ["Among these cases, the percentages of co-infections were associated with the severity and geographic regions.", [["co-infections", "DISEASE", 38, 51], ["co-infections", "PROBLEM", 38, 51], ["co-infections", "OBSERVATION", 38, 51]]], ["11 Clinical guideline for the treatment of community-acquired pneumonia in Taiwan shall be considered for these cases.", [["pneumonia", "DISEASE", 62, 71], ["community-acquired pneumonia", "PROBLEM", 43, 71], ["pneumonia", "OBSERVATION", 62, 71]]], ["12 In conclusion, we reported the clinical features of two patients with COVID-19 in Taiwan, and highlight the nonspecific nature of clinical presentations of COVID-19 and the importance of laboratory-based diagnosis.Declaration of Competing InterestThe authors declare no conflicts of interest.", [["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["COVID", "TEST", 73, 78], ["COVID", "TEST", 159, 164], ["nonspecific", "OBSERVATION_MODIFIER", 111, 122]]]], "PMC7158302": [["AnatomyThe regional lymph node groups of the head and neck are shown in Figure 57-1.", [["lymph node", "ANATOMY", 20, 30], ["head", "ANATOMY", 45, 49], ["neck", "ANATOMY", 54, 58], ["lymph node", "MULTI-TISSUE_STRUCTURE", 20, 30], ["head", "ORGANISM_SUBDIVISION", 45, 49], ["neck", "ORGAN", 54, 58], ["regional", "OBSERVATION_MODIFIER", 11, 19], ["lymph node", "OBSERVATION", 20, 30], ["head", "ANATOMY", 45, 49], ["neck", "ANATOMY", 54, 58]]], ["The precise borders for these groups have been classified by the American Head and Neck Society and are shown in Figure 57-2.4 Drainage to lymphatic basins usually follows predictable, anatomic routes, with the nomenclature reflecting the site of the lymph nodes.", [["lymphatic basins", "ANATOMY", 139, 155], ["lymph nodes", "ANATOMY", 251, 262], ["lymphatic", "MULTI-TISSUE_STRUCTURE", 139, 148], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 251, 262], ["Figure", "TEST", 113, 119], ["Drainage", "TREATMENT", 127, 135], ["the lymph nodes", "PROBLEM", 247, 262], ["Neck", "ANATOMY", 83, 87], ["lymphatic", "ANATOMY", 139, 148], ["basins", "ANATOMY_MODIFIER", 149, 155], ["lymph nodes", "OBSERVATION", 251, 262]]], ["The face and oropharynx drain predominantly to the preauricular, submandibular, and submental nodes; the posterior scalp drains to the occipital nodal group; and the mouth, tongue, tonsils, oropharynx, and nasopharynx drain to superficial and deep chains of the anterior cervical nodes.", [["face", "ANATOMY", 4, 8], ["oropharynx", "ANATOMY", 13, 23], ["preauricular", "ANATOMY", 51, 63], ["submandibular", "ANATOMY", 65, 78], ["submental nodes", "ANATOMY", 84, 99], ["scalp", "ANATOMY", 115, 120], ["occipital nodal", "ANATOMY", 135, 150], ["mouth", "ANATOMY", 166, 171], ["tongue", "ANATOMY", 173, 179], ["tonsils", "ANATOMY", 181, 188], ["oropharynx", "ANATOMY", 190, 200], ["nasopharynx", "ANATOMY", 206, 217], ["superficial", "ANATOMY", 227, 238], ["anterior cervical nodes", "ANATOMY", 262, 285], ["face", "ORGANISM_SUBDIVISION", 4, 8], ["oropharynx", "ORGAN", 13, 23], ["preauricular", "ORGAN", 51, 63], ["submandibular", "ORGAN", 65, 78], ["submental nodes", "MULTI-TISSUE_STRUCTURE", 84, 99], ["posterior scalp", "MULTI-TISSUE_STRUCTURE", 105, 120], ["occipital nodal", "MULTI-TISSUE_STRUCTURE", 135, 150], ["mouth", "ORGANISM_SUBDIVISION", 166, 171], ["tongue", "ORGAN", 173, 179], ["tonsils", "ORGAN", 181, 188], ["oropharynx", "ORGAN", 190, 200], ["nasopharynx", "ORGAN", 206, 217], ["anterior cervical nodes", "MULTI-TISSUE_STRUCTURE", 262, 285], ["The face and oropharynx drain", "TREATMENT", 0, 29], ["submandibular, and submental nodes", "PROBLEM", 65, 99], ["the posterior scalp drains", "TREATMENT", 101, 127], ["the mouth, tongue, tonsils, oropharynx, and nasopharynx drain to superficial and deep chains of the anterior cervical nodes", "PROBLEM", 162, 285], ["face", "ANATOMY", 4, 8], ["oropharynx", "ANATOMY", 13, 23], ["drain", "OBSERVATION", 24, 29], ["preauricular", "ANATOMY", 51, 63], ["submandibular", "ANATOMY", 65, 78], ["submental", "ANATOMY", 84, 93], ["nodes", "OBSERVATION", 94, 99], ["posterior", "ANATOMY_MODIFIER", 105, 114], ["scalp", "ANATOMY", 115, 120], ["drains", "OBSERVATION", 121, 127], ["occipital nodal", "ANATOMY", 135, 150], ["mouth", "ANATOMY", 166, 171], ["tongue", "ANATOMY", 173, 179], ["tonsils", "ANATOMY", 181, 188], ["oropharynx", "ANATOMY", 190, 200], ["nasopharynx", "ANATOMY", 206, 217], ["drain", "OBSERVATION", 218, 223], ["superficial", "ANATOMY_MODIFIER", 227, 238], ["deep", "ANATOMY_MODIFIER", 243, 247], ["chains", "ANATOMY_MODIFIER", 248, 254], ["anterior", "ANATOMY_MODIFIER", 262, 270], ["cervical", "ANATOMY", 271, 279], ["nodes", "OBSERVATION", 280, 285]]], ["Significant lymphatic collateralization exists.Malignancy ::: Differential DiagnosisMalignancy accounts for 11% to 24% of the diagnoses, depending on the nature of the group reporting their result.", [["lymphatic", "ANATOMY", 12, 21], ["Malignancy", "DISEASE", 47, 57], ["Malignancy", "DISEASE", 84, 94], ["lymphatic", "MULTI-TISSUE_STRUCTURE", 12, 21], ["Significant lymphatic collateralization", "PROBLEM", 0, 39], ["Malignancy", "PROBLEM", 84, 94], ["lymphatic", "ANATOMY", 12, 21], ["collateralization", "OBSERVATION", 22, 39]]], ["The higher rates are reported in series from oncology practices.5,6 Malignant processes are more common in the age group of 2 to 12 years old and very rare in the age group of less than 2 years old.", [["Malignant processes", "PROBLEM", 68, 87], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["rates", "OBSERVATION_MODIFIER", 11, 16], ["more common", "OBSERVATION_MODIFIER", 92, 103]]], ["Malignancy as a cause is also more common in children with chronic generalized lymphadenopathy, nodes greater than 3 cm in diameter, and nodes in the supraclavicular region.", [["nodes", "ANATOMY", 96, 101], ["nodes", "ANATOMY", 137, 142], ["supraclavicular region", "ANATOMY", 150, 172], ["Malignancy", "DISEASE", 0, 10], ["lymphadenopathy", "DISEASE", 79, 94], ["children", "ORGANISM", 45, 53], ["supraclavicular region", "MULTI-TISSUE_STRUCTURE", 150, 172], ["children", "SPECIES", 45, 53], ["Malignancy", "PROBLEM", 0, 10], ["chronic generalized lymphadenopathy", "PROBLEM", 59, 94], ["nodes", "PROBLEM", 96, 101], ["nodes in the supraclavicular region", "PROBLEM", 137, 172], ["more common", "OBSERVATION_MODIFIER", 30, 41], ["chronic", "OBSERVATION_MODIFIER", 59, 66], ["generalized", "OBSERVATION_MODIFIER", 67, 78], ["lymphadenopathy", "OBSERVATION", 79, 94], ["nodes", "OBSERVATION", 96, 101], ["greater", "OBSERVATION_MODIFIER", 102, 109], ["than 3 cm", "OBSERVATION_MODIFIER", 110, 119], ["diameter", "OBSERVATION_MODIFIER", 123, 131], ["nodes", "OBSERVATION", 137, 142], ["supraclavicular", "ANATOMY", 150, 165], ["region", "ANATOMY_MODIFIER", 166, 172]]], ["Associated symptoms of night sweats, weight loss, and hepatosplenomegaly also increase the chance of malignancy.", [["night sweats", "DISEASE", 23, 35], ["weight loss", "DISEASE", 37, 48], ["hepatosplenomegaly", "DISEASE", 54, 72], ["malignancy", "DISEASE", 101, 111], ["malignancy", "CANCER", 101, 111], ["Associated symptoms", "PROBLEM", 0, 19], ["night sweats", "PROBLEM", 23, 35], ["weight loss", "PROBLEM", 37, 48], ["hepatosplenomegaly", "PROBLEM", 54, 72], ["malignancy", "PROBLEM", 101, 111], ["hepatosplenomegaly", "OBSERVATION", 54, 72], ["increase", "OBSERVATION_MODIFIER", 78, 86], ["malignancy", "OBSERVATION", 101, 111]]], ["Finally abnormal laboratory and radiologic evaluation are associated with increased malignancy rates.7 Soldes and colleagues reviewed predictors of malignancy in children with peripheral lymphadenopathy and determined that increasing node size, increasing number of sites of adenopathy, and age were associated with an increasing risk of malignancy (P < 0.05).8 In addition, supraclavicular adenopathy, an abnormal chest radiograph, and fixed nodes were all significantly associated with malignancy.Malignancy ::: Differential DiagnosisThe most common malignancies as a cause of lymphadenopathy are Hodgkin and non-Hodgkin lymphomas, leukemia, and metastatic disease.Laboratory Studies ::: Investigation ::: EvaluationMost patients have had a laboratory evaluation prior to referral to surgery.", [["node", "ANATOMY", 234, 238], ["sites", "ANATOMY", 266, 271], ["supraclavicular adenopathy", "ANATOMY", 375, 401], ["chest", "ANATOMY", 415, 420], ["nodes", "ANATOMY", 443, 448], ["malignancies", "ANATOMY", 552, 564], ["lymphadenopathy", "ANATOMY", 579, 594], ["Hodgkin", "ANATOMY", 599, 606], ["non-Hodgkin lymphomas", "ANATOMY", 611, 632], ["leukemia", "ANATOMY", 634, 642], ["metastatic disease", "ANATOMY", 648, 666], ["malignancy", "DISEASE", 84, 94], ["malignancy", "DISEASE", 148, 158], ["peripheral lymphadenopathy", "DISEASE", 176, 202], ["adenopathy", "DISEASE", 275, 285], ["malignancy", "DISEASE", 338, 348], ["adenopathy", "DISEASE", 391, 401], ["malignancy", "DISEASE", 488, 498], ["Malignancy", "DISEASE", 499, 509], ["malignancies", "DISEASE", 552, 564], ["lymphadenopathy", "DISEASE", 579, 594], ["Hodgkin and non-Hodgkin lymphomas", "DISEASE", 599, 632], ["leukemia", "DISEASE", 634, 642], ["malignancy", "CANCER", 148, 158], ["children", "ORGANISM", 162, 170], ["node", "MULTI-TISSUE_STRUCTURE", 234, 238], ["nodes", "MULTI-TISSUE_STRUCTURE", 443, 448], ["malignancies", "CANCER", 552, 564], ["lymphadenopathy", "CANCER", 579, 594], ["Hodgkin", "CANCER", 599, 606], ["non-Hodgkin lymphomas", "CANCER", 611, 632], ["leukemia", "CANCER", 634, 642], ["metastatic disease", "CANCER", 648, 666], ["patients", "ORGANISM", 723, 731], ["children", "SPECIES", 162, 170], ["patients", "SPECIES", 723, 731], ["abnormal laboratory", "PROBLEM", 8, 27], ["radiologic evaluation", "TEST", 32, 53], ["increased malignancy rates", "PROBLEM", 74, 100], ["malignancy", "PROBLEM", 148, 158], ["peripheral lymphadenopathy", "PROBLEM", 176, 202], ["increasing node size", "PROBLEM", 223, 243], ["adenopathy", "PROBLEM", 275, 285], ["malignancy", "PROBLEM", 338, 348], ["supraclavicular adenopathy", "PROBLEM", 375, 401], ["an abnormal chest radiograph", "TEST", 403, 431], ["fixed nodes", "PROBLEM", 437, 448], ["malignancy", "PROBLEM", 488, 498], ["Malignancy", "PROBLEM", 499, 509], ["The most common malignancies", "PROBLEM", 536, 564], ["lymphadenopathy", "PROBLEM", 579, 594], ["Hodgkin and non-Hodgkin lymphomas", "PROBLEM", 599, 632], ["leukemia", "PROBLEM", 634, 642], ["metastatic disease", "PROBLEM", 648, 666], ["Evaluation", "TEST", 708, 718], ["a laboratory evaluation", "TEST", 741, 764], ["surgery", "TREATMENT", 786, 793], ["increased", "OBSERVATION_MODIFIER", 74, 83], ["malignancy", "OBSERVATION", 84, 94], ["malignancy", "OBSERVATION", 148, 158], ["peripheral", "ANATOMY", 176, 186], ["lymphadenopathy", "OBSERVATION", 187, 202], ["increasing", "OBSERVATION_MODIFIER", 223, 233], ["node", "OBSERVATION", 234, 238], ["size", "OBSERVATION_MODIFIER", 239, 243], ["increasing", "OBSERVATION_MODIFIER", 245, 255], ["number", "OBSERVATION_MODIFIER", 256, 262], ["sites", "OBSERVATION_MODIFIER", 266, 271], ["adenopathy", "OBSERVATION", 275, 285], ["increasing", "OBSERVATION_MODIFIER", 319, 329], ["malignancy", "OBSERVATION", 338, 348], ["supraclavicular", "ANATOMY", 375, 390], ["adenopathy", "OBSERVATION", 391, 401], ["abnormal", "OBSERVATION_MODIFIER", 406, 414], ["chest", "ANATOMY", 415, 420], ["fixed", "OBSERVATION_MODIFIER", 437, 442], ["nodes", "OBSERVATION", 443, 448], ["malignancy", "OBSERVATION", 488, 498], ["most common", "OBSERVATION_MODIFIER", 540, 551], ["malignancies", "OBSERVATION", 552, 564], ["lymphadenopathy", "OBSERVATION", 579, 594], ["Hodgkin", "OBSERVATION", 599, 606], ["non-Hodgkin lymphomas", "OBSERVATION", 611, 632], ["leukemia", "OBSERVATION", 634, 642], ["metastatic", "OBSERVATION", 648, 658]]], ["These tests usually include a complete blood count (CBC) with manual differential, sedimentation rate, and C-reactive protein.", [["blood", "ANATOMY", 39, 44], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 107, 125], ["C-reactive protein", "PROTEIN", 107, 125], ["These tests", "TEST", 0, 11], ["a complete blood count", "TEST", 28, 50], ["CBC", "TEST", 52, 55], ["manual differential", "TEST", 62, 81], ["sedimentation rate", "TEST", 83, 101], ["C", "TEST", 107, 108], ["reactive protein", "OBSERVATION", 109, 125]]], ["However, these are not always helpful in determining the specific etiology of the disease process.", [["the disease process", "PROBLEM", 78, 97], ["disease", "OBSERVATION", 82, 89]]], ["Pancytopenia can be seen in leukemia; lymphocytosis is seen with mononucleosis, cytomegalovirus (CMV), and toxoplasmosis.Laboratory Studies ::: Investigation ::: EvaluationBased on the history and physical examination, more specific tests for Epstein-Barr virus (EBV), CMV, toxoplasmosis, brucellosis, histoplasmosis, syphilis, bartonellosis, and coccidioidomycosis should be considered.", [["leukemia", "ANATOMY", 28, 36], ["Pancytopenia", "DISEASE", 0, 12], ["leukemia", "DISEASE", 28, 36], ["lymphocytosis", "DISEASE", 38, 51], ["mononucleosis, cytomegalovirus (CMV), and toxoplasmosis", "DISEASE", 65, 120], ["Epstein-Barr virus (EBV), CMV, toxoplasmosis", "DISEASE", 243, 287], ["brucellosis", "DISEASE", 289, 300], ["histoplasmosis", "DISEASE", 302, 316], ["syphilis", "DISEASE", 318, 326], ["bartonellosis", "DISEASE", 328, 341], ["coccidioidomycosis", "DISEASE", 347, 365], ["leukemia", "CANCER", 28, 36], ["cytomegalovirus", "ORGANISM", 80, 95], ["CMV", "ORGANISM", 97, 100], ["Epstein-Barr virus", "ORGANISM", 243, 261], ["EBV", "ORGANISM", 263, 266], ["CMV", "ORGANISM", 269, 272], ["CMV", "SPECIES", 97, 100], ["Epstein-Barr virus", "SPECIES", 243, 261], ["EBV", "SPECIES", 263, 266], ["CMV", "SPECIES", 269, 272], ["Pancytopenia", "PROBLEM", 0, 12], ["leukemia", "PROBLEM", 28, 36], ["lymphocytosis", "PROBLEM", 38, 51], ["mononucleosis", "PROBLEM", 65, 78], ["cytomegalovirus (CMV)", "PROBLEM", 80, 101], ["toxoplasmosis", "PROBLEM", 107, 120], ["physical examination", "TEST", 197, 217], ["specific tests", "TEST", 224, 238], ["Epstein-Barr virus (EBV)", "PROBLEM", 243, 267], ["CMV", "PROBLEM", 269, 272], ["toxoplasmosis", "PROBLEM", 274, 287], ["brucellosis", "PROBLEM", 289, 300], ["histoplasmosis", "PROBLEM", 302, 316], ["syphilis", "PROBLEM", 318, 326], ["bartonellosis", "PROBLEM", 328, 341], ["coccidioidomycosis", "PROBLEM", 347, 365], ["can be seen", "UNCERTAINTY", 13, 24], ["leukemia", "OBSERVATION", 28, 36], ["lymphocytosis", "OBSERVATION", 38, 51], ["mononucleosis", "OBSERVATION", 65, 78], ["cytomegalovirus", "OBSERVATION", 80, 95], ["toxoplasmosis", "OBSERVATION", 107, 120], ["Barr virus", "OBSERVATION", 251, 261], ["toxoplasmosis", "OBSERVATION", 274, 287], ["brucellosis", "OBSERVATION", 289, 300], ["histoplasmosis", "OBSERVATION", 302, 316], ["syphilis", "OBSERVATION", 318, 326], ["coccidioidomycosis", "OBSERVATION", 347, 365]]], ["Tests for human immunodeficiency virus (HIV) should also be considered, based on the history as well as the tuberculin skin test.Laboratory Studies ::: Investigation ::: EvaluationSerum lactate dehydrogenase should be assayed when suspecting leukemia or lymphoma as a byproduct of high cell turnover.Radiologic Evaluation ::: Investigation ::: EvaluationDiagnostic imaging can be used to determine the characteristic of the lymphadenopathy, identify potential sources of infection, identify mediastinal and abdominal masses, and to help differentiate enlarged lymph nodes from other pathology.", [["skin", "ANATOMY", 119, 123], ["leukemia", "ANATOMY", 242, 250], ["lymphoma", "ANATOMY", 254, 262], ["cell", "ANATOMY", 286, 290], ["mediastinal", "ANATOMY", 491, 502], ["abdominal masses", "ANATOMY", 507, 523], ["lymph nodes", "ANATOMY", 560, 571], ["human immunodeficiency virus (HIV)", "DISEASE", 10, 44], ["lactate", "CHEMICAL", 186, 193], ["leukemia", "DISEASE", 242, 250], ["lymphoma", "DISEASE", 254, 262], ["lymphadenopathy", "DISEASE", 424, 439], ["infection", "DISEASE", 471, 480], ["lactate", "CHEMICAL", 186, 193], ["human immunodeficiency virus", "ORGANISM", 10, 38], ["HIV", "ORGANISM", 40, 43], ["skin", "ORGAN", 119, 123], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 186, 207], ["leukemia", "CANCER", 242, 250], ["lymphoma", "CANCER", 254, 262], ["cell", "CELL", 286, 290], ["abdominal masses", "CANCER", 507, 523], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 560, 571], ["lactate dehydrogenase", "PROTEIN", 186, 207], ["human immunodeficiency virus (HIV", "SPECIES", 10, 43], ["human immunodeficiency virus", "SPECIES", 10, 38], ["HIV", "SPECIES", 40, 43], ["Tests", "TEST", 0, 5], ["human immunodeficiency virus", "PROBLEM", 10, 38], ["HIV", "PROBLEM", 40, 43], ["the tuberculin skin test", "TEST", 104, 128], ["EvaluationSerum lactate dehydrogenase", "TEST", 170, 207], ["leukemia", "PROBLEM", 242, 250], ["lymphoma", "PROBLEM", 254, 262], ["high cell turnover", "PROBLEM", 281, 299], ["Radiologic Evaluation", "TEST", 300, 321], ["EvaluationDiagnostic imaging", "TEST", 344, 372], ["the lymphadenopathy", "PROBLEM", 420, 439], ["infection", "PROBLEM", 471, 480], ["mediastinal and abdominal masses", "PROBLEM", 491, 523], ["enlarged lymph nodes", "PROBLEM", 551, 571], ["other pathology", "PROBLEM", 577, 592], ["leukemia", "OBSERVATION", 242, 250], ["lymphoma", "OBSERVATION", 254, 262], ["high cell turnover", "OBSERVATION", 281, 299], ["lymphadenopathy", "OBSERVATION", 424, 439], ["infection", "OBSERVATION", 471, 480], ["mediastinal", "ANATOMY", 491, 502], ["abdominal", "ANATOMY", 507, 516], ["masses", "OBSERVATION", 517, 523], ["enlarged", "OBSERVATION_MODIFIER", 551, 559], ["lymph nodes", "OBSERVATION", 560, 571]]], ["Chest radiographs, ultrasonography with Doppler, and computer tomography have all been used in the evaluation of adenopathy.Radiologic Evaluation ::: Investigation ::: EvaluationIn children with long-term lymphadenopathy, a two-view chest radiograph is helpful to rule out mediastinal masses that may compress the airway with or without significant symptoms.", [["mediastinal masses", "ANATOMY", 273, 291], ["airway", "ANATOMY", 314, 320], ["adenopathy", "DISEASE", 113, 123], ["lymphadenopathy", "DISEASE", 205, 220], ["children", "ORGANISM", 181, 189], ["mediastinal masses", "CANCER", 273, 291], ["airway", "MULTI-TISSUE_STRUCTURE", 314, 320], ["children", "SPECIES", 181, 189], ["Chest radiographs", "TEST", 0, 17], ["ultrasonography", "TEST", 19, 34], ["Doppler", "TEST", 40, 47], ["computer tomography", "TEST", 53, 72], ["the evaluation", "TEST", 95, 109], ["adenopathy", "PROBLEM", 113, 123], ["Radiologic Evaluation", "TEST", 124, 145], ["long-term lymphadenopathy", "PROBLEM", 195, 220], ["a two-view chest radiograph", "TEST", 222, 249], ["mediastinal masses", "PROBLEM", 273, 291], ["significant symptoms", "PROBLEM", 337, 357], ["adenopathy", "OBSERVATION", 113, 123], ["long-term", "OBSERVATION_MODIFIER", 195, 204], ["lymphadenopathy", "OBSERVATION", 205, 220], ["mediastinal", "ANATOMY", 273, 284], ["masses", "OBSERVATION", 285, 291], ["airway", "ANATOMY", 314, 320]]], ["A chest radiograph should be performed prior to any operative intervention, including biopsies done under general anesthesia.", [["chest", "ANATOMY", 2, 7], ["chest", "ORGAN", 2, 7], ["A chest radiograph", "TEST", 0, 18], ["any operative intervention", "TREATMENT", 48, 74], ["biopsies", "TEST", 86, 94], ["general anesthesia", "TREATMENT", 106, 124], ["chest", "ANATOMY", 2, 7]]], ["Patients with large mediastinal masses compressing the airway should not undergo general anesthesia, because this could result in airway collapse (see Chapter 38).9", [["mediastinal masses", "ANATOMY", 20, 38], ["airway", "ANATOMY", 55, 61], ["airway", "ANATOMY", 130, 136], ["airway collapse", "DISEASE", 130, 145], ["Patients", "ORGANISM", 0, 8], ["mediastinal masses", "CANCER", 20, 38], ["airway", "MULTI-TISSUE_STRUCTURE", 55, 61], ["airway", "MULTI-TISSUE_STRUCTURE", 130, 136], ["Patients", "SPECIES", 0, 8], ["large mediastinal masses", "PROBLEM", 14, 38], ["general anesthesia", "TREATMENT", 81, 99], ["airway collapse", "PROBLEM", 130, 145], ["large", "OBSERVATION_MODIFIER", 14, 19], ["mediastinal", "ANATOMY", 20, 31], ["masses", "OBSERVATION", 32, 38], ["airway", "ANATOMY", 55, 61], ["anesthesia", "OBSERVATION", 89, 99], ["airway", "ANATOMY", 130, 136], ["collapse", "OBSERVATION", 137, 145]]]], "5db1d7bf85b9650e4eaed42ba76edd2ee79cba10": [["This chapter is primarily about components of volunteer blood donations that are each transfused as a single unit, usually \"as is.\"", [["blood", "ANATOMY", 56, 61], ["blood", "ORGANISM_SUBSTANCE", 56, 61], ["volunteer blood donations", "TREATMENT", 46, 71]]], ["A single donation of a pint of whole blood is virtually always separated by centrifugation into a unit of red blood cells and a unit of plasma; a unit of platelets or a unit of cryoprecipitated plasma can also be prepared, but this is done for less than half of whole blood donations, since patients' clinical needs for platelets and cryoprecipitated plasma are much less than patients' needs for red blood cell transfusion.", [["whole blood", "ANATOMY", 31, 42], ["red blood cells", "ANATOMY", 106, 121], ["plasma", "ANATOMY", 136, 142], ["platelets", "ANATOMY", 154, 163], ["plasma", "ANATOMY", 194, 200], ["blood", "ANATOMY", 268, 273], ["platelets", "ANATOMY", 320, 329], ["plasma", "ANATOMY", 351, 357], ["red blood cell", "ANATOMY", 397, 411], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["red blood cells", "CELL", 106, 121], ["plasma", "ORGANISM_SUBSTANCE", 136, 142], ["platelets", "CELL", 154, 163], ["plasma", "ORGANISM_SUBSTANCE", 194, 200], ["blood", "ORGANISM_SUBSTANCE", 268, 273], ["patients", "ORGANISM", 291, 299], ["platelets", "CELL", 320, 329], ["plasma", "ORGANISM_SUBSTANCE", 351, 357], ["patients", "ORGANISM", 377, 385], ["red blood cell", "CELL", 397, 411], ["red blood cells", "CELL_TYPE", 106, 121], ["platelets", "CELL_TYPE", 154, 163], ["platelets", "CELL_TYPE", 320, 329], ["patients", "SPECIES", 291, 299], ["patients", "SPECIES", 377, 385], ["a pint of whole blood", "TREATMENT", 21, 42], ["red blood cells", "TREATMENT", 106, 121], ["a unit of plasma", "TREATMENT", 126, 142], ["a unit of platelets", "TREATMENT", 144, 163], ["a unit of cryoprecipitated plasma", "TREATMENT", 167, 200], ["whole blood donations", "TREATMENT", 262, 283], ["platelets", "TEST", 320, 329], ["cryoprecipitated plasma", "TEST", 334, 357], ["red blood cell transfusion", "TREATMENT", 397, 423]]], ["While today virtually all of these blood components from whole blood donation are from volunteer donors, the FDA would permit paying these donors, but requires that the component's label be marked conspicuously with the words \"PAID DONOR\" as opposed to \"VOLUNTEER DONOR.\"", [["blood", "ANATOMY", 35, 40], ["whole blood", "ANATOMY", 57, 68], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["blood", "ORGANISM_SUBSTANCE", 63, 68], ["donors", "ORGANISM", 139, 145], ["these blood components", "PROBLEM", 29, 51], ["whole blood donation", "TREATMENT", 57, 77]]], ["Whole blood donation is permitted no more often than once every eight weeks (to prevent development of iron defi ciency in the donor).", [["blood", "ANATOMY", 6, 11], ["iron", "CHEMICAL", 103, 107], ["iron", "CHEMICAL", 103, 107], ["blood", "ORGANISM_SUBSTANCE", 6, 11], ["iron", "SIMPLE_CHEMICAL", 103, 107], ["Whole blood donation", "TREATMENT", 0, 20], ["iron defi ciency", "PROBLEM", 103, 119]]]], "0beeac7692f61dbadfb0857565a957314b9232b0": [["IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-COV2) causes coronavirus disease , a potentially fatal disease that is of immense global public health concern.", [["acute respiratory syndrome coronavirus", "DISEASE", 19, 57], ["coronavirus disease", "DISEASE", 79, 98], ["IntroductionSevere acute respiratory syndrome coronavirus 2", "ORGANISM", 0, 59], ["SARS-COV2", "ORGANISM", 61, 70], ["coronavirus", "ORGANISM", 79, 90], ["IntroductionSevere acute respiratory syndrome coronavirus", "SPECIES", 0, 57], ["SARS-COV2", "SPECIES", 61, 70], ["acute respiratory syndrome coronavirus", "PROBLEM", 19, 57], ["coronavirus disease", "PROBLEM", 79, 98], ["a potentially fatal disease", "PROBLEM", 101, 128], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45], ["coronavirus disease", "OBSERVATION", 79, 98], ["potentially", "UNCERTAINTY", 103, 114], ["fatal", "OBSERVATION_MODIFIER", 115, 120], ["disease", "OBSERVATION", 121, 128]]], ["Since then, there have been 3,041,764 confirmed COVID-19 patients in the world as of April 27th ,2020 with a total of 211,167 deaths.", [["deaths", "DISEASE", 126, 132], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65]]], ["The United States has the maximum number (988,189) of confirmed cases with a total of 56,259 deaths.", [["deaths", "DISEASE", 93, 99]]], ["Most cases were diagnosed in New York (291,996) with a total of 22,668 deaths [2] .IntroductionSeveral studies, including a recent meta-analysis have reported that coexisting conditions, including hypertension, cardiac diseases, cerebrovascular diseases and diabetes were common among patients with Covid-19 who had severe illness, got admitted to the intensive care unit (ICU), received mechanical ventilation, or died than among patients who had mild illness [3, 4] .IntroductionNotably, the most frequent comorbidities reported in these studies of patients with COVID-19, especially hypertension is often treated with angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) [5] .", [["cardiac", "ANATOMY", 211, 218], ["cerebrovascular", "ANATOMY", 229, 244], ["deaths", "DISEASE", 71, 77], ["hypertension", "DISEASE", 197, 209], ["cardiac diseases", "DISEASE", 211, 227], ["cerebrovascular diseases", "DISEASE", 229, 253], ["diabetes", "DISEASE", 258, 266], ["illness", "DISEASE", 323, 330], ["illness", "DISEASE", 453, 460], ["hypertension", "DISEASE", 586, 598], ["angiotensin", "CHEMICAL", 621, 632], ["ACEI", "CHEMICAL", 663, 667], ["angiotensin", "CHEMICAL", 673, 684], ["ARB", "CHEMICAL", 704, 707], ["cardiac", "ORGAN", 211, 218], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 229, 244], ["patients", "ORGANISM", 285, 293], ["patients", "ORGANISM", 431, 439], ["patients", "ORGANISM", 551, 559], ["angiotensin-converting enzyme inhibitors", "SIMPLE_CHEMICAL", 621, 661], ["ACEI", "SIMPLE_CHEMICAL", 663, 667], ["angiotensin receptor blockers", "SIMPLE_CHEMICAL", 673, 702], ["ARB", "SIMPLE_CHEMICAL", 704, 707], ["patients", "SPECIES", 285, 293], ["patients", "SPECIES", 431, 439], ["patients", "SPECIES", 551, 559], ["Several studies", "TEST", 95, 110], ["a recent meta-analysis", "TEST", 122, 144], ["coexisting conditions", "PROBLEM", 164, 185], ["hypertension", "PROBLEM", 197, 209], ["cardiac diseases", "PROBLEM", 211, 227], ["cerebrovascular diseases", "PROBLEM", 229, 253], ["diabetes", "PROBLEM", 258, 266], ["severe illness", "PROBLEM", 316, 330], ["mechanical ventilation", "TREATMENT", 388, 410], ["mild illness", "PROBLEM", 448, 460], ["the most frequent comorbidities", "PROBLEM", 490, 521], ["these studies", "TEST", 534, 547], ["COVID", "TEST", 565, 570], ["hypertension", "PROBLEM", 586, 598], ["angiotensin", "TREATMENT", 621, 632], ["converting enzyme inhibitors", "TREATMENT", 633, 661], ["ACEI", "TREATMENT", 663, 667], ["angiotensin receptor blockers", "TREATMENT", 673, 702], ["ARB)", "TREATMENT", 704, 708], ["hypertension", "OBSERVATION", 197, 209], ["cardiac", "ANATOMY", 211, 218], ["diseases", "OBSERVATION", 219, 227], ["cerebrovascular diseases", "OBSERVATION", 229, 253], ["mechanical ventilation", "OBSERVATION", 388, 410]]], ["This could theoretically result in an upregulation of ACE2 in the epithelial cells of the lung, intestine, kidney, and blood vessels, which is an active binding target for SARS-CoV-2 virus [6] .IntroductionAlthough this raised concerns regarding the use of these drugs in COVID-19 patients, several animal studies presented conflicting findings regarding increased ACE2 expression due to ACEI and ARB in animal studies and the previous human studies suggested that administration of ACEI/ARBs does not increase ACE2 expression [7] .", [["epithelial cells", "ANATOMY", 66, 82], ["lung", "ANATOMY", 90, 94], ["intestine", "ANATOMY", 96, 105], ["kidney", "ANATOMY", 107, 113], ["blood vessels", "ANATOMY", 119, 132], ["ACEI", "CHEMICAL", 388, 392], ["ARB", "CHEMICAL", 397, 400], ["ACEI", "CHEMICAL", 483, 487], ["ARBs", "CHEMICAL", 488, 492], ["ACE2", "GENE_OR_GENE_PRODUCT", 54, 58], ["epithelial cells", "CELL", 66, 82], ["lung", "ORGAN", 90, 94], ["intestine", "ORGAN", 96, 105], ["kidney", "ORGAN", 107, 113], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 119, 132], ["SARS-CoV-2 virus", "ORGANISM", 172, 188], ["COVID-19", "ORGANISM", 272, 280], ["patients", "ORGANISM", 281, 289], ["ACE2", "GENE_OR_GENE_PRODUCT", 365, 369], ["ACEI", "SIMPLE_CHEMICAL", 388, 392], ["ARB", "SIMPLE_CHEMICAL", 397, 400], ["human", "ORGANISM", 436, 441], ["ACEI", "SIMPLE_CHEMICAL", 483, 487], ["ARBs", "SIMPLE_CHEMICAL", 488, 492], ["ACE2", "GENE_OR_GENE_PRODUCT", 511, 515], ["ACE2", "PROTEIN", 54, 58], ["epithelial cells", "CELL_TYPE", 66, 82], ["ACE2", "PROTEIN", 365, 369], ["ACE2", "PROTEIN", 511, 515], ["CoV-2 virus", "SPECIES", 177, 188], ["patients", "SPECIES", 281, 289], ["human", "SPECIES", 436, 441], ["SARS-CoV-2 virus", "SPECIES", 172, 188], ["human", "SPECIES", 436, 441], ["SARS", "PROBLEM", 172, 176], ["CoV", "TEST", 177, 180], ["these drugs", "TREATMENT", 257, 268], ["several animal studies", "TEST", 291, 313], ["increased ACE2 expression", "PROBLEM", 355, 380], ["ACEI", "TREATMENT", 388, 392], ["ARB", "TREATMENT", 397, 400], ["animal studies", "TEST", 404, 418], ["the previous human studies", "TEST", 423, 449], ["ACEI", "TREATMENT", 483, 487], ["ARBs", "TREATMENT", 488, 492], ["upregulation", "OBSERVATION", 38, 50], ["ACE2", "OBSERVATION", 54, 58], ["epithelial cells", "OBSERVATION", 66, 82], ["lung", "ANATOMY", 90, 94], ["intestine", "ANATOMY", 96, 105], ["kidney", "ANATOMY", 107, 113], ["blood vessels", "ANATOMY", 119, 132], ["active", "OBSERVATION_MODIFIER", 146, 152]]], ["In light of these findings and a paucity of clinical outcome studies, many professional cardiovascular and hypertension societies including the Italian Society of Pharmacology, International Society of Hypertension (ISH), European Society of Hypertension, Joint American Heart Association/American College of Cardiology/American Heart Failure Association and others recommended the continued use of ACEI/ARBs in COVID-19 patients [8] [9] [10] [11] .IntroductionHowever, since the conception of these recommendations, several clinical studies have been conducted which evaluated the association of ACEI and ARB with clinical severity and mortality outcomes in COVID-19 patients.", [["cardiovascular", "ANATOMY", 88, 102], ["hypertension", "DISEASE", 107, 119], ["Hypertension", "DISEASE", 202, 214], ["ISH", "DISEASE", 216, 219], ["Hypertension", "DISEASE", 242, 254], ["Heart Failure", "DISEASE", 329, 342], ["ACEI/ARBs", "CHEMICAL", 399, 408], ["ACEI", "CHEMICAL", 597, 601], ["ARB", "CHEMICAL", 606, 609], ["ACEI", "SIMPLE_CHEMICAL", 399, 403], ["patients", "ORGANISM", 421, 429], ["[8] [9] [10", "SIMPLE_CHEMICAL", 430, 441], ["ACEI", "SIMPLE_CHEMICAL", 597, 601], ["ARB", "SIMPLE_CHEMICAL", 606, 609], ["patients", "ORGANISM", 668, 676], ["patients", "SPECIES", 421, 429], ["patients", "SPECIES", 668, 676], ["clinical outcome studies", "TEST", 44, 68], ["many professional cardiovascular and hypertension societies", "PROBLEM", 70, 129], ["Hypertension", "PROBLEM", 202, 214], ["Hypertension", "PROBLEM", 242, 254], ["Heart Failure", "PROBLEM", 329, 342], ["ACEI", "TREATMENT", 399, 403], ["ARBs", "TREATMENT", 404, 408], ["several clinical studies", "TEST", 517, 541], ["ACEI", "TREATMENT", 597, 601], ["ARB", "TREATMENT", 606, 609], ["clinical severity", "PROBLEM", 615, 632], ["COVID", "TEST", 659, 664], ["hypertension", "OBSERVATION", 107, 119], ["Hypertension", "OBSERVATION", 202, 214], ["Hypertension", "OBSERVATION", 242, 254], ["Joint", "ANATOMY", 256, 261], ["Heart", "ANATOMY", 271, 276], ["Heart", "ANATOMY", 329, 334], ["Failure", "OBSERVATION", 335, 342]]], ["Therefore, the medical literature was systematically reviewed for the current clinical evidence evaluating the safety and efficacy of ACE inhibitors and ARB in COVID-19 patients.Literature SearchLiterature search was conducted on the PubMed/MEDLINE database using key words, viz., \"ACE inhibitors AND coronavirus.\" and \"ARB AND coronavirus.\"", [["ACE inhibitors", "CHEMICAL", 134, 148], ["ARB", "CHEMICAL", 153, 156], ["coronavirus", "DISEASE", 301, 312], ["ARB", "CHEMICAL", 320, 323], ["coronavirus", "DISEASE", 328, 339], ["ACE", "GENE_OR_GENE_PRODUCT", 134, 137], ["ARB", "SIMPLE_CHEMICAL", 153, 156], ["patients", "ORGANISM", 169, 177], ["ACE", "GENE_OR_GENE_PRODUCT", 282, 285], ["patients", "SPECIES", 169, 177], ["ACE inhibitors", "TREATMENT", 134, 148], ["ARB", "TREATMENT", 153, 156], ["viz.", "TREATMENT", 275, 279], ["\"ACE inhibitors", "TREATMENT", 281, 296], ["coronavirus", "PROBLEM", 301, 312], ["coronavirus", "PROBLEM", 328, 339]]], ["We applied search filters to include humans and English language published till April 26 th , 2020.", [["humans", "ORGANISM", 37, 43], ["humans", "SPECIES", 37, 43], ["humans", "SPECIES", 37, 43], ["search filters", "TREATMENT", 11, 25]]], ["Additional papers of possible interest were identified by examining references of pertinent review articles and searching Google Scholar and preprint servers like MedRxiv and Biorxiv.", [["MedRxiv", "TREATMENT", 163, 170], ["Biorxiv", "TREATMENT", 175, 182]]], ["We included studies which evaluated clinical severity and mortality outcomes for patients with COVID-19 on ACEinhibitors or ARB or both.Literature SearchWe excluded those studies which dealt with in-vitro or animal studies as well as those which only evaluated only ACE expression levels.", [["ACEinhibitors", "CHEMICAL", 107, 120], ["ARB", "CHEMICAL", 124, 127], ["patients", "ORGANISM", 81, 89], ["ACEinhibitors", "SIMPLE_CHEMICAL", 107, 120], ["ARB", "SIMPLE_CHEMICAL", 124, 127], ["ACE", "GENE_OR_GENE_PRODUCT", 266, 269], ["ACE", "PROTEIN", 266, 269], ["patients", "SPECIES", 81, 89], ["studies", "TEST", 12, 19], ["COVID", "TEST", 95, 100], ["ACEinhibitors", "TREATMENT", 107, 120], ["ARB", "TREATMENT", 124, 127], ["those studies", "TEST", 165, 178], ["animal studies", "TEST", 208, 222], ["ACE expression levels", "TEST", 266, 287]]], ["(Figure 1 The information on the demographics, comorbidities, pharmacotherapy with ACE-I, ARBs and other drugs, clinical severity outcomes and mortality was extracted.Literature SearchArticles from preliminary search of PubMed, Google Scholar and preprint servers (n=79) Articles included for further review after screening the titles and abstracts (n=56) Articles whose full text was reviewed (n=35) Articles included after review and addition of pertinent crossreferences (n=8)ResultsA total of 79 articles were found in the search.", [["ACE-I, ARBs", "CHEMICAL", 83, 94], ["ACE-I", "GENE_OR_GENE_PRODUCT", 83, 88], ["ARBs", "SIMPLE_CHEMICAL", 90, 94], ["pharmacotherapy", "TREATMENT", 62, 77], ["ACE-I", "TREATMENT", 83, 88], ["ARBs", "TREATMENT", 90, 94], ["other drugs", "TREATMENT", 99, 110], ["clinical severity outcomes", "PROBLEM", 112, 138], ["screening", "TEST", 314, 323]]], ["Of these, six articles were shortlisted which compared the clinical and/or mortality outcomes of COVID-19 patients on ACEI or ARB with non-users [12] [13] [14] [15] [16] [17] .", [["ACEI", "CHEMICAL", 118, 122], ["ARB", "CHEMICAL", 126, 129], ["patients", "ORGANISM", 106, 114], ["ACEI", "SIMPLE_CHEMICAL", 118, 122], ["ARB", "SIMPLE_CHEMICAL", 126, 129], ["[12] [13] [14] [15] [16] [17]", "SIMPLE_CHEMICAL", 145, 174], ["patients", "SPECIES", 106, 114], ["COVID", "TEST", 97, 102], ["ACEI", "TREATMENT", 118, 122], ["ARB", "TREATMENT", 126, 129]]], ["Finally, eight studies were included for review.", [["eight studies", "TEST", 9, 22]]], ["(Table 1) All the included studies compared clinical severity related outcomes in COVID-19 patients on ACEI or ARB with non-users.", [["ACEI", "CHEMICAL", 103, 107], ["ARB", "CHEMICAL", 111, 114], ["patients", "ORGANISM", 91, 99], ["ACEI", "SIMPLE_CHEMICAL", 103, 107], ["ARB", "SIMPLE_CHEMICAL", 111, 114], ["patients", "SPECIES", 91, 99], ["COVID", "TEST", 82, 87], ["ACEI", "TREATMENT", 103, 107], ["ARB", "TREATMENT", 111, 114]]], ["However, there was non-uniformity in the definition of the severe outcomes amongst the studies.", [["the severe outcomes", "PROBLEM", 55, 74], ["the studies", "TEST", 83, 94], ["non-uniformity", "OBSERVATION_MODIFIER", 19, 33], ["severe", "OBSERVATION_MODIFIER", 59, 65]]], ["Table 2) Richardson S. et al and Zhang P. et al compared the rates of invasive ventilation and found that they were slightly higher or equivalent in patients on ACEI/ARB as compared to non-users, respectively.", [["ACEI", "CHEMICAL", 161, 165], ["ARB", "CHEMICAL", 166, 169], ["patients", "ORGANISM", 149, 157], ["ACEI", "SIMPLE_CHEMICAL", 161, 165], ["ARB", "SIMPLE_CHEMICAL", 166, 169], ["patients", "SPECIES", 149, 157], ["invasive ventilation", "TREATMENT", 70, 90], ["ACEI", "TREATMENT", 161, 165], ["ARB", "TREATMENT", 166, 169], ["slightly", "OBSERVATION_MODIFIER", 116, 124], ["higher", "OBSERVATION_MODIFIER", 125, 131]]], ["In addition, Richardson S. et al also reported slightly higher rates of ICU admissions in patients on ACEI (21.4%) and ARB (20.8%) as compared to non-users (14.8%).", [["ACEI", "CHEMICAL", 102, 106], ["ARB", "CHEMICAL", 119, 122], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["ACEI", "TREATMENT", 102, 106], ["ARB", "TREATMENT", 119, 122]]], ["Zhang P. et al reported that the patients on ACEI/ARB had lower rates of septic shock (HR = 0.32, p value = 0.01) and acute respiratory distress syndrome (ARDS) (HR = 0.65, p value = 0.07) as compared to non-users [15, 16] .", [["ACEI", "CHEMICAL", 45, 49], ["ARB", "CHEMICAL", 50, 53], ["septic shock", "DISEASE", 73, 85], ["acute respiratory distress syndrome", "DISEASE", 118, 153], ["ARDS", "DISEASE", 155, 159], ["patients", "ORGANISM", 33, 41], ["ACEI", "SIMPLE_CHEMICAL", 45, 49], ["ARB", "SIMPLE_CHEMICAL", 50, 53], ["patients", "SPECIES", 33, 41], ["ACEI", "TREATMENT", 45, 49], ["ARB", "TREATMENT", 50, 53], ["septic shock", "PROBLEM", 73, 85], ["HR", "TEST", 87, 89], ["p value", "TEST", 98, 105], ["acute respiratory distress syndrome", "PROBLEM", 118, 153], ["ARDS", "PROBLEM", 155, 159], ["HR", "TEST", 162, 164], ["p value", "TEST", 173, 180], ["septic shock", "OBSERVATION", 73, 85], ["acute", "OBSERVATION_MODIFIER", 118, 123], ["respiratory distress", "OBSERVATION", 124, 144]]], ["On the other hand, Guo J. et al found that patients on ACEI/ARB had higher rates of cardiovascular disease and elevated troponin T (TnT) levels as compared to non-users (21.1% vs 5.9%) [17] .", [["cardiovascular", "ANATOMY", 84, 98], ["ACEI", "CHEMICAL", 55, 59], ["ARB", "CHEMICAL", 60, 63], ["cardiovascular disease", "DISEASE", 84, 106], ["patients", "ORGANISM", 43, 51], ["ACEI", "SIMPLE_CHEMICAL", 55, 59], ["ARB", "SIMPLE_CHEMICAL", 60, 63], ["cardiovascular", "ANATOMICAL_SYSTEM", 84, 98], ["troponin T", "GENE_OR_GENE_PRODUCT", 120, 130], ["TnT", "GENE_OR_GENE_PRODUCT", 132, 135], ["troponin T", "PROTEIN", 120, 130], ["TnT", "PROTEIN", 132, 135], ["patients", "SPECIES", 43, 51], ["ACEI", "TREATMENT", 55, 59], ["ARB", "TREATMENT", 60, 63], ["cardiovascular disease", "PROBLEM", 84, 106], ["elevated troponin T (TnT) levels", "PROBLEM", 111, 143], ["cardiovascular", "ANATOMY", 84, 98], ["disease", "OBSERVATION", 99, 106]]], ["(Table 2DiscussionDespite the worldwide implementation of public health measures like social distancing, contact tracing and mass testing to aid in the control of COVID-19, the global cases have risen to more than 3 million and over 200.000 patients lost their lives by April 27 th , 2020 [2, 21] , which further requires attention.", [["patients", "ORGANISM", 241, 249], ["patients", "SPECIES", 241, 249], ["public health measures", "TREATMENT", 58, 80], ["contact tracing", "TEST", 105, 120], ["mass testing", "TEST", 125, 137], ["COVID", "TEST", 163, 168]]], ["Several studies have reported increased rates of COVID-19 associated mortality in patients with significant comorbidities viz hypertension, cardiovascular disease, chronic kidney disease, heart failure etc. [3, 4] Although ACEI and ARB are commonly prescribed to treat some of these comorbidities, the fact that ACE2 receptor is the main binding site for entry of SARS-CoV-2, caused concerns regarding the use of ACEI and ARB in such patients [5, 22] .DiscussionSeveral evidence-based consensus and position statements were formulated by various cardiovascular and hypertension societies which recommended continued use of ACE inhibitors and ARB in COVID-19 patients citing the lack of any contrary clinical evidence [8] [9] [10] [11] .", [["cardiovascular", "ANATOMY", 140, 154], ["kidney", "ANATOMY", 172, 178], ["heart", "ANATOMY", 188, 193], ["cardiovascular", "ANATOMY", 546, 560], ["hypertension", "DISEASE", 126, 138], ["cardiovascular disease", "DISEASE", 140, 162], ["chronic kidney disease", "DISEASE", 164, 186], ["heart failure", "DISEASE", 188, 201], ["ACEI", "CHEMICAL", 223, 227], ["ARB", "CHEMICAL", 232, 235], ["SARS", "DISEASE", 364, 368], ["ACEI", "CHEMICAL", 413, 417], ["ARB", "CHEMICAL", 422, 425], ["hypertension", "DISEASE", 565, 577], ["ACE inhibitors", "CHEMICAL", 623, 637], ["ARB", "CHEMICAL", 642, 645], ["patients", "ORGANISM", 82, 90], ["kidney", "ORGAN", 172, 178], ["heart", "ORGAN", 188, 193], ["ACEI", "SIMPLE_CHEMICAL", 223, 227], ["ARB", "SIMPLE_CHEMICAL", 232, 235], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 312, 325], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 364, 374], ["ACEI", "SIMPLE_CHEMICAL", 413, 417], ["ARB", "SIMPLE_CHEMICAL", 422, 425], ["patients", "ORGANISM", 434, 442], ["ACE", "GENE_OR_GENE_PRODUCT", 623, 626], ["ARB", "SIMPLE_CHEMICAL", 642, 645], ["patients", "ORGANISM", 658, 666], ["[8] [9] [10] [11]", "SIMPLE_CHEMICAL", 717, 734], ["ACE2 receptor", "PROTEIN", 312, 325], ["patients", "SPECIES", 82, 90], ["patients", "SPECIES", 434, 442], ["patients", "SPECIES", 658, 666], ["Several studies", "TEST", 0, 15], ["increased rates of COVID", "PROBLEM", 30, 54], ["significant comorbidities viz hypertension", "PROBLEM", 96, 138], ["cardiovascular disease", "PROBLEM", 140, 162], ["chronic kidney disease", "PROBLEM", 164, 186], ["heart failure etc", "PROBLEM", 188, 205], ["ACEI", "TREATMENT", 223, 227], ["ARB", "TREATMENT", 232, 235], ["these comorbidities", "PROBLEM", 277, 296], ["ACE2 receptor", "TREATMENT", 312, 325], ["SARS", "PROBLEM", 364, 368], ["ACEI", "TREATMENT", 413, 417], ["ARB", "TREATMENT", 422, 425], ["various cardiovascular and hypertension societies", "PROBLEM", 538, 587], ["ACE inhibitors", "TREATMENT", 623, 637], ["ARB in COVID", "TREATMENT", 642, 654], ["increased", "OBSERVATION_MODIFIER", 30, 39], ["hypertension", "OBSERVATION", 126, 138], ["cardiovascular disease", "OBSERVATION", 140, 162], ["chronic", "OBSERVATION_MODIFIER", 164, 171], ["kidney", "ANATOMY", 172, 178], ["disease", "OBSERVATION", 179, 186], ["heart", "ANATOMY", 188, 193], ["failure", "OBSERVATION", 194, 201], ["hypertension", "OBSERVATION", 565, 577]]], ["Since then, however, several clinical studies have evaluated the association of ACE inhibitors and ARB in COVID-19 patients and comorbidities.DiscussionIt is imperative to accurately predict clinical outcomes of COVID-19 patients especially those with comorbidities and taking ACEI or ARB to decide whether to continue or switch to another medication.", [["ARB", "CHEMICAL", 99, 102], ["ACEI", "CHEMICAL", 277, 281], ["ARB", "CHEMICAL", 285, 288], ["ACE", "GENE_OR_GENE_PRODUCT", 80, 83], ["ARB", "SIMPLE_CHEMICAL", 99, 102], ["patients", "ORGANISM", 115, 123], ["patients", "ORGANISM", 221, 229], ["ARB", "SIMPLE_CHEMICAL", 285, 288], ["patients", "SPECIES", 115, 123], ["patients", "SPECIES", 221, 229], ["several clinical studies", "TEST", 21, 45], ["ACE inhibitors", "TREATMENT", 80, 94], ["ARB", "TREATMENT", 99, 102], ["comorbidities", "PROBLEM", 128, 141], ["comorbidities", "PROBLEM", 252, 265], ["ACEI", "TREATMENT", 277, 281], ["ARB", "TREATMENT", 285, 288], ["another medication", "TREATMENT", 332, 350]]], ["However, there were conflicting findings reported in several studies as Meng J. et al, Liu Y. et al and Feng Y. reported that patients on ACE inhibitors/ARB had lower rates of severe outcomes whereas Richardson S. et al reported higher rates of invasive ventilation and ICU admissions in patients on ACE inhibitors/ARB as compared to non-users and Guo J. et al found that patients on ACE inhibitors/ARB had higher rates of cardiovascular disease and elevated troponin T (TnT) levels.", [["cardiovascular", "ANATOMY", 423, 437], ["ACE inhibitors", "CHEMICAL", 138, 152], ["ARB", "CHEMICAL", 153, 156], ["ACE inhibitors", "CHEMICAL", 300, 314], ["ARB", "CHEMICAL", 315, 318], ["ACE inhibitors", "CHEMICAL", 384, 398], ["ARB", "CHEMICAL", 399, 402], ["cardiovascular disease", "DISEASE", 423, 445], ["patients", "ORGANISM", 126, 134], ["ACE", "GENE_OR_GENE_PRODUCT", 138, 141], ["ARB", "SIMPLE_CHEMICAL", 153, 156], ["patients", "ORGANISM", 288, 296], ["ACE", "GENE_OR_GENE_PRODUCT", 300, 303], ["ARB", "SIMPLE_CHEMICAL", 315, 318], ["patients", "ORGANISM", 372, 380], ["ACE", "GENE_OR_GENE_PRODUCT", 384, 387], ["ARB", "SIMPLE_CHEMICAL", 399, 402], ["cardiovascular", "ANATOMICAL_SYSTEM", 423, 437], ["troponin T", "GENE_OR_GENE_PRODUCT", 459, 469], ["TnT", "GENE_OR_GENE_PRODUCT", 471, 474], ["troponin T", "PROTEIN", 459, 469], ["TnT", "PROTEIN", 471, 474], ["patients", "SPECIES", 126, 134], ["patients", "SPECIES", 288, 296], ["patients", "SPECIES", 372, 380], ["conflicting findings", "PROBLEM", 20, 40], ["several studies", "TEST", 53, 68], ["ACE inhibitors", "TREATMENT", 138, 152], ["ARB", "TREATMENT", 153, 156], ["severe outcomes", "PROBLEM", 176, 191], ["invasive ventilation", "TREATMENT", 245, 265], ["ACE inhibitors", "TREATMENT", 300, 314], ["ARB", "TREATMENT", 315, 318], ["ACE inhibitors", "TREATMENT", 384, 398], ["ARB", "TREATMENT", 399, 402], ["cardiovascular disease", "PROBLEM", 423, 445], ["elevated troponin T (TnT) levels", "PROBLEM", 450, 482], ["invasive ventilation", "OBSERVATION", 245, 265], ["cardiovascular", "ANATOMY", 423, 437], ["disease", "OBSERVATION", 438, 445]]], ["It is pertinent to note that all above studies did not perform adjustment for covariates or matching for analysis, undermining the statistical strength of their results to a certain extent [12, 14, 15, 17, 18] .", [["all above studies", "TEST", 29, 46], ["analysis", "TEST", 105, 113]]], ["However, Zhang P. et al did perform matching and an adjusted analysis of 348 patients in which he found slightly higher rates of ICU admissions in patients on ACE inhibitors (21.4%) and ARB (20.8%) as compared to non-users (14.8%) [16] .", [["ARB", "CHEMICAL", 186, 189], ["patients", "ORGANISM", 77, 85], ["patients", "ORGANISM", 147, 155], ["ACE", "GENE_OR_GENE_PRODUCT", 159, 162], ["patients", "SPECIES", 77, 85], ["patients", "SPECIES", 147, 155], ["an adjusted analysis", "TEST", 49, 69], ["ACE inhibitors", "TREATMENT", 159, 173], ["ARB", "TEST", 186, 189]]], ["Zhang P. et al again performed matching and adjustment in assessing the mortality outcomes strengthening their conclusions regarding safety of ACEI/ARB, however a large sample size study conducted in New York in over 1000 COVID-19 patients by Richardson S. et al raised concerns of worse mortality outcomes with ACEI/ ARB and cannot be overlooked [15, 16] .DiscussionSeveral hypotheses have been put forward explaining the positive and negative aspects of ACEI/ARB administration in COVID-19 patients.", [["ACEI", "CHEMICAL", 143, 147], ["ARB", "CHEMICAL", 148, 151], ["ACEI", "CHEMICAL", 312, 316], ["ARB", "CHEMICAL", 318, 321], ["ACEI", "CHEMICAL", 456, 460], ["ARB", "CHEMICAL", 461, 464], ["ACEI", "SIMPLE_CHEMICAL", 143, 147], ["ARB", "SIMPLE_CHEMICAL", 148, 151], ["patients", "ORGANISM", 231, 239], ["ACEI", "SIMPLE_CHEMICAL", 312, 316], ["ARB", "SIMPLE_CHEMICAL", 318, 321], ["ACEI", "SIMPLE_CHEMICAL", 456, 460], ["ARB", "SIMPLE_CHEMICAL", 461, 464], ["patients", "ORGANISM", 492, 500], ["patients", "SPECIES", 231, 239], ["patients", "SPECIES", 492, 500], ["ACEI", "TREATMENT", 143, 147], ["ARB", "TREATMENT", 148, 151], ["a large sample size study", "TEST", 161, 186], ["ACEI", "TREATMENT", 312, 316], ["ARB", "TREATMENT", 318, 321], ["ACEI", "TREATMENT", 456, 460], ["ARB administration", "TREATMENT", 461, 479]]], ["Positive effects include ACE2 receptor blockade, disabling viral entry into the heart and lungs, and an overall decrease in inflammation secondary to ACEI/ARB, suggesting the use of ACEI might be protective against respiratory complications.", [["heart", "ANATOMY", 80, 85], ["lungs", "ANATOMY", 90, 95], ["respiratory", "ANATOMY", 215, 226], ["inflammation", "DISEASE", 124, 136], ["ACEI", "CHEMICAL", 150, 154], ["ARB", "CHEMICAL", 155, 158], ["ACEI", "CHEMICAL", 182, 186], ["respiratory complications", "DISEASE", 215, 240], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 25, 38], ["heart", "ORGAN", 80, 85], ["lungs", "ORGAN", 90, 95], ["ACEI", "SIMPLE_CHEMICAL", 150, 154], ["ARB", "SIMPLE_CHEMICAL", 155, 158], ["ACEI", "SIMPLE_CHEMICAL", 182, 186], ["ACE2", "PROTEIN", 25, 29], ["ACE2 receptor blockade", "TREATMENT", 25, 47], ["disabling viral entry into the heart and lungs", "PROBLEM", 49, 95], ["inflammation", "PROBLEM", 124, 136], ["ACEI", "TREATMENT", 150, 154], ["ARB", "TREATMENT", 155, 158], ["ACEI", "TREATMENT", 182, 186], ["respiratory complications", "PROBLEM", 215, 240], ["receptor blockade", "OBSERVATION", 30, 47], ["disabling", "OBSERVATION_MODIFIER", 49, 58], ["viral", "OBSERVATION", 59, 64], ["heart", "ANATOMY", 80, 85], ["lungs", "ANATOMY", 90, 95], ["overall", "OBSERVATION_MODIFIER", 104, 111], ["decrease", "OBSERVATION_MODIFIER", 112, 120], ["inflammation", "OBSERVATION", 124, 136]]], ["Negative effects include a possible retrograde feedback mechanism, by which .", [["retrograde feedback mechanism", "PROBLEM", 36, 65], ["possible", "UNCERTAINTY", 27, 35], ["feedback mechanism", "OBSERVATION", 47, 65]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 5, 2020. .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["ACE2 receptors are upregulated, which may lead to severe pneumonia increasing risk of severe outcomes and mortality [23] .", [["pneumonia", "DISEASE", 57, 66], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["ACE2 receptors", "PROTEIN", 0, 14], ["ACE2 receptors", "TREATMENT", 0, 14], ["severe pneumonia", "PROBLEM", 50, 66], ["severe outcomes", "PROBLEM", 86, 101], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["pneumonia", "OBSERVATION", 57, 66], ["severe", "OBSERVATION_MODIFIER", 86, 92]]], ["Individuals with ACE2 polymorphisms have an increased genetic predisposition for an increased risk of SARS-CoV-2 infection and may have harmful effects of ACEI/ARB [24] .", [["SARS-CoV-2 infection", "DISEASE", 102, 122], ["ACEI", "CHEMICAL", 155, 159], ["ARB", "CHEMICAL", 160, 163], ["ACE2", "GENE_OR_GENE_PRODUCT", 17, 21], ["SARS-CoV-2", "ORGANISM", 102, 112], ["ACEI", "SIMPLE_CHEMICAL", 155, 159], ["ACE2", "PROTEIN", 17, 21], ["SARS-CoV", "SPECIES", 102, 110], ["ACE2 polymorphisms", "TREATMENT", 17, 35], ["an increased genetic predisposition", "TREATMENT", 41, 76], ["SARS", "PROBLEM", 102, 106], ["CoV", "PROBLEM", 107, 110], ["2 infection", "PROBLEM", 111, 122], ["ACEI", "TREATMENT", 155, 159], ["ARB", "TREATMENT", 160, 163]]], ["This aspect is worth considering and needs to be evaluated in future studies .(which was not certified by peer review)To best of our knowledge, this systematic review is a comprehensive exploration and analysis of existing literature in this topic till date.", [["a comprehensive exploration", "TEST", 170, 197]]], ["Our review has limitations in its rigor due to the scarce existing data and diverse study types available.", [["diverse study", "TEST", 76, 89]]], ["The rapidly emerging knowledge base of COVID-19 poses the possibility that few studies (particularly unpublished/under peer review) remain un-captured.", [["COVID-19", "CHEMICAL", 39, 47], ["COVID", "TEST", 39, 44], ["few studies", "TEST", 75, 86]]], ["We have also tried to comprehensively review and analyze the existing data.(which was not certified by peer review)Considering the inconsistent clinical studies and conflicting hypothesis, it is essential to evaluate the clinical outcomes in COVID-19 patients on ACEI/ARB in future large studies, particularly randomized controlled trials and additionally evaluate the association of clinical outcomes with ACE2 polymorphisms.", [["ACEI", "CHEMICAL", 263, 267], ["ARB", "CHEMICAL", 268, 271], ["patients", "ORGANISM", 251, 259], ["ACEI", "SIMPLE_CHEMICAL", 263, 267], ["ARB", "SIMPLE_CHEMICAL", 268, 271], ["ACE2", "GENE_OR_GENE_PRODUCT", 407, 411], ["ACE2", "PROTEIN", 407, 411], ["patients", "SPECIES", 251, 259], ["ACEI", "TREATMENT", 263, 267], ["ARB", "TREATMENT", 268, 271], ["large studies", "TEST", 282, 295], ["randomized controlled trials", "TREATMENT", 310, 338], ["ACE2 polymorphisms", "PROBLEM", 407, 425]]], ["Based on this, there are ongoing trials studying the effect of Losartan (an ARB) in patients with COVID-19 in outpatient and inpatient settings (NCT04311177, NCT04312009) [25, 26] .ConclusionIt is concluded that ACEI and ARB should be continued in COVID-19 patients, albeit while exercising caution until larger clinical studies and RCT confirm their safety.", [["Losartan", "CHEMICAL", 63, 71], ["ARB", "CHEMICAL", 76, 79], ["ACEI", "CHEMICAL", 212, 216], ["ARB", "CHEMICAL", 221, 224], ["Losartan", "CHEMICAL", 63, 71], ["Losartan", "SIMPLE_CHEMICAL", 63, 71], ["ARB", "SIMPLE_CHEMICAL", 76, 79], ["patients", "ORGANISM", 84, 92], ["ACEI", "SIMPLE_CHEMICAL", 212, 216], ["ARB", "SIMPLE_CHEMICAL", 221, 224], ["patients", "ORGANISM", 257, 265], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 257, 265], ["Losartan", "TREATMENT", 63, 71], ["an ARB", "TREATMENT", 73, 79], ["COVID", "TEST", 98, 103], ["ACEI", "TREATMENT", 212, 216], ["ARB", "TREATMENT", 221, 224], ["larger clinical studies", "TEST", 305, 328], ["RCT", "TEST", 333, 336]]], ["Additionally, the individual patient factors like ACE2 polymorphisms which might confer higher risk of adverse outcomes need to be evaluated further.Conclusion.", [["patient", "ORGANISM", 29, 36], ["ACE2", "GENE_OR_GENE_PRODUCT", 50, 54], ["ACE2", "PROTEIN", 50, 54], ["patient", "SPECIES", 29, 36], ["ACE2 polymorphisms", "PROBLEM", 50, 68], ["adverse outcomes", "PROBLEM", 103, 119]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 5, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 5, 2020. . https://doi.org/10.1101/2020.04.29.20085787 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 5, 2020. . https://doi.org/10.1101/2020.04.29.20085787 doi: medRxiv preprint * The severity of COVID-19 was identified during the hospitalization according to the guidelines established by the National Health Commission of the People's Republic of China * Mortality rates for patients with hypertension # Among the 78 patients, 40 were classified as having mild disease (COVID-19-M), and 38 were classified as severe condition (COVID-19-S) according to New Coronavirus Pneumonia Prevention and Control Program published by the National Health Commission of China + Other regimens $ Primary endpoint primary endpoint being death or transfer to a critical care unit for organ support within 7-days of symptom onset. @ Before matching; !", [["organ", "ANATOMY", 1409, 1414], ["CC", "CHEMICAL", 0, 2], ["hypertension", "DISEASE", 1031, 1043], ["Pneumonia", "DISEASE", 1210, 1219], ["death", "DISEASE", 1363, 1368], ["patients", "ORGANISM", 1017, 1025], ["patients", "ORGANISM", 1059, 1067], ["organ", "ORGAN", 1409, 1414], ["patients", "SPECIES", 1017, 1025], ["patients", "SPECIES", 1059, 1067], ["The copyright holder", "TREATMENT", 198, 218], ["The copyright holder", "TREATMENT", 404, 424], ["The copyright holder", "TREATMENT", 678, 698], ["COVID", "TEST", 836, 841], ["hypertension", "PROBLEM", 1031, 1043], ["mild disease", "PROBLEM", 1098, 1110], ["COVID", "TEST", 1112, 1117], ["severe condition", "PROBLEM", 1151, 1167], ["COVID", "TEST", 1169, 1174], ["New Coronavirus Pneumonia", "PROBLEM", 1194, 1219], ["organ support", "TREATMENT", 1409, 1422], ["symptom onset", "PROBLEM", 1440, 1453], ["med", "ANATOMY", 102, 105], ["med", "ANATOMY", 308, 311], ["med", "ANATOMY", 582, 585], ["mild", "OBSERVATION_MODIFIER", 1098, 1102], ["disease", "OBSERVATION", 1103, 1110], ["Coronavirus", "OBSERVATION_MODIFIER", 1198, 1209], ["Pneumonia", "OBSERVATION", 1210, 1219]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted May 5, 2020. . https://doi.org/10.1101/2020.04.29.20085787 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 239, 259], ["medRxiv", "TREATMENT", 362, 369], ["med", "ANATOMY", 102, 105]]]], "PMC7152307": [["Standard Precautions ::: Infection Control ConsiderationsStandard precautions include preventing contact with blood, all body fluids, secretions and excretions, nonintact skin, and mucous membranes by (1) careful handwashing before and after every patient contact; (2) use of gloves when touching body fluids, nonintact skin, or mucous membranes or any items contaminated with body fluids (linens, equipment, devices, etc.); (3) use of nonsterile gowns to prevent contact of clothing with body fluids; (4) use of masks, eye protection, or face shields when splashing with body fluids is possible; and (5) appropriate disposal of these materials.", [["blood", "ANATOMY", 110, 115], ["body fluids", "ANATOMY", 121, 132], ["secretions", "ANATOMY", 134, 144], ["skin", "ANATOMY", 171, 175], ["mucous membranes", "ANATOMY", 181, 197], ["body fluids", "ANATOMY", 297, 308], ["skin", "ANATOMY", 320, 324], ["mucous membranes", "ANATOMY", 329, 345], ["body", "ANATOMY", 377, 381], ["body", "ANATOMY", 489, 493], ["eye", "ANATOMY", 520, 523], ["body", "ANATOMY", 572, 576], ["blood", "ORGANISM_SUBSTANCE", 110, 115], ["body", "ORGANISM_SUBDIVISION", 121, 125], ["secretions", "ORGANISM_SUBSTANCE", 134, 144], ["skin", "ORGAN", 171, 175], ["mucous membranes", "TISSUE", 181, 197], ["patient", "ORGANISM", 248, 255], ["body", "ORGANISM_SUBDIVISION", 297, 301], ["skin", "ORGAN", 320, 324], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 329, 345], ["body", "ORGANISM_SUBDIVISION", 377, 381], ["body", "ORGANISM_SUBDIVISION", 489, 493], ["eye", "ORGANISM_SUBDIVISION", 520, 523], ["body", "ORGANISM_SUBDIVISION", 572, 576], ["patient", "SPECIES", 248, 255], ["Infection Control", "TREATMENT", 25, 42], ["Standard precautions", "TREATMENT", 57, 77], ["all body fluids", "TREATMENT", 117, 132], ["secretions and excretions", "TEST", 134, 159], ["gloves", "TREATMENT", 276, 282], ["touching body fluids", "TREATMENT", 288, 308], ["mucous membranes", "PROBLEM", 329, 345], ["any items", "PROBLEM", 349, 358], ["body fluids (linens", "TREATMENT", 377, 396], ["equipment, devices", "TREATMENT", 398, 416], ["nonsterile gowns", "TREATMENT", 436, 452], ["clothing with body fluids", "TREATMENT", 475, 500], ["masks", "TREATMENT", 513, 518], ["eye protection", "TREATMENT", 520, 534], ["face shields", "TREATMENT", 539, 551], ["body fluids", "TREATMENT", 572, 583], ["Infection", "OBSERVATION", 25, 34], ["skin", "ANATOMY", 171, 175], ["mucous membranes", "ANATOMY", 181, 197], ["skin", "ANATOMY", 320, 324], ["mucous", "ANATOMY", 329, 335]]], ["Standard precautions should be applied to all patients regardless of actual or perceived risks.", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["Standard precautions", "TREATMENT", 0, 20]]], ["The Centers for Disease Control and Prevention (CDC) does not consider breast milk a body fluid with infectious risks and thus these policies do not apply to breast milk.", [["breast milk", "ANATOMY", 71, 82], ["body fluid", "ANATOMY", 85, 95], ["breast milk", "ANATOMY", 158, 169], ["breast milk", "DISEASE", 158, 169], ["breast milk", "ORGANISM_SUBSTANCE", 71, 82], ["body", "ORGANISM_SUBDIVISION", 85, 89], ["fluid", "ORGANISM_SUBSTANCE", 90, 95], ["breast milk", "ORGANISM_SUBSTANCE", 158, 169], ["Disease Control", "TREATMENT", 16, 31], ["infectious risks", "TREATMENT", 101, 117]]], ["(See section on misadministration of breast milk later in this chapter as a possible exception to this concept.)Standard Precautions ::: Infection Control ConsiderationsIn considering breastfeeding infant-mother dyads and standard precautions, body fluids other than breast milk should be avoided, and only in specified situations should breast milk also be avoided.", [["breast milk", "ANATOMY", 37, 48], ["body fluids", "ANATOMY", 244, 255], ["breast milk", "ANATOMY", 267, 278], ["breast milk", "ANATOMY", 338, 349], ["body", "ORGANISM_SUBDIVISION", 244, 248], ["breast", "ORGANISM_SUBDIVISION", 267, 273], ["milk", "ORGANISM_SUBSTANCE", 274, 278], ["milk", "ORGANISM_SUBSTANCE", 345, 349], ["infant", "SPECIES", 198, 204], ["misadministration of breast milk", "TREATMENT", 16, 48], ["Infection", "PROBLEM", 137, 146], ["standard precautions", "TREATMENT", 222, 242], ["body fluids other than breast milk", "TREATMENT", 244, 278]]], ["In general, clothing or a gown for the mother and bandages, if necessary, should prevent direct contact with nonintact skin or secretions.", [["skin", "ANATOMY", 119, 123], ["secretions", "ANATOMY", 127, 137], ["skin", "ORGAN", 119, 123], ["secretions", "ORGANISM_SUBSTANCE", 127, 137], ["bandages", "TREATMENT", 50, 58], ["secretions", "PROBLEM", 127, 137], ["skin", "ANATOMY", 119, 123], ["secretions", "OBSERVATION", 127, 137]]], ["Avoiding infant contact with maternal mucous membranes requires mothers to be aware of and understand the risks and to make a conscious effort to avoid this type of contact.", [["mucous membranes", "ANATOMY", 38, 54], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 38, 54], ["maternal mucous membranes", "PROBLEM", 29, 54], ["mucous membranes", "ANATOMY", 38, 54]]], ["The use of gloves, gowns, and masks on infants for protection is neither practical nor appropriate.", [["infants", "ORGANISM", 39, 46], ["infants", "SPECIES", 39, 46], ["gloves", "TREATMENT", 11, 17], ["gowns", "TREATMENT", 19, 24], ["protection", "TREATMENT", 51, 61]]], ["The recommendations concerning the appropriateness of breastfeeding and breast milk are addressed for specific infectious agents throughout this chapter.", [["breast milk", "ANATOMY", 72, 83], ["breast milk", "ORGANISM_SUBSTANCE", 72, 83], ["breastfeeding and breast milk", "TREATMENT", 54, 83], ["specific infectious agents", "TREATMENT", 102, 128], ["breast", "ANATOMY", 72, 78]]], ["Human immunodeficiency virus (HIV) infection is an example of one infection that can be prevented by the use of standard precautions, including avoiding breast milk and breastfeeding.", [["breast milk", "ANATOMY", 153, 164], ["Human immunodeficiency virus (HIV) infection", "DISEASE", 0, 44], ["infection", "DISEASE", 66, 75], ["breast milk", "DISEASE", 153, 164], ["Human immunodeficiency virus", "ORGANISM", 0, 28], ["HIV", "ORGANISM", 30, 33], ["Human immunodeficiency virus (HIV", "SPECIES", 0, 33], ["Human immunodeficiency virus", "SPECIES", 0, 28], ["HIV", "SPECIES", 30, 33], ["Human immunodeficiency virus (HIV) infection", "PROBLEM", 0, 44], ["one infection", "PROBLEM", 62, 75], ["standard precautions", "TREATMENT", 112, 132], ["avoiding breast milk", "TREATMENT", 144, 164], ["immunodeficiency virus", "OBSERVATION", 6, 28], ["infection", "OBSERVATION", 66, 75]]], ["The recommendations concerning breastfeeding and HIV and the various variables and considerations involved are discussed later.", [["HIV", "SPECIES", 49, 52], ["HIV", "SPECIES", 49, 52], ["breastfeeding", "TREATMENT", 31, 44], ["HIV", "PROBLEM", 49, 52]]]], "3849959f1c28390d6e68f118cc8de3c79da8bbc7": [["IntroductionNovel coronavirus disease 2019 (COVID-19) outbreak emerged in Wuhan in Hubei province, 1 2 3 which the text body contains the words \"No COVID.\"IntroductionUltimately, a total of 18 patients (median age: 57 years) who were considered positive for COVID-19 viral pneumonia on CT imaging were selected for the study (Figure 1 ).FIGURE 1: Study algorithmCOVID-19: coronavirus disease 2019; CT: computed tomography; RT-PCR: reverse transcriptionpolymerase chain reactionCT protocolsHigh-resolution CT (HRCT), CT of the chest, abdomen, and pelvis (CT-CAP), and/or CT pulmonary angiography (CTPA) were used for detecting pulmonary lesions.", [["chest", "ANATOMY", 526, 531], ["abdomen", "ANATOMY", 533, 540], ["pelvis", "ANATOMY", 546, 552], ["pulmonary", "ANATOMY", 573, 582], ["pulmonary lesions", "ANATOMY", 626, 643], ["coronavirus disease", "DISEASE", 18, 37], ["COVID-19", "CHEMICAL", 44, 52], ["viral pneumonia", "DISEASE", 267, 282], ["coronavirus disease", "DISEASE", 372, 391], ["pulmonary lesions", "DISEASE", 626, 643], ["patients", "ORGANISM", 193, 201], ["coronavirus", "ORGANISM", 372, 383], ["chest", "MULTI-TISSUE_STRUCTURE", 526, 531], ["abdomen", "ORGAN", 533, 540], ["pelvis", "ORGAN", 546, 552], ["pulmonary", "ORGAN", 573, 582], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 626, 643], ["patients", "SPECIES", 193, 201], ["Novel coronavirus disease", "PROBLEM", 12, 37], ["COVID", "TEST", 258, 263], ["viral pneumonia", "PROBLEM", 267, 282], ["CT imaging", "TEST", 286, 296], ["the study", "TEST", 315, 324], ["Study algorithmCOVID", "TEST", 347, 367], ["coronavirus disease", "PROBLEM", 372, 391], ["CT", "TEST", 398, 400], ["computed tomography", "TEST", 402, 421], ["RT-PCR", "TEST", 423, 429], ["High-resolution CT (HRCT", "TEST", 489, 513], ["CT of the chest, abdomen, and pelvis (CT-CAP)", "TEST", 516, 561], ["CT pulmonary angiography", "TEST", 570, 594], ["CTPA", "TEST", 596, 600], ["pulmonary lesions", "PROBLEM", 626, 643], ["coronavirus disease", "OBSERVATION", 18, 37], ["viral", "OBSERVATION_MODIFIER", 267, 272], ["pneumonia", "OBSERVATION", 273, 282], ["chest", "ANATOMY", 526, 531], ["abdomen", "ANATOMY", 533, 540], ["pelvis", "ANATOMY", 546, 552], ["pulmonary", "ANATOMY", 573, 582], ["pulmonary", "ANATOMY", 626, 635], ["lesions", "OBSERVATION", 636, 643]]], ["All images were obtained with a CT scan (GE Frontier; GE Healthcare, Chicago, IL) with patients in the supine position.", [["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["All images", "TEST", 0, 10], ["a CT scan", "TEST", 30, 39]]], ["Scans were performed with the following technical parameters: HRCT and CT-CAP: 120 kV, auto modulated mA, 0.625 slice thickness, 512\u00d7512 matrix; CTPA: 100 kV, auto modulated mA, 0.625 slice thickness, 512\u00d7512 matrix.", [["slice", "ANATOMY", 184, 189], ["Scans", "TEST", 0, 5], ["HRCT", "TEST", 62, 66], ["CT", "TEST", 71, 73], ["auto modulated mA", "TREATMENT", 87, 104], ["slice thickness", "TEST", 112, 127], ["CTPA", "TEST", 145, 149], ["auto modulated mA", "TREATMENT", 159, 176], ["slice thickness", "TEST", 184, 199]]], ["Reconstructed images were also obtained and used for the current study.Image analysisTwo board-certified radiologists (E.P. and U.M., with 25 and five years of experience, respectively) 2020 reviewed the chest CT images on a picture archiving and communication system (PACS, Carestream Health, Inc, Rochester, NY).", [["Reconstructed images", "TEST", 0, 20], ["the current study", "TEST", 53, 70], ["Image analysis", "TEST", 71, 85], ["the chest CT images", "TEST", 200, 219], ["chest", "ANATOMY", 204, 209]]], ["Chest CT images were evaluated with both mediastinal (width: 350 HU, level: 40 HU) and lung (width: 1500 HU, level: -500 HU) window level settings.", [["mediastinal", "ANATOMY", 41, 52], ["lung", "ANATOMY", 87, 91], ["lung", "ORGAN", 87, 91], ["Chest CT images", "TEST", 0, 15], ["level", "TEST", 109, 114], ["mediastinal", "ANATOMY", 41, 52], ["350 HU", "OBSERVATION_MODIFIER", 61, 67], ["40 HU", "OBSERVATION_MODIFIER", 76, 81], ["lung", "ANATOMY", 87, 91], ["1500 HU", "OBSERVATION_MODIFIER", 100, 107], ["500 HU", "OBSERVATION_MODIFIER", 117, 123]]], ["The two radiologists identified pulmonary lesions based on their density, shape, and margin.", [["pulmonary lesions", "ANATOMY", 32, 49], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 32, 49], ["pulmonary lesions", "PROBLEM", 32, 49], ["pulmonary", "ANATOMY", 32, 41], ["lesions", "OBSERVATION", 42, 49], ["density", "OBSERVATION_MODIFIER", 65, 72], ["shape", "OBSERVATION_MODIFIER", 74, 79], ["margin", "OBSERVATION_MODIFIER", 85, 91]]], ["The locations of the lung lesions were recorded as lobar, axial, anterior, and posterior.", [["lung lesions", "ANATOMY", 21, 33], ["lobar", "ANATOMY", 51, 56], ["axial", "ANATOMY", 58, 63], ["anterior", "ANATOMY", 65, 73], ["lung lesions", "CANCER", 21, 33], ["anterior", "MULTI-TISSUE_STRUCTURE", 65, 73], ["the lung lesions", "PROBLEM", 17, 33], ["lung", "ANATOMY", 21, 25], ["lesions", "OBSERVATION", 26, 33], ["lobar", "ANATOMY_MODIFIER", 51, 56], ["axial", "OBSERVATION_MODIFIER", 58, 63], ["anterior", "ANATOMY_MODIFIER", 65, 73], ["posterior", "ANATOMY_MODIFIER", 79, 88]]], ["Axial locations were categorized as central (inner two-thirds of the lung) or peripheral (outer one-third of the lung).", [["lung", "ANATOMY", 69, 73], ["lung", "ANATOMY", 113, 117], ["lung", "ORGAN", 69, 73], ["lung", "ORGAN", 113, 117], ["central", "OBSERVATION_MODIFIER", 36, 43], ["lung", "ANATOMY", 69, 73], ["peripheral", "ANATOMY_MODIFIER", 78, 88], ["lung", "ANATOMY", 113, 117]]], ["Each lung was divided by an axial line into anterior and posterior halves (Figures 2, 7) .", [["lung", "ANATOMY", 5, 9], ["axial line", "ANATOMY", 28, 38], ["anterior", "ANATOMY", 44, 52], ["lung", "ORGAN", 5, 9], ["anterior", "MULTI-TISSUE_STRUCTURE", 44, 52], ["lung", "ANATOMY", 5, 9], ["axial line", "OBSERVATION", 28, 38], ["anterior", "ANATOMY_MODIFIER", 44, 52], ["posterior", "ANATOMY_MODIFIER", 57, 66], ["halves", "ANATOMY_MODIFIER", 67, 73]]], ["The densities of the patchy-confluent lesions were classified as pure GGO, pure consolidation, or mixed.", [["lesions", "ANATOMY", 38, 45], ["lesions", "PATHOLOGICAL_FORMATION", 38, 45], ["the patchy-confluent lesions", "PROBLEM", 17, 45], ["pure GGO", "PROBLEM", 65, 73], ["pure consolidation", "PROBLEM", 75, 93], ["densities", "OBSERVATION_MODIFIER", 4, 13], ["patchy", "OBSERVATION_MODIFIER", 21, 27], ["confluent", "OBSERVATION_MODIFIER", 28, 37], ["lesions", "OBSERVATION", 38, 45], ["pure", "OBSERVATION_MODIFIER", 65, 69], ["GGO", "OBSERVATION", 70, 73], ["pure", "OBSERVATION_MODIFIER", 75, 79], ["consolidation", "OBSERVATION", 80, 93], ["mixed", "OBSERVATION_MODIFIER", 98, 103]]], ["Nodular lesion densities were classified as pure GGO, solid, or partly solid.", [["Nodular lesion", "ANATOMY", 0, 14], ["Nodular lesion", "CANCER", 0, 14], ["Nodular lesion densities", "PROBLEM", 0, 24], ["lesion", "OBSERVATION", 8, 14], ["pure", "OBSERVATION_MODIFIER", 44, 48], ["GGO", "OBSERVATION", 49, 52]]], ["Margins were classified as well-defined or ill-defined.", [["ill", "OBSERVATION_MODIFIER", 43, 46]]], ["As most of the lesions were patchy, confluent, and illdefined margins, lesion sizes were not assessed.", [["lesions", "ANATOMY", 15, 22], ["lesion", "ANATOMY", 71, 77], ["lesions", "PATHOLOGICAL_FORMATION", 15, 22], ["the lesions", "PROBLEM", 11, 22], ["patchy, confluent, and illdefined margins", "PROBLEM", 28, 69], ["lesion sizes", "PROBLEM", 71, 83], ["lesions", "OBSERVATION", 15, 22], ["patchy", "OBSERVATION_MODIFIER", 28, 34], ["confluent", "OBSERVATION_MODIFIER", 36, 45], ["illdefined", "OBSERVATION_MODIFIER", 51, 61], ["margins", "OBSERVATION_MODIFIER", 62, 69], ["lesion", "OBSERVATION_MODIFIER", 71, 77], ["sizes", "OBSERVATION_MODIFIER", 78, 83]]], ["Instead, a visual severity score, which was slightly modified from Pan et al., ranging from 0 to 4 for each individual lobes was calculated.", [["lobes", "ANATOMY", 119, 124], ["lobes", "MULTI-TISSUE_STRUCTURE", 119, 124], ["a visual severity score", "TEST", 9, 32], ["Pan et al.", "TEST", 67, 77]]], ["Each of the five lung lobes was visually scored on a scale of 0 to 4 as follows: 0: no involvement; 1: less than 25% involvement; 2: 25-50% involvement; 3: 50-75% involvement; and 4: 75-100% involvement.Image analysisThe total CT score was the sum of all individual five lobar scores ranging from 0 (no involvement) to 20 (maximum involvement).FIGURE 2: Division of lung fields in the axial planeDividing lung fields equally into two axial planes on CT: blue represents the anterior half; brown represents the posterior half CT: computed tomographyLaboratory testsAll patients underwent nose-throat swab tests for RT-PCR (Xpert\u00ae Xpress SARS-CoV-2, Cepheid Inc, Sunnyvale, CA; FDA-endorsed) and film array, neutrophil, lymphocyte, C-reactive protein (CRP), and D-dimer tests.Statistical analysisThe distributions of the lesion pattern and severity score proportions were analyzed.", [["lung lobes", "ANATOMY", 17, 27], ["lobar", "ANATOMY", 271, 276], ["lung", "ANATOMY", 366, 370], ["axial planeDividing lung", "ANATOMY", 385, 409], ["anterior half", "ANATOMY", 474, 487], ["neutrophil", "ANATOMY", 706, 716], ["lymphocyte", "ANATOMY", 718, 728], ["lesion", "ANATOMY", 819, 825], ["lung lobes", "MULTI-TISSUE_STRUCTURE", 17, 27], ["lung", "ORGAN", 366, 370], ["lung", "ORGAN", 405, 409], ["patients", "ORGANISM", 568, 576], ["nose", "ORGANISM_SUBDIVISION", 587, 591], ["neutrophil", "CELL", 706, 716], ["lymphocyte", "CELL", 718, 728], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 730, 748], ["CRP", "GENE_OR_GENE_PRODUCT", 750, 753], ["D-dimer", "GENE_OR_GENE_PRODUCT", 760, 767], ["neutrophil, lymphocyte, C-reactive protein", "PROTEIN", 706, 748], ["CRP", "PROTEIN", 750, 753], ["patients", "SPECIES", 568, 576], ["a scale", "TEST", 51, 58], ["Image analysis", "TEST", 203, 217], ["The total CT score", "TEST", 217, 235], ["lobar scores", "TEST", 271, 283], ["CT", "TEST", 450, 452], ["the posterior half CT", "TEST", 506, 527], ["computed tomographyLaboratory tests", "TEST", 529, 564], ["nose-throat swab tests", "TEST", 587, 609], ["RT-PCR", "TEST", 614, 620], ["Xpert", "TEST", 622, 627], ["SARS", "TEST", 636, 640], ["CoV", "TEST", 641, 644], ["film array", "TEST", 694, 704], ["neutrophil", "TEST", 706, 716], ["lymphocyte", "TEST", 718, 728], ["C", "TEST", 730, 731], ["CRP", "TEST", 750, 753], ["D-dimer tests", "TEST", 760, 773], ["Statistical analysis", "TEST", 774, 794], ["the lesion pattern", "PROBLEM", 815, 833], ["five", "ANATOMY_MODIFIER", 12, 16], ["lung", "ANATOMY", 17, 21], ["lobes", "ANATOMY_MODIFIER", 22, 27], ["no", "UNCERTAINTY", 84, 86], ["lobar", "OBSERVATION_MODIFIER", 271, 276], ["lung", "ANATOMY", 366, 370], ["fields", "ANATOMY_MODIFIER", 371, 377], ["lung", "ANATOMY", 405, 409], ["anterior", "ANATOMY_MODIFIER", 474, 482], ["posterior", "ANATOMY_MODIFIER", 510, 519], ["nose", "ANATOMY", 587, 591], ["throat", "ANATOMY", 592, 598], ["lymphocyte", "ANATOMY", 718, 728], ["lesion", "OBSERVATION", 819, 825]]], ["Fisher's exact test (SPSS Statistics version 25; IBM, Armonk, NY) was applied to analyze the relationship between the severity score and death.", [["death", "DISEASE", 137, 142], ["Fisher's exact test", "TEST", 0, 19], ["death", "PROBLEM", 137, 142]]], ["A p-value of <0.05 was considered statistically significant.ResultsA total of 18 patients (median age: 57) who were considered positive for COVID-19 viral pneumonia on CT imaging were selected.", [["viral pneumonia", "DISEASE", 149, 164], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["A p-value", "TEST", 0, 9], ["COVID", "TEST", 140, 145], ["viral pneumonia", "PROBLEM", 149, 164], ["CT imaging", "TEST", 168, 178], ["viral", "OBSERVATION_MODIFIER", 149, 154], ["pneumonia", "OBSERVATION", 155, 164]]], ["Patient demographics are summarized in Table 1 .", [["Patient", "SPECIES", 0, 7]]], ["No gender predilection was encountered in our cohort (nine men and nine women).", [["men", "ORGANISM", 59, 62], ["women", "ORGANISM", 72, 77], ["men", "SPECIES", 59, 62], ["women", "SPECIES", 72, 77], ["gender predilection", "PROBLEM", 3, 22], ["gender", "OBSERVATION_MODIFIER", 3, 9], ["predilection", "OBSERVATION", 10, 22]]], ["In a majority of cases (15 out of 18), symptoms were chest-related.", [["symptoms", "PROBLEM", 39, 47], ["chest", "ANATOMY", 53, 58]]], ["The remaining cases presented with abdominal symptoms.", [["abdominal", "ANATOMY", 35, 44], ["abdominal symptoms", "DISEASE", 35, 53], ["abdominal", "ORGANISM_SUBDIVISION", 35, 44], ["abdominal symptoms", "PROBLEM", 35, 53], ["abdominal", "ANATOMY", 35, 44], ["symptoms", "OBSERVATION", 45, 53]]], ["One patient was diagnosed with small-bowel obstruction.Chest image resultsOf the 18 cases, 11 had positive X-ray examination results, four had equivocal bilateral ill-defined subtle X-ray changes, and one had negative X-ray results but with CT images consistent with COVID-19 pneumonia.Chest image resultsIn the CT images, GGO plus consolidation was observed bilaterally in all 18 (100%) patients.", [["bowel", "ANATOMY", 37, 42], ["small-bowel obstruction", "DISEASE", 31, 54], ["pneumonia", "DISEASE", 276, 285], ["patient", "ORGANISM", 4, 11], ["-bowel obstruction", "PATHOLOGICAL_FORMATION", 36, 54], ["patients", "ORGANISM", 388, 396], ["patient", "SPECIES", 4, 11], ["patients", "SPECIES", 388, 396], ["small-bowel obstruction", "PROBLEM", 31, 54], ["Chest image", "TEST", 55, 66], ["positive X-ray examination", "TEST", 98, 124], ["equivocal bilateral ill-defined subtle X-ray changes", "PROBLEM", 143, 195], ["CT images", "TEST", 241, 250], ["COVID", "TEST", 267, 272], ["pneumonia", "PROBLEM", 276, 285], ["Chest image", "TEST", 286, 297], ["the CT images", "TEST", 308, 321], ["GGO plus consolidation", "PROBLEM", 323, 345], ["small", "OBSERVATION_MODIFIER", 31, 36], ["bowel", "ANATOMY", 37, 42], ["obstruction", "OBSERVATION", 43, 54], ["bilateral", "ANATOMY_MODIFIER", 153, 162], ["ill", "OBSERVATION", 163, 166], ["subtle", "OBSERVATION_MODIFIER", 175, 181], ["X-ray", "OBSERVATION_MODIFIER", 182, 187], ["consistent with", "UNCERTAINTY", 251, 266], ["pneumonia", "OBSERVATION", 276, 285], ["GGO", "OBSERVATION", 323, 326], ["consolidation", "OBSERVATION", 332, 345], ["bilaterally", "ANATOMY_MODIFIER", 359, 370]]], ["No pure GGO or pure consolidation was encountered in our cohort.", [["GGO", "DISEASE", 8, 11], ["pure GGO", "PROBLEM", 3, 11], ["pure consolidation", "PROBLEM", 15, 33], ["pure", "OBSERVATION_MODIFIER", 3, 7], ["GGO", "OBSERVATION", 8, 11], ["pure", "OBSERVATION_MODIFIER", 15, 19], ["consolidation", "OBSERVATION", 20, 33]]], ["The predominant shape was amorphous (72%).", [["predominant", "OBSERVATION_MODIFIER", 4, 15], ["shape", "OBSERVATION_MODIFIER", 16, 21], ["amorphous", "OBSERVATION_MODIFIER", 26, 35]]], ["Lesions showed no specific lobar predilection, but most lesions were localized posteriorly and peripherally.Laboratory testsOf the 18 patients with epidemiological, clinical, and radiological findings consistent with COVID-19 pneumonia, 14 had positive and four had negative RT-PCR test results.", [["lobar", "ANATOMY", 27, 32], ["lesions", "ANATOMY", 56, 63], ["pneumonia", "DISEASE", 226, 235], ["lesions", "PATHOLOGICAL_FORMATION", 56, 63], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["Lesions", "PROBLEM", 0, 7], ["specific lobar predilection", "PROBLEM", 18, 45], ["most lesions", "PROBLEM", 51, 63], ["Laboratory testsOf", "TEST", 108, 126], ["radiological findings", "TEST", 179, 200], ["COVID", "TEST", 217, 222], ["pneumonia", "PROBLEM", 226, 235], ["PCR test", "TEST", 278, 286], ["no", "UNCERTAINTY", 15, 17], ["specific", "OBSERVATION_MODIFIER", 18, 26], ["lobar", "OBSERVATION_MODIFIER", 27, 32], ["predilection", "OBSERVATION", 33, 45], ["most", "OBSERVATION_MODIFIER", 51, 55], ["lesions", "OBSERVATION", 56, 63], ["posteriorly", "ANATOMY_MODIFIER", 79, 90], ["peripherally", "ANATOMY_MODIFIER", 95, 107], ["consistent with", "UNCERTAINTY", 201, 216], ["pneumonia", "OBSERVATION", 226, 235]]], ["Film arrays were negative for the vast majority of cases, particularly for patients with negative RT-PCR test results, except for one case (film array was not performed for that particular patient).", [["patients", "ORGANISM", 75, 83], ["patient", "ORGANISM", 189, 196], ["patients", "SPECIES", 75, 83], ["patient", "SPECIES", 189, 196], ["Film arrays", "TEST", 0, 11], ["PCR test", "TEST", 101, 109], ["film array", "TEST", 140, 150]]], ["White blood cell counts were normal in 15 out of 18 patients and low in three out of 18 patients.", [["blood cell", "ANATOMY", 6, 16], ["White blood cell", "CELL", 0, 16], ["patients", "ORGANISM", 52, 60], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 88, 96], ["White blood cell counts", "TEST", 0, 23]]], ["Lymphocyte counts were low in 10 out of 18 cases.", [["Lymphocyte", "ANATOMY", 0, 10], ["Lymphocyte", "CELL", 0, 10], ["Lymphocyte counts", "TEST", 0, 17], ["low", "OBSERVATION_MODIFIER", 23, 26]]], ["CRP levels were elevated in 17 of 18 cases.", [["CRP", "GENE_OR_GENE_PRODUCT", 0, 3], ["CRP", "PROTEIN", 0, 3], ["CRP levels", "TEST", 0, 10], ["elevated", "PROBLEM", 16, 24], ["elevated", "OBSERVATION_MODIFIER", 16, 24]]], ["Of 18 patients, four had positive D-dimer test results, but no pulmonary embolus (PE) was encountered on CTPA.Laboratory testsThe distinctive CT features in our cohort are summarized in Table 3 , including GGO and consolidative patchy mostly amorphous (72%) lesions, bilateral posterior and peripheral multilobar lung involvement, pleural effusions, subpleural fibrotic lines, subpleural sparing, vascular engorgement, occasional crazy paving, occasional mediastinal lymphadenopathy, pleural thickening, lack of cavitation, and absence of reverse halo (atoll) signs.Laboratory testsSubpleural sparing, which was observed in this patient cohort, has never been reported before, whereas mediastinal lymphadenopathy has been reported occasionally in the literature in English [11] .", [["pulmonary embolus", "ANATOMY", 63, 80], ["lesions", "ANATOMY", 258, 265], ["peripheral multilobar lung", "ANATOMY", 291, 317], ["pleural effusions", "ANATOMY", 331, 348], ["subpleural fibrotic lines", "ANATOMY", 350, 375], ["subpleural", "ANATOMY", 377, 387], ["vascular", "ANATOMY", 397, 405], ["mediastinal lymphadenopathy", "ANATOMY", 455, 482], ["pleural", "ANATOMY", 484, 491], ["testsSubpleural", "ANATOMY", 577, 592], ["mediastinal lymphadenopathy", "ANATOMY", 685, 712], ["pulmonary embolus", "DISEASE", 63, 80], ["PE", "DISEASE", 82, 84], ["pleural effusions", "DISEASE", 331, 348], ["vascular engorgement", "DISEASE", 397, 417], ["lymphadenopathy", "DISEASE", 467, 482], ["pleural thickening", "DISEASE", 484, 502], ["cavitation", "DISEASE", 512, 522], ["mediastinal lymphadenopathy", "DISEASE", 685, 712], ["patients", "ORGANISM", 6, 14], ["D-dimer", "GENE_OR_GENE_PRODUCT", 34, 41], ["pulmonary embolus", "MULTI-TISSUE_STRUCTURE", 63, 80], ["lesions", "PATHOLOGICAL_FORMATION", 258, 265], ["lung", "ORGAN", 313, 317], ["pleural effusions", "PATHOLOGICAL_FORMATION", 331, 348], ["subpleural", "TISSUE", 377, 387], ["vascular", "MULTI-TISSUE_STRUCTURE", 397, 405], ["pleural", "PATHOLOGICAL_FORMATION", 484, 491], ["patient", "ORGANISM", 629, 636], ["patients", "SPECIES", 6, 14], ["patient", "SPECIES", 629, 636], ["positive D-dimer test", "TEST", 25, 46], ["pulmonary embolus", "PROBLEM", 63, 80], ["PE", "PROBLEM", 82, 84], ["CTPA", "TEST", 105, 109], ["Laboratory tests", "TEST", 110, 126], ["The distinctive CT features", "TEST", 126, 153], ["GGO", "TEST", 206, 209], ["consolidative patchy mostly amorphous (72%) lesions", "PROBLEM", 214, 265], ["bilateral posterior and peripheral multilobar lung involvement", "PROBLEM", 267, 329], ["pleural effusions", "PROBLEM", 331, 348], ["subpleural fibrotic lines", "PROBLEM", 350, 375], ["subpleural sparing", "PROBLEM", 377, 395], ["vascular engorgement", "PROBLEM", 397, 417], ["occasional crazy paving", "PROBLEM", 419, 442], ["occasional mediastinal lymphadenopathy", "PROBLEM", 444, 482], ["pleural thickening", "PROBLEM", 484, 502], ["cavitation", "PROBLEM", 512, 522], ["reverse halo", "PROBLEM", 539, 551], ["Laboratory testsSubpleural sparing", "PROBLEM", 566, 600], ["mediastinal lymphadenopathy", "PROBLEM", 685, 712], ["no", "UNCERTAINTY", 60, 62], ["pulmonary", "ANATOMY", 63, 72], ["embolus", "OBSERVATION", 73, 80], ["PE", "OBSERVATION", 82, 84], ["distinctive", "OBSERVATION_MODIFIER", 130, 141], ["GGO", "OBSERVATION", 206, 209], ["consolidative", "OBSERVATION_MODIFIER", 214, 227], ["patchy", "OBSERVATION_MODIFIER", 228, 234], ["mostly", "OBSERVATION_MODIFIER", 235, 241], ["amorphous", "OBSERVATION_MODIFIER", 242, 251], ["lesions", "OBSERVATION", 258, 265], ["bilateral", "ANATOMY_MODIFIER", 267, 276], ["posterior", "ANATOMY_MODIFIER", 277, 286], ["peripheral", "ANATOMY_MODIFIER", 291, 301], ["multilobar", "OBSERVATION_MODIFIER", 302, 312], ["lung", "ANATOMY", 313, 317], ["involvement", "OBSERVATION", 318, 329], ["pleural", "ANATOMY", 331, 338], ["effusions", "OBSERVATION", 339, 348], ["subpleural", "ANATOMY_MODIFIER", 350, 360], ["fibrotic lines", "OBSERVATION", 361, 375], ["subpleural", "ANATOMY_MODIFIER", 377, 387], ["sparing", "OBSERVATION_MODIFIER", 388, 395], ["vascular", "ANATOMY", 397, 405], ["engorgement", "OBSERVATION", 406, 417], ["occasional", "OBSERVATION_MODIFIER", 419, 429], ["crazy", "OBSERVATION_MODIFIER", 430, 435], ["occasional", "OBSERVATION_MODIFIER", 444, 454], ["mediastinal", "ANATOMY", 455, 466], ["lymphadenopathy", "OBSERVATION", 467, 482], ["pleural", "ANATOMY", 484, 491], ["thickening", "OBSERVATION", 492, 502], ["cavitation", "OBSERVATION", 512, 522], ["reverse halo", "OBSERVATION", 539, 551], ["sparing", "OBSERVATION_MODIFIER", 593, 600], ["mediastinal", "ANATOMY", 685, 696], ["lymphadenopathy", "OBSERVATION", 697, 712]]], ["Focal vascular engorgement, septal thickening, and a subpleural fibrotic line were seen frequently in our cohort, with frequencies of 83%, 72%, and 61%, respectively.Laboratory testsPatients' CT features are presented in detail in Figures 3, 4, 5, 6, 7, 8 .", [["vascular", "ANATOMY", 6, 14], ["septal", "ANATOMY", 28, 34], ["subpleural fibrotic line", "ANATOMY", 53, 77], ["vascular engorgement", "DISEASE", 6, 26], ["vascular", "MULTI-TISSUE_STRUCTURE", 6, 14], ["septal", "TISSUE", 28, 34], ["Focal vascular engorgement", "PROBLEM", 0, 26], ["septal thickening", "PROBLEM", 28, 45], ["a subpleural fibrotic line", "PROBLEM", 51, 77], ["frequencies", "TEST", 119, 130], ["Laboratory testsPatients' CT features", "TEST", 166, 203], ["vascular", "ANATOMY", 6, 14], ["engorgement", "OBSERVATION", 15, 26], ["septal", "ANATOMY_MODIFIER", 28, 34], ["thickening", "OBSERVATION", 35, 45], ["subpleural", "ANATOMY_MODIFIER", 53, 63], ["fibrotic line", "OBSERVATION", 64, 77]]], ["A majority of cases (56%) had moderate severity scores.", [["cases", "TEST", 14, 19], ["moderate severity scores", "PROBLEM", 30, 54], ["moderate", "OBSERVATION_MODIFIER", 30, 38], ["severity", "OBSERVATION_MODIFIER", 39, 47]]], ["There was no correlation between the severity score and mortality, p=0.790 ( Table 4) .Predominant density Number of cases PercentageGround-glass opacity 8 44%FIGURE 4: Axial CT through lung bases of a male patient (lung parenchymal window level settings)A 45-year-old male patient presented with cough, fever, and progressive shortness of breath while selfisolating.", [["lung", "ANATOMY", 186, 190], ["lung parenchymal window", "ANATOMY", 216, 239], ["cough", "DISEASE", 297, 302], ["fever", "DISEASE", 304, 309], ["shortness of breath", "DISEASE", 327, 346], ["lung", "ORGAN", 186, 190], ["patient", "ORGANISM", 207, 214], ["lung parenchymal", "MULTI-TISSUE_STRUCTURE", 216, 232], ["patient", "ORGANISM", 274, 281], ["patient", "SPECIES", 207, 214], ["patient", "SPECIES", 274, 281], ["the severity score", "TEST", 33, 51], ["glass opacity", "PROBLEM", 140, 153], ["Axial CT through lung bases", "TEST", 169, 196], ["cough", "PROBLEM", 297, 302], ["fever", "PROBLEM", 304, 309], ["progressive shortness of breath", "PROBLEM", 315, 346], ["density", "OBSERVATION_MODIFIER", 99, 106], ["Number", "OBSERVATION_MODIFIER", 107, 113], ["glass opacity", "OBSERVATION", 140, 153], ["lung", "ANATOMY", 186, 190], ["bases", "ANATOMY_MODIFIER", 191, 196], ["lung", "ANATOMY", 216, 220], ["parenchymal", "ANATOMY_MODIFIER", 221, 232], ["cough", "OBSERVATION", 297, 302], ["fever", "OBSERVATION", 304, 309], ["progressive", "OBSERVATION_MODIFIER", 315, 326]]], ["His respiratory function deteriorated and he was admitted to the hospital.", [["respiratory", "ANATOMY", 4, 15], ["His respiratory function", "TEST", 0, 24], ["respiratory function", "OBSERVATION", 4, 24], ["deteriorated", "OBSERVATION_MODIFIER", 25, 37]]], ["A chest CT was performed, which showed evidence of COVID-19 and subsequent RT-PCR was positive.", [["chest", "ANATOMY", 2, 7], ["chest", "ORGAN", 2, 7], ["COVID-19", "DNA", 51, 59], ["A chest CT", "TEST", 0, 10], ["COVID", "TEST", 51, 56], ["subsequent RT-PCR", "TEST", 64, 81], ["chest", "ANATOMY", 2, 7], ["positive", "OBSERVATION", 86, 94]]], ["An axial contrast-enhanced CT image of the chest showed bilateral patchy ground-glass and consolidative changes with areas of confluence.", [["chest", "ANATOMY", 43, 48], ["chest", "ORGAN", 43, 48], ["An axial contrast-enhanced CT image of the chest", "TEST", 0, 48], ["bilateral patchy ground-glass and consolidative changes", "PROBLEM", 56, 111], ["chest", "ANATOMY", 43, 48], ["bilateral", "ANATOMY_MODIFIER", 56, 65], ["patchy", "OBSERVATION_MODIFIER", 66, 72], ["ground-glass", "OBSERVATION", 73, 85], ["consolidative", "OBSERVATION", 90, 103], ["areas", "OBSERVATION_MODIFIER", 117, 122], ["confluence", "OBSERVATION_MODIFIER", 126, 136]]], ["There was a linear air bronchogram seen in the right upper lobe (black arrows).", [["right upper lobe", "ANATOMY", 47, 63], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 53, 63], ["a linear air bronchogram", "PROBLEM", 10, 34], ["linear", "OBSERVATION_MODIFIER", 12, 18], ["air bronchogram", "OBSERVATION", 19, 34], ["right upper lobe", "ANATOMY", 47, 63], ["black arrows", "OBSERVATION", 65, 77]]], ["This was surrounded by peri-bronchial consolidation and ground-glass changesFIGURE 8: A 67-year-old female patient with positive RT-PCR test for COVID-19The patient's CT images showed a subpleural band, a common finding in our cohort of patients.", [["peri-bronchial", "ANATOMY", 23, 37], ["subpleural band", "ANATOMY", 186, 201], ["female", "ORGANISM", 100, 106], ["patient", "ORGANISM", 107, 114], ["patient", "ORGANISM", 157, 164], ["patients", "ORGANISM", 237, 245], ["patient", "SPECIES", 107, 114], ["patient", "SPECIES", 157, 164], ["patients", "SPECIES", 237, 245], ["peri-bronchial consolidation", "PROBLEM", 23, 51], ["ground-glass changes", "PROBLEM", 56, 76], ["PCR test", "TEST", 132, 140], ["COVID", "TEST", 145, 150], ["The patient's CT images", "TEST", 153, 176], ["a subpleural band", "PROBLEM", 184, 201], ["peri-bronchial", "OBSERVATION_MODIFIER", 23, 37], ["consolidation", "OBSERVATION", 38, 51], ["ground-glass changes", "OBSERVATION", 56, 76], ["subpleural", "ANATOMY", 186, 196]]], ["An axial contrast-enhanced CT image demonstrated a thin curvilinear subpleural band seen posteriorly in both lower lobes (black arrows).", [["subpleural band", "ANATOMY", 68, 83], ["lower lobes", "ANATOMY", 109, 120], ["lower lobes", "MULTI-TISSUE_STRUCTURE", 109, 120], ["An axial contrast-enhanced CT image", "TEST", 0, 35], ["a thin curvilinear subpleural band", "PROBLEM", 49, 83], ["thin", "OBSERVATION_MODIFIER", 51, 55], ["curvilinear", "OBSERVATION_MODIFIER", 56, 67], ["subpleural", "ANATOMY_MODIFIER", 68, 78], ["band", "OBSERVATION", 79, 83], ["posteriorly", "ANATOMY_MODIFIER", 89, 100], ["both", "ANATOMY_MODIFIER", 104, 108], ["lower lobes", "ANATOMY", 109, 120], ["black arrows", "OBSERVATION", 122, 134]]], ["In addition, there were patches of peripheral ground-glass opacification (red boxes) and thickened interlobular septa (white arrows) COVID-19: coronavirus disease 2019; CT: computed tomography; RT-PCR: reverse transcriptionpolymerase chain reactionDiscussionThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen for COVID-19, is an animal-to-human and human-to-human transmissible and potentially lethal virus that belongs to the coronavirus viridine family.", [["interlobular septa", "ANATOMY", 99, 117], ["coronavirus disease", "DISEASE", 143, 162], ["acute respiratory syndrome coronavirus", "DISEASE", 269, 307], ["COVID-19", "CHEMICAL", 341, 349], ["interlobular septa", "MULTI-TISSUE_STRUCTURE", 99, 117], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 262, 309], ["SARS-CoV-2", "ORGANISM", 311, 321], ["human", "ORGANISM", 367, 372], ["human", "ORGANISM", 377, 382], ["human", "ORGANISM", 386, 391], ["coronavirus", "ORGANISM", 455, 466], ["viridine", "GENE_OR_GENE_PRODUCT", 467, 475], ["coronavirus viridine family", "PROTEIN", 455, 482], ["human", "SPECIES", 367, 372], ["human", "SPECIES", 377, 382], ["human", "SPECIES", 386, 391], ["coronavirus", "SPECIES", 455, 466], ["severe acute respiratory syndrome coronavirus", "SPECIES", 262, 307], ["SARS-CoV-2", "SPECIES", 311, 321], ["human", "SPECIES", 367, 372], ["human", "SPECIES", 377, 382], ["human", "SPECIES", 386, 391], ["peripheral ground-glass opacification (red boxes)", "PROBLEM", 35, 84], ["thickened interlobular septa (white arrows", "PROBLEM", 89, 131], ["COVID", "TEST", 133, 138], ["coronavirus disease", "PROBLEM", 143, 162], ["CT", "TEST", 169, 171], ["computed tomography", "TEST", 173, 192], ["RT-PCR", "TEST", 194, 200], ["reverse transcriptionpolymerase chain reaction", "PROBLEM", 202, 248], ["The severe acute respiratory syndrome coronavirus", "PROBLEM", 258, 307], ["SARS", "TEST", 311, 315], ["CoV", "TEST", 316, 319], ["the pathogen", "TEST", 324, 336], ["COVID", "TEST", 341, 346], ["lethal virus", "PROBLEM", 422, 434], ["patches", "OBSERVATION_MODIFIER", 24, 31], ["peripheral", "ANATOMY_MODIFIER", 35, 45], ["ground-glass opacification", "OBSERVATION", 46, 72], ["thickened", "OBSERVATION_MODIFIER", 89, 98], ["interlobular", "ANATOMY_MODIFIER", 99, 111], ["septa", "ANATOMY_MODIFIER", 112, 117], ["coronavirus disease", "OBSERVATION", 143, 162], ["severe", "OBSERVATION_MODIFIER", 262, 268], ["acute", "OBSERVATION_MODIFIER", 269, 274], ["respiratory syndrome", "OBSERVATION", 275, 295]]], ["Its clinic-radiological lung manifestations strongly differ between Chinese, Korean, and Italian populations.", [["lung", "ANATOMY", 24, 28], ["lung", "ORGAN", 24, 28], ["lung", "ANATOMY", 24, 28], ["manifestations", "OBSERVATION", 29, 43]]], ["To the best of our knowledge, this is the first preliminary report describing the chest CT features of COVID-19 in a cohort from London, UK.DiscussionIn our patients, the initial symptoms were similar to those described in the existing literature, including cough, fever, and shortness of breath.", [["chest", "ANATOMY", 82, 87], ["cough", "DISEASE", 258, 263], ["fever", "DISEASE", 265, 270], ["shortness of breath", "DISEASE", 276, 295], ["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 157, 165], ["the chest CT", "TEST", 78, 90], ["COVID", "TEST", 103, 108], ["the initial symptoms", "PROBLEM", 167, 187], ["cough", "PROBLEM", 258, 263], ["fever", "PROBLEM", 265, 270], ["shortness of breath", "PROBLEM", 276, 295], ["chest", "ANATOMY", 82, 87], ["cough", "OBSERVATION", 258, 263], ["fever", "OBSERVATION", 265, 270]]], ["However, two out of 18 patients (11%) in our cohort presented with abdominal pain and one (6%) with vomiting.", [["abdominal", "ANATOMY", 67, 76], ["abdominal pain", "DISEASE", 67, 81], ["vomiting", "DISEASE", 100, 108], ["patients", "ORGANISM", 23, 31], ["abdominal", "ORGANISM_SUBDIVISION", 67, 76], ["patients", "SPECIES", 23, 31], ["abdominal pain", "PROBLEM", 67, 81], ["vomiting", "PROBLEM", 100, 108], ["abdominal", "ANATOMY", 67, 76], ["pain", "OBSERVATION", 77, 81]]], ["CRP levels were high in all cases, which is consistent with previous studies [12] [13] [14] [15] .", [["CRP", "GENE_OR_GENE_PRODUCT", 0, 3], ["[12] [13] [14] [15]", "SIMPLE_CHEMICAL", 77, 96], ["CRP", "PROTEIN", 0, 3], ["CRP levels", "TEST", 0, 10], ["previous studies", "TEST", 60, 76], ["high", "OBSERVATION_MODIFIER", 16, 20], ["consistent with", "UNCERTAINTY", 44, 59]]], ["In the early stage of COVID-19 pneumonia, CRP levels could be positively correlated with lung lesion sizes.", [["lung lesion", "ANATOMY", 89, 100], ["pneumonia", "DISEASE", 31, 40], ["CRP", "GENE_OR_GENE_PRODUCT", 42, 45], ["lung", "ORGAN", 89, 93], ["CRP", "PROTEIN", 42, 45], ["COVID", "TEST", 22, 27], ["pneumonia", "PROBLEM", 31, 40], ["CRP levels", "TEST", 42, 52], ["lung lesion sizes", "PROBLEM", 89, 106], ["early stage", "OBSERVATION_MODIFIER", 7, 18], ["pneumonia", "OBSERVATION", 31, 40], ["lung", "ANATOMY", 89, 93], ["lesion", "OBSERVATION", 94, 100], ["sizes", "OBSERVATION_MODIFIER", 101, 106]]], ["CRP levels could reflect disease severity and could be used as a key indicator of disease prognosis [15] .", [["CRP", "GENE_OR_GENE_PRODUCT", 0, 3], ["CRP", "PROTEIN", 0, 3], ["CRP levels", "TEST", 0, 10], ["disease severity", "PROBLEM", 25, 41], ["disease prognosis", "PROBLEM", 82, 99], ["could reflect", "UNCERTAINTY", 11, 24], ["disease", "OBSERVATION", 25, 32]]], ["D-dimer levels were measured in five cases in our cohort [16] .", [["D-dimer", "GENE_OR_GENE_PRODUCT", 0, 7], ["D-dimer levels", "TEST", 0, 14]]], ["Four out of five tests were positive.", [["five tests", "TEST", 12, 22], ["positive", "OBSERVATION", 28, 36]]], ["All five cases underwent CTPA with negative results for PE.", [["PE", "DISEASE", 56, 58], ["CTPA", "TEST", 25, 29], ["PE", "PROBLEM", 56, 58], ["PE", "OBSERVATION", 56, 58]]], ["PE rates have previously been reported to be around 20% [17] [18] , which contrasted with our findings with no PE encountered.", [["PE", "DISEASE", 111, 113], ["PE rates", "TEST", 0, 8], ["PE", "PROBLEM", 111, 113], ["no", "UNCERTAINTY", 108, 110], ["PE", "OBSERVATION", 111, 113]]], ["Lymphopenia is one of the prominent features of COVID-19.", [["Lymphopenia", "DISEASE", 0, 11], ["COVID-19", "CHEMICAL", 48, 56], ["Lymphopenia", "PROBLEM", 0, 11], ["COVID", "TEST", 48, 53], ["one of the prominent", "OBSERVATION_MODIFIER", 15, 35]]], ["Lymphocyte counts may be a useful biomarker in predicting the severity of the disease [19] .", [["Lymphocyte", "ANATOMY", 0, 10], ["Lymphocyte", "CELL", 0, 10], ["Lymphocyte counts", "TEST", 0, 17], ["the disease", "PROBLEM", 74, 85], ["disease", "OBSERVATION", 78, 85]]], ["Lymphocyte counts were low (56%) or normal (44%) in all cases in our patient cohort.DiscussionLung manifestations of COVID-19 are similar to those of SARS and MERS.", [["Lymphocyte", "ANATOMY", 0, 10], ["SARS", "DISEASE", 150, 154], ["MERS", "DISEASE", 159, 163], ["COVID-19", "CHEMICAL", 117, 125], ["Lymphocyte", "CELL", 0, 10], ["patient", "ORGANISM", 69, 76], ["patient", "SPECIES", 69, 76], ["Lymphocyte counts", "TEST", 0, 17], ["COVID", "TEST", 117, 122], ["SARS", "PROBLEM", 150, 154], ["low", "OBSERVATION_MODIFIER", 23, 26]]], ["Radiological studies have shown cardinal similarities, including bilateral patchy GGO and consolidations, subpleural involvement, and predominant posterior and peripheral lesion distributions [2, [4] [5] [6] [8] [9] [10] [11] [12] [13] 20, 21] .", [["subpleural", "ANATOMY", 106, 116], ["peripheral lesion", "ANATOMY", 160, 177], ["subpleural", "MULTI-TISSUE_STRUCTURE", 106, 116], ["2, [4] [5] [6] [8] [9] [10] [11] [12] [13] 20", "SIMPLE_CHEMICAL", 193, 238], ["Radiological studies", "TEST", 0, 20], ["cardinal similarities", "TEST", 32, 53], ["bilateral patchy GGO", "PROBLEM", 65, 85], ["consolidations", "PROBLEM", 90, 104], ["subpleural involvement", "PROBLEM", 106, 128], ["predominant posterior and peripheral lesion distributions", "PROBLEM", 134, 191], ["cardinal", "ANATOMY", 32, 40], ["bilateral", "ANATOMY_MODIFIER", 65, 74], ["patchy", "OBSERVATION_MODIFIER", 75, 81], ["GGO", "OBSERVATION", 82, 85], ["consolidations", "OBSERVATION", 90, 104], ["subpleural", "ANATOMY_MODIFIER", 106, 116], ["predominant", "OBSERVATION_MODIFIER", 134, 145], ["posterior", "ANATOMY_MODIFIER", 146, 155], ["peripheral", "ANATOMY_MODIFIER", 160, 170], ["lesion", "OBSERVATION", 171, 177]]], ["The CT findings of COVID-19 pneumonia in the UK have been generally consistent with those in the Far East [20, 22] .", [["pneumonia", "DISEASE", 28, 37], ["The CT findings", "TEST", 0, 15], ["COVID", "TEST", 19, 24], ["pneumonia", "PROBLEM", 28, 37], ["pneumonia", "OBSERVATION", 28, 37], ["consistent with", "UNCERTAINTY", 68, 83]]], ["However, the proportion of predominantly consolidative lesions in a Chinese cohort was found to be approximately 30-60% [22, 23] .", [["consolidative lesions", "ANATOMY", 41, 62], ["consolidative lesions", "CANCER", 41, 62], ["predominantly consolidative lesions", "PROBLEM", 27, 62], ["predominantly", "OBSERVATION_MODIFIER", 27, 40], ["consolidative", "OBSERVATION_MODIFIER", 41, 54], ["lesions", "OBSERVATION", 55, 62]]], ["In Korean patients, no predominantly consolidative lesions were observed, which is consistent with our study findings [2] .", [["consolidative lesions", "ANATOMY", 37, 58], ["patients", "ORGANISM", 10, 18], ["consolidative lesions", "CANCER", 37, 58], ["patients", "SPECIES", 10, 18], ["predominantly consolidative lesions", "PROBLEM", 23, 58], ["our study findings", "TEST", 99, 117], ["no", "UNCERTAINTY", 20, 22], ["predominantly", "OBSERVATION_MODIFIER", 23, 36], ["consolidative", "OBSERVATION_MODIFIER", 37, 50], ["lesions", "OBSERVATION", 51, 58], ["consistent with", "UNCERTAINTY", 83, 98]]], ["In addition, the proportion of chest radiographic abnormalities was 60% in Chinese COVID-19 patients [24] , but 33% in Korean patients [2] .", [["chest", "ANATOMY", 31, 36], ["COVID", "DISEASE", 83, 88], ["chest", "ORGAN", 31, 36], ["patients", "ORGANISM", 92, 100], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 92, 100], ["patients", "SPECIES", 126, 134], ["Chinese COVID-19", "SPECIES", 75, 91], ["chest radiographic abnormalities", "TEST", 31, 63], ["Chinese COVID", "TEST", 75, 88], ["chest", "ANATOMY", 31, 36]]], ["Considering these radiologic observations and five deaths from COVID-19 in the UK, UK patients seem to experience a harsher disease course than Korean patients.", [["deaths", "DISEASE", 51, 57], ["patients", "ORGANISM", 86, 94], ["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 86, 94], ["patients", "SPECIES", 151, 159], ["COVID", "TEST", 63, 68], ["a harsher disease course", "PROBLEM", 114, 138]]], ["We did not observe the reversed halo signs in our cohort, but a few cases with the reversed halo sign were observed in some other recent reports [2, [24] [25] [26] .", [["[24] [25] [26]", "SIMPLE_CHEMICAL", 149, 163], ["the reversed halo signs", "PROBLEM", 19, 42], ["the reversed halo sign", "PROBLEM", 79, 101]]], ["Septal thickening, a subpleural fibrotic line, and focal vascular engorgements were seen frequently in our study.DiscussionThis study was performed at one of the epicenters of the COVID-19 pandemic, in London, UK.", [["Septal", "ANATOMY", 0, 6], ["subpleural fibrotic line", "ANATOMY", 21, 45], ["vascular", "ANATOMY", 57, 65], ["Septal", "TISSUE", 0, 6], ["vascular", "MULTI-TISSUE_STRUCTURE", 57, 65], ["Septal thickening", "PROBLEM", 0, 17], ["a subpleural fibrotic line", "PROBLEM", 19, 45], ["focal vascular engorgements", "PROBLEM", 51, 78], ["our study", "TEST", 103, 112], ["This study", "TEST", 123, 133], ["the COVID", "TEST", 176, 185], ["thickening", "OBSERVATION", 7, 17], ["subpleural", "ANATOMY_MODIFIER", 21, 31], ["fibrotic line", "OBSERVATION", 32, 45], ["focal", "OBSERVATION_MODIFIER", 51, 56], ["vascular", "ANATOMY", 57, 65], ["engorgements", "OBSERVATION", 66, 78]]], ["Our hospital has received a high number of COVID-19 patients, but CT scanning has been reserved for equivocal chest X-Ray findings, excluding complications like PE and preoperative patients scanning to exclude COVID-19 before the RT-PCR test result.", [["PE", "DISEASE", 161, 163], ["patients", "ORGANISM", 52, 60], ["patients", "ORGANISM", 181, 189], ["COVID-19", "DNA", 210, 218], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 181, 189], ["CT scanning", "TEST", 66, 77], ["equivocal chest X-Ray findings", "TEST", 100, 130], ["complications", "PROBLEM", 142, 155], ["PE", "PROBLEM", 161, 163], ["preoperative patients scanning", "TEST", 168, 198], ["COVID", "TEST", 210, 215], ["the RT-PCR test result", "TEST", 226, 248], ["chest", "ANATOMY", 110, 115], ["PE", "OBSERVATION", 161, 163]]], ["Therefore, the initial recommendation in our institution, as in several other UK hospitals, was to perform CT-CAP in all preoperative patients.", [["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["CT", "TEST", 107, 109]]], ["Currently, only limited sections through both lung bases appear sufficient to detect COVID-19 lung pneumonia for patients who undergo semi-elective or urgent surgery [27] .DiscussionAccording to a statement that was recently published by the British Society of Thoracic Imaging, the assumed role of CT in the diagnosis, triage, and prognosis of patients with COVID-19 infection continues to be refined, and is reserved for clinically and laboratory-suspected COVID-19 patients who are seriously ill with oxygen saturation of less than 94% or a National Early Warning Score (NEWS) equal to or greater than 3.", [["sections", "ANATOMY", 24, 32], ["lung", "ANATOMY", 46, 50], ["lung", "ANATOMY", 94, 98], ["lung pneumonia", "DISEASE", 94, 108], ["COVID-19", "CHEMICAL", 359, 367], ["infection", "DISEASE", 368, 377], ["oxygen", "CHEMICAL", 504, 510], ["oxygen", "CHEMICAL", 504, 510], ["sections", "MULTI-TISSUE_STRUCTURE", 24, 32], ["lung", "ORGAN", 46, 50], ["lung", "ORGAN", 94, 98], ["patients", "ORGANISM", 113, 121], ["patients", "ORGANISM", 345, 353], ["patients", "ORGANISM", 468, 476], ["oxygen", "SIMPLE_CHEMICAL", 504, 510], ["patients", "SPECIES", 113, 121], ["patients", "SPECIES", 345, 353], ["patients", "SPECIES", 468, 476], ["COVID", "TEST", 85, 90], ["19 lung pneumonia", "PROBLEM", 91, 108], ["urgent surgery", "TREATMENT", 151, 165], ["Thoracic Imaging", "TEST", 261, 277], ["CT", "TEST", 299, 301], ["triage", "TEST", 320, 326], ["COVID-19 infection", "PROBLEM", 359, 377], ["oxygen saturation", "TEST", 504, 521], ["lung", "ANATOMY", 46, 50], ["bases", "ANATOMY_MODIFIER", 51, 56], ["lung", "ANATOMY", 94, 98], ["pneumonia", "OBSERVATION", 99, 108], ["Thoracic", "ANATOMY", 261, 269], ["infection", "OBSERVATION", 368, 377]]], ["Normal or equivocal chest X-ray and CT examinations can be carried out with or without contrast as in our study [28] .", [["equivocal chest X-ray", "TEST", 10, 31], ["CT examinations", "TEST", 36, 51], ["our study", "TEST", 102, 111], ["chest", "ANATOMY", 20, 25]]], ["Furthermore, in line with the British Society of Thoracic Imaging guidelines, patients with persistent significant abnormalities on the second chest X-ray, abnormal pulmonary function tests, and/or significant unexplained breathlessness may require further investigations, which can include a pre-contrast high-resolution volumetric CT and CTPA to assess the presence of interstitial lung disease and PE, respectively [29] .DiscussionThere are several limitations to our current study.", [["pulmonary", "ANATOMY", 165, 174], ["interstitial lung", "ANATOMY", 371, 388], ["breathlessness", "DISEASE", 222, 236], ["interstitial lung disease", "DISEASE", 371, 396], ["PE", "DISEASE", 401, 403], ["patients", "ORGANISM", 78, 86], ["pulmonary", "ORGAN", 165, 174], ["lung", "ORGAN", 384, 388], ["patients", "SPECIES", 78, 86], ["persistent significant abnormalities", "PROBLEM", 92, 128], ["the second chest X-ray", "TEST", 132, 154], ["abnormal pulmonary function tests", "PROBLEM", 156, 189], ["significant unexplained breathlessness", "PROBLEM", 198, 236], ["further investigations", "TEST", 249, 271], ["a pre-contrast high-resolution volumetric CT", "TEST", 291, 335], ["CTPA", "TEST", 340, 344], ["interstitial lung disease", "PROBLEM", 371, 396], ["PE", "PROBLEM", 401, 403], ["our current study", "TEST", 467, 484], ["Thoracic", "ANATOMY", 49, 57], ["persistent", "OBSERVATION_MODIFIER", 92, 102], ["significant", "OBSERVATION_MODIFIER", 103, 114], ["abnormalities", "OBSERVATION", 115, 128], ["chest", "ANATOMY", 143, 148], ["pulmonary", "ANATOMY", 165, 174], ["interstitial", "ANATOMY_MODIFIER", 371, 383], ["lung", "ANATOMY", 384, 388], ["disease", "OBSERVATION", 389, 396], ["PE", "OBSERVATION", 401, 403]]], ["Firstly, it was a retrospective single-center study with a limited patient cohort without follow-up CT examinations.", [["patient", "ORGANISM", 67, 74], ["patient", "SPECIES", 67, 74], ["follow-up CT examinations", "TEST", 90, 115]]], ["Secondly, CT examinations were carried out with and without contrast enhancement, but we did not face great difficulties to see the lung lesions, and we clearly observed vascular engorgement signs on post-IV contrastenhanced CT examinations.", [["lung lesions", "ANATOMY", 132, 144], ["vascular", "ANATOMY", 170, 178], ["lung lesions", "CANCER", 132, 144], ["vascular", "MULTI-TISSUE_STRUCTURE", 170, 178], ["CT examinations", "TEST", 10, 25], ["the lung lesions", "PROBLEM", 128, 144], ["vascular engorgement signs", "PROBLEM", 170, 196], ["post-IV contrastenhanced CT examinations", "TEST", 200, 240], ["lung", "ANATOMY", 132, 136], ["lesions", "OBSERVATION", 137, 144], ["vascular", "ANATOMY", 170, 178], ["engorgement", "OBSERVATION", 179, 190]]], ["Thirdly, the RT-PCR test was only performed twice in our institute.", [["the RT-PCR test", "TEST", 9, 24]]], ["And lastly, the time interval between initial symptom onset and CT was not precisely defined, but RT-PCR and chest X-ray were performed on the patient admission date, and subsequent CT scans were performed either on the same day or within a week's time, with or without RT-PCR test results.ConclusionsChest CT scanning was not a first-line investigation modality for suspected COVID-19 patients; all patients had initial chest X-ray at the time of admission along with an RT-PCR nasopharyngeal swab test.", [["nasopharyngeal swab", "ANATOMY", 479, 498], ["patient", "ORGANISM", 143, 150], ["patients", "ORGANISM", 386, 394], ["patients", "ORGANISM", 400, 408], ["patient", "SPECIES", 143, 150], ["patients", "SPECIES", 386, 394], ["patients", "SPECIES", 400, 408], ["CT", "TEST", 64, 66], ["RT-PCR", "TEST", 98, 104], ["chest X-ray", "TEST", 109, 120], ["subsequent CT scans", "TEST", 171, 190], ["RT-PCR test", "TEST", 270, 281], ["Chest CT scanning", "TEST", 301, 318], ["initial chest X-ray", "TEST", 413, 432], ["an RT-PCR nasopharyngeal swab test", "TEST", 469, 503], ["chest", "ANATOMY", 109, 114], ["Chest", "ANATOMY", 301, 306], ["chest", "ANATOMY", 421, 426], ["nasopharyngeal", "ANATOMY", 479, 493]]], ["Mixed GGO-consolidation, amorphous morphology, and posterior and peripheral lung distributions of the COVID-19 pneumonia lesions were the cardinal findings in our limited but diverse UK patient cohort.", [["lung", "ANATOMY", 76, 80], ["COVID-19 pneumonia lesions", "ANATOMY", 102, 128], ["pneumonia", "DISEASE", 111, 120], ["peripheral lung", "MULTI-TISSUE_STRUCTURE", 65, 80], ["lesions", "PATHOLOGICAL_FORMATION", 121, 128], ["patient", "ORGANISM", 186, 193], ["patient", "SPECIES", 186, 193], ["Mixed GGO", "PROBLEM", 0, 9], ["consolidation", "PROBLEM", 10, 23], ["amorphous morphology", "TEST", 25, 45], ["posterior and peripheral lung distributions", "PROBLEM", 51, 94], ["the COVID-19 pneumonia lesions", "PROBLEM", 98, 128], ["GGO", "OBSERVATION", 6, 9], ["consolidation", "OBSERVATION", 10, 23], ["amorphous", "OBSERVATION_MODIFIER", 25, 34], ["morphology", "OBSERVATION_MODIFIER", 35, 45], ["posterior", "ANATOMY_MODIFIER", 51, 60], ["peripheral", "ANATOMY_MODIFIER", 65, 75], ["lung", "ANATOMY", 76, 80], ["distributions", "OBSERVATION_MODIFIER", 81, 94], ["pneumonia", "OBSERVATION_MODIFIER", 111, 120], ["lesions", "OBSERVATION", 121, 128]]], ["Subpleural sparing, bilateral pleural effusion, presence of a halo sign, subpleural fibrotic lines, septal thickening, focal vascular engorgements, mediastinal lymphadenopathy, absence of a reverse halo sign, and absence of cavitation were observed in our study.", [["Subpleural", "ANATOMY", 0, 10], ["pleural", "ANATOMY", 30, 37], ["subpleural fibrotic lines", "ANATOMY", 73, 98], ["septal", "ANATOMY", 100, 106], ["vascular", "ANATOMY", 125, 133], ["mediastinal", "ANATOMY", 148, 159], ["pleural effusion", "DISEASE", 30, 46], ["lymphadenopathy", "DISEASE", 160, 175], ["pleural", "ORGAN", 30, 37], ["septal", "MULTI-TISSUE_STRUCTURE", 100, 106], ["vascular", "MULTI-TISSUE_STRUCTURE", 125, 133], ["Subpleural sparing", "PROBLEM", 0, 18], ["bilateral pleural effusion", "PROBLEM", 20, 46], ["a halo sign", "PROBLEM", 60, 71], ["subpleural fibrotic lines", "PROBLEM", 73, 98], ["septal thickening", "PROBLEM", 100, 117], ["focal vascular engorgements", "PROBLEM", 119, 146], ["mediastinal lymphadenopathy", "PROBLEM", 148, 175], ["a reverse halo sign", "PROBLEM", 188, 207], ["cavitation", "PROBLEM", 224, 234], ["our study", "TEST", 252, 261], ["sparing", "OBSERVATION_MODIFIER", 11, 18], ["bilateral", "ANATOMY_MODIFIER", 20, 29], ["pleural", "ANATOMY", 30, 37], ["effusion", "OBSERVATION", 38, 46], ["halo", "OBSERVATION_MODIFIER", 62, 66], ["subpleural", "ANATOMY_MODIFIER", 73, 83], ["fibrotic lines", "OBSERVATION", 84, 98], ["septal", "ANATOMY_MODIFIER", 100, 106], ["thickening", "OBSERVATION", 107, 117], ["focal", "OBSERVATION_MODIFIER", 119, 124], ["vascular", "ANATOMY", 125, 133], ["engorgements", "OBSERVATION", 134, 146], ["mediastinal", "ANATOMY", 148, 159], ["lymphadenopathy", "OBSERVATION", 160, 175], ["reverse halo", "OBSERVATION", 190, 202], ["cavitation", "OBSERVATION", 224, 234]]], ["Subpleural sparing, which has never been reported in the literature in English, was observed in our cohort.", [["Subpleural", "ANATOMY", 0, 10], ["Subpleural sparing", "PROBLEM", 0, 18], ["sparing", "OBSERVATION", 11, 18]]], ["A majority of the UK cases presented with cardinal symptoms including fever, shortness of breath, and cough.", [["fever", "DISEASE", 70, 75], ["shortness of breath", "DISEASE", 77, 96], ["cough", "DISEASE", 102, 107], ["cardinal symptoms", "PROBLEM", 42, 59], ["fever", "PROBLEM", 70, 75], ["shortness of breath", "PROBLEM", 77, 96], ["cough", "PROBLEM", 102, 107], ["fever", "OBSERVATION", 70, 75], ["cough", "OBSERVATION", 102, 107]]], ["All patients' CRP levels were elevated.", [["patients", "ORGANISM", 4, 12], ["CRP", "GENE_OR_GENE_PRODUCT", 14, 17], ["CRP", "PROTEIN", 14, 17], ["patients", "SPECIES", 4, 12], ["All patients' CRP levels", "TEST", 0, 24], ["elevated", "PROBLEM", 30, 38]]], ["Lymphopenia and normal lymphocyte counts were observed in our patient cohort.", [["lymphocyte", "ANATOMY", 23, 33], ["Lymphopenia", "DISEASE", 0, 11], ["lymphocyte", "CELL", 23, 33], ["patient", "ORGANISM", 62, 69], ["patient", "SPECIES", 62, 69], ["Lymphopenia", "PROBLEM", 0, 11], ["normal lymphocyte counts", "PROBLEM", 16, 40], ["normal lymphocyte counts", "OBSERVATION", 16, 40]]], ["All D-dimer-positive cases did not show any PE, which has never been reported in the literature in English.ConclusionsThe findings from our limited cohort are generally in line with CT imaging findings from the published literature worldwide with a few exceptions, such as the presence of pleural effusion, mediastinal lymphadenopathy, and the lack of reverse halo sign.", [["pleural effusion", "ANATOMY", 289, 305], ["mediastinal", "ANATOMY", 307, 318], ["PE", "DISEASE", 44, 46], ["pleural effusion", "DISEASE", 289, 305], ["mediastinal lymphadenopathy", "DISEASE", 307, 334], ["D-dimer", "GENE_OR_GENE_PRODUCT", 4, 11], ["pleural", "ORGAN", 289, 296], ["dimer", "PROTEIN", 6, 11], ["All D-dimer", "TEST", 0, 11], ["any PE", "PROBLEM", 40, 46], ["CT imaging", "TEST", 182, 192], ["pleural effusion", "PROBLEM", 289, 305], ["mediastinal lymphadenopathy", "PROBLEM", 307, 334], ["reverse halo sign", "PROBLEM", 352, 369], ["PE", "OBSERVATION", 44, 46], ["pleural", "ANATOMY", 289, 296], ["effusion", "OBSERVATION", 297, 305], ["mediastinal", "ANATOMY", 307, 318], ["lymphadenopathy", "OBSERVATION", 319, 334], ["reverse halo", "OBSERVATION", 352, 364]]]]}